CINXE.COM

<!DOCTYPE html><html lang="en" class="h-100"><head><meta charset="utf-8"><meta http-equiv="X-UA-Compatible" content="IE=edge"><meta name="viewport" content="width=device-width, initial-scale=1, shrink-to-fit=no"><title> University of California Health Glioma Clinical Trials for 2024 — California</title><meta property="og:title" content="University of California Health Glioma Clinical Trials — California"><meta name="description" content="Do you qualify for these Glioma studies? We offer 53 options."><meta property="og:description" content="Do you qualify for these Glioma studies? We offer 53 options."><meta property="og:url" content="https://clinicaltrials.ucbraid.org/glioma"><link rel="canonical" href="https://clinicaltrials.ucbraid.org/glioma"><meta name="author" content="University of California Health"><meta name="generator" content="edu.ucsf.ctsi.rt.trialfinder"><meta name="referrer" content="origin-when-cross-origin"><meta name="google-site-verification" content="UTQ9rwZMafn66BKfZ97YetmUPcYNDdDiV01qhvzc8lk"><meta name="msvalidate.01" content="4E5209CC6688B86BBDD2FE074176C029"><link rel="shortcut icon" href="https://clinicaltrials.ucbraid.org/assets/local/uchealth/img/favicon.png"><link rel="alternate" type="application/atom+xml" title="University of California Health Clinical Trials" href="https://clinicaltrials.ucbraid.org/meta/feed.atom"><meta property="og:type" content="website"><meta name="twitter:card" content="summary"><meta name="twitter:site" content="@UofCalifornia"><meta property="og:image" content="https://clinicaltrials.ucbraid.org/assets/local/uchealth/img/hero.jpg"> <link rel="stylesheet" href="https://cdn.jsdelivr.net/npm/bootstrap@4.4.1/dist/css/bootstrap.min.css" integrity="sha256-L/W5Wfqfa0sdBNIKN9cG6QA5F2qx4qICmU2VgLruv9Y=" crossorigin="anonymous"><link rel="stylesheet" href="https://cdn.jsdelivr.net/gh/coliff/bootstrap-rfs@4.3.1/bootstrap-rfs.css" media="screen and (max-width: 1200px)" integrity="sha256-DgOE2c1ekD0TaTyiCQuH2NdeiZ6VifYJdLdfDwq6C+U=" crossorigin="anonymous"><link rel="stylesheet" href="https://cdn.jsdelivr.net/npm/animate.css@3.7.2/animate.min.css" integrity="sha256-PHcOkPmOshsMBC+vtJdVr5Mwb7r0LkSVJPlPrp/IMpU=" crossorigin="anonymous"><link rel="stylesheet" href="https://cdn.jsdelivr.net/npm/font-awesome@4.7.0/css/font-awesome.min.css" integrity="sha256-eZrrJcwDc/3uDhsdt61sL2oOBY362qM3lon1gyExkL0=" crossorigin="anonymous"><link rel="stylesheet" href="https://clinicaltrials.ucbraid.org/assets/css/style.css"><link rel="stylesheet" href="https://clinicaltrials.ucbraid.org/assets/local/uchealth/css/style-local.css"> <script src="https://polyfill-fastly.io/v3/polyfill.min.js?features=default%2CObject.assign%2CObject.entries%2CPromise%2CURLSearchParams%2CURL" crossorigin="anonymous" defer></script> <script src="https://cdn.jsdelivr.net/jquery/2.2.4/jquery.min.js" integrity="sha256-BbhdlvQf/xTY9gja0Dq3HiwQF8LaCRTXxZKRutelT44=" crossorigin="anonymous" defer></script><script src="https://cdn.jsdelivr.net/npm/bootstrap@4.4.1/dist/js/bootstrap.bundle.min.js" integrity="sha256-OUFW7hFO0/r5aEGTQOz9F/aXQOt+TwqI1Z4fbVvww04=" crossorigin="anonymous" defer></script><link rel="dns-prefetch" href="https://www.google.com/"> <script src="https://clinicaltrials.ucbraid.org/assets/js/app.js" defer></script><script>var google_analytics_live_mode=0;var google_analytics_id='UA-1142388-32';var google_analytics_hostname='clinicaltrials.ucbraid.org';if(google_analytics_id&&google_analytics_hostname&&window.location&&window.location.hostname&&window.location.hostname===google_analytics_hostname){google_analytics_live_mode=1}var google_analytics_js_url='https://www.google-analytics.com/analytics_debug.js';if(google_analytics_live_mode){google_analytics_js_url='https://www.google-analytics.com/analytics.js'}(function(c,h,e,b,f,a,d){c['GoogleAnalyticsObject']=f;c[f]=c[f]||function(){(c[f].q=c[f].q||[]).push(arguments)},c[f].l=1*new Date();a=h.createElement(e),d=h.getElementsByTagName(e)[0];a.async=1;a.src=b;d.parentNode.insertBefore(a,d)})(window,document,'script',google_analytics_js_url,'ga');if(!google_analytics_live_mode){}if(google_analytics_live_mode){ga('create',google_analytics_id,'auto')}else{ga('set','sendHitTask',null)}ga('require','outboundLinkTracker');ga('require','pageVisibilityTracker');ga('send','pageview');var s_opt={};s_opt['s_apid']='53G5XLK75T';s_opt['s_ixnm']='trials_uchealth';s_opt['s_ixky']='6e038166fd15da69c2ed075975c00816';s_opt['s_plac']=undefined;s_opt['s_mlti']=true;var _paq=window._paq=window._paq||[];_paq.push(['setTrackerUrl','https://clinicaltrials.ucbraid.org/action/t/l/']);_paq.push(['setSiteId','12']);_paq.push(['setCustomDimension',1,'condition\u002dpage']);_paq.push(['trackPageView']);_paq.push(['enableLinkTracking']);_paq.push(['enableHeartBeatTimer']);(function(){var a=document,g=a.createElement('script'),s=a.getElementsByTagName('script')[0];g.type='text/javascript';g.async=true;g.src='https://clinicaltrials.ucbraid.org/action/t/js/';s.parentNode.insertBefore(g,s)})();</script><script async src="https://cdn.jsdelivr.net/npm/autotrack@1.0.3/autotrack.js" integrity="sha256-MFv0PQKCj7HPlACiJTgQ+3rHnOSY1a510jcQGGwtemQ=" crossorigin="anonymous"></script><script type="application/ld+json"> { "@context": "https://schema.org/", "@type": "WebSite", "publisher": { "@type": "MedicalOrganization", "name": "University of California Health", "address": "California", "url": "https://www.ucop.edu/uc-health/", "logo": "https://s2.googleusercontent.com/s2/favicons?domain_url=https%3A%2F%2Fwww.ucop.edu%2Fuc-health%2F", "sameAs": [ "https://twitter.com/@UofCalifornia" ] } } </script></head><body class="condition-page bg-light d-flex flex-column"> <a id="skip-to-main-content" class="sr-only sr-only-focusable" href="#content">Skip to main content</a> <header id="header" class="mb-4"><div id="uchealth-top-header" style="background: white" class="container-fluid" data-nosnippet><div class="row align-items-center"><div id="uchealth-wordmark-container" class="col-xl-2 col-md-3 col-12"> <a href="https://health.universityofcalifornia.edu/"> <img src="https://clinicaltrials.ucbraid.org/assets/local/uchealth/img/uchealth-wordmark-transparent.png" id="uchealth-wordmark" alt="University of California Health"> </a> </div><div id="uchealth-top-header-links" class="col-xl-10 col-md-9 d-md-block d-none text-right"> <a href="https://health.universityofcalifornia.edu/patient-care/cancer-consortium">Cancer Consortium</a> <a href="https://health.universityofcalifornia.edu/patient-care/cardiac-surgery-consortium">Cardiac Surgery Consortium</a> <a href="https://health.universityofcalifornia.edu/research">Research at UCH</a> <a href="https://www.ucbraid.org/"><span class="font-weight-light">Powered by</span> <span class="font-weight-bold">UC BRAID</span></a> </div></div></div><nav class="navbar navbar-expand-md navbar-light d-print"> <a class="navbar-brand" href="https://clinicaltrials.ucbraid.org/"> <img src="https://clinicaltrials.ucbraid.org/assets/local/uchealth/img/site-name.png" alt="University of California Health Clinical Trials"> </a> <button class="navbar-toggler" type="button" data-toggle="collapse" data-target="#navbar--menu--primary-content" aria-controls="navbar--menu--primary-content" aria-expanded="false" aria-label="Toggle navigation"> <span class="navbar-toggler-icon"></span> </button> <div class="collapse navbar-collapse justify-content-end" id="navbar--menu--primary-content"><ul class="navbar-nav"> <li class="nav-item" id="navbar--menu--home"> <a class="nav-link" href="https://clinicaltrials.ucbraid.org/">Search</a> </li> <li class="nav-item dropdown"> <a class="nav-link dropdown-toggle" href="https://clinicaltrials.ucbraid.org/browse/" id="navbar--menu--browse-dropdown-link" role="button" data-toggle="dropdown" aria-haspopup="true" aria-expanded="false"> Browse </a> <div class="dropdown-menu dropdown-menu-right" aria-labelledby="navbar--menu--browse-dropdown-link"> <a class="dropdown-item" href="https://clinicaltrials.ucbraid.org/browse/">All trials</a> <div class="dropdown-divider"></div><div class="dropdown-header">Trials for…</div> <a class="dropdown-item" href="https://clinicaltrials.ucbraid.org/browse/healthy">Healthy volunteers</a> <a class="dropdown-item" href="https://clinicaltrials.ucbraid.org/browse/pediatric" title="Pediatric clinical trials, for people under age 18">People under 18</a> <a class="dropdown-item" href="https://clinicaltrials.ucbraid.org/browse/geriatric" title="Geriatric clinical trials, for people over age 65">People over 65</a> </div></li> <li class="nav-item dropdown"> <a class="nav-link dropdown-toggle" href="https://clinicaltrials.ucbraid.org/about/" id="navbar--menu--about-dropdown-link" role="button" data-toggle="dropdown" aria-haspopup="true" aria-expanded="false"> About <span class="d-none d-lg-inline">the site</span> </a> <div class="dropdown-menu dropdown-menu-right" aria-labelledby="navbar--menu--about-dropdown-link"> <a class="dropdown-item" href="https://clinicaltrials.ucbraid.org/about/">About University of California Health Clinical Trials</a> </div></li></ul></div> </nav><nav class="breadcrumb-and-search-bar navbar navbar-expand navbar-light d-print d-flex justify-content-between"> <div><ol class="breadcrumb navbar-text my-0 pl-1" itemscope="itemscope" itemtype="https://schema.org/BreadcrumbList"><li itemprop="itemListElement" itemscope itemtype="https://schema.org/ListItem"> <a href="https://clinicaltrials.ucbraid.org/" itemscope="itemscope" itemprop="item" itemtype="https://schema.org/Thing" id="navbar--breadcrumb--link-1"> Home <meta itemprop="name" content="University of California Health Clinical Trials"> </a> <meta itemprop="position" content="1"></li><li class="active">Glioma Studies</li></ol></div> <div><div class="d-none d-md-block navbar-text"><form method="GET" action="https://clinicaltrials.ucbraid.org/" class="form-inline my-1" role="search"> <label class="sr-only" for="header-search--input">Search</label> <input id="header-search--input" name="q" type="text" class="form-control form-control-sm" placeholder="Search University of California Health clinical trials" title="Search clinical trials at University of California Health"> <input class="sr-only form-control-sm btn btn-sm btn-secondary" type="submit" value="Search trials"> </form></div></div> </nav></header><main id="content" class="mx-1 mx-md-0"> <div class="container-md"><div id="condition-header"><h1 class="mb-2"> <strong>Glioma</strong> clinical trials at University of California Health </h1><p class="h3 mb-5 text-muted" id="condition-header--clinical-trial-counts"><span> 135 in progress, 53 open to eligible people </span></p></div><div class="row"> <div class="col col-xs-12 col-lg-10 "> <div class="trials-list--filter-container card bg-light text-center mb-3 d-none d-print-none" data-nosnippet><div class="card-body p-1"><span class="trials-list--filter-main-heading d-none d-md-inline"> Showing <span class="trials-list--number-of-trials-shown" aria-live="assertive"></span> trials for </span><div class="btn-group btn-group-sm btn-group-toggle ml-3" role="group" aria-label="Filter trials by sex/gender" data-toggle="buttons"> <label class="btn btn-light mr-1 active"> <input checked type="radio" name="trials-list--filter-sex" data-class-wanted=""> <i class="fa fa-male d-none d-lg-inline" aria-hidden="true"></i><i class="fa fa-female d-none d-lg-inline" aria-hidden="true"></i> All </label> <label class="btn btn-light mr-1"> <input type="radio" name="trials-list--filter-sex" data-class-wanted="trials-list--trial-open-to-sex-female"> <i class="fa fa-female d-none d-lg-inline" aria-hidden="true"></i> Female </label> <label class="btn btn-light mr-1"> <input type="radio" name="trials-list--filter-sex" data-class-wanted="trials-list--trial-open-to-sex-male"> <i class="fa fa-male d-none d-lg-inline" aria-hidden="true"></i> Male </label> </div><div class="btn-group btn-group-sm btn-group-toggle ml-3" role="group" aria-label="Filter trials by age range" data-toggle="buttons"> <label class="btn btn-light active"><input checked type="radio" name="trials-list--filter-age" data-class-wanted="">All ages</label> <label class="btn btn-light"><input type="radio" name="trials-list--filter-age" data-class-wanted="trials-list--trial-open-to-age-under-18">Under 18</label> <label class="btn btn-light"><input type="radio" name="trials-list--filter-age" data-class-wanted="trials-list--trial-open-to-age-18-and-over">Over 18</label> </div></div></div> <ul class="list-unstyled" id="trials-list"><li class="trials-list--trial card border trials-list--trial-joinable trials-list--trial-open-to-age-under-18 trials-list--trial-open-to-age-18-and-over trials-list--trial-open-to-sex-female trials-list--trial-open-to-sex-male trials-list--trial-institution-name-UCSF "><div class="card-body"><h2 class="h4 card-title"> <a href="https://clinicaltrials.ucbraid.org/trial/NCT04239092" class="stretched-link">9-ING-41 in Pediatric Patients with Refractory Malignancies.</a> </h2><div class="trials-list--trial-details"><p class="h6 "> <i class="fa fa-user d-none d-md-inline fa-small-icon" aria-hidden="true"></i> <i class="fa fa-user d-none d-md-inline" aria-hidden="true"></i> open to eligible people ages up to 22 years </p><div class="trials-list--trial-summary"><p>9-ING-41 has anti-cancer clinical activity with no significant toxicity in adult patients. This Phase 1 study will study its efficacy in paediatric patients with advanced malignancies.</p></div><p class="comma-list text-right text-muted"><small> <i class="fa fa-map-marker fa-fw" aria-hidden="true"></i> at <span class="comma-list-item"> <strong>UCSF</strong></span> </small></p></div></div></li><li class="trials-list--trial card border trials-list--trial-joinable trials-list--trial-open-to-age-18-and-over trials-list--trial-open-to-sex-female trials-list--trial-open-to-sex-male trials-list--trial-institution-name-UCSF "><div class="card-body"><h2 class="h4 card-title"> <a href="https://clinicaltrials.ucbraid.org/trial/NCT05753007" class="stretched-link">Hemp-Derived, High Cannabidiol Product for Anxiety in Glioblastoma Patients</a> </h2><div class="trials-list--trial-details"><p class="h6 "> <i class="fa fa-user d-none d-md-inline" aria-hidden="true"></i> open to eligible people ages 18 years and up </p><div class="trials-list--trial-summary"><p>Glioblastoma (GBM) is the most common malignant brain tumor among adults. As the diagnosis is generally considered terminal, patients with GBM often suffer from anxiety and other comorbid conditions, including depression, pain, and sleep disturbance, all of which significantly impact their quality of life. Previous studies have demonstrated the potential of cannabinoids, particularly cannabidiol (CBD), to improve the aforementioned symptoms without conferring significant risks or side effects. Further, recent in-vitro and in-vivo work suggests potential cytotoxic and anti-tumor effects of CBD and other cannabinoids. This study includes a double-blind, placebo-controlled, 8-week randomized clinical trial assessing the impact of a custom formulated, full-spectrum, hemp-derived ultra-high CBD product on measures of anxiety, pain, and quality of life in newly-diagnosed GBM patients undergoing standard of care (SOC) treatment; the impact of this product vs. placebo on tumor progression will also be assessed. The proposed clinical trial will provide important information that does not currently exist regarding the potential efficacy of a novel full-spectrum, ultra-high CBD product to address clinical symptoms in patients with GBM.</p></div><p class="comma-list text-right text-muted"><small> <i class="fa fa-map-marker fa-fw" aria-hidden="true"></i> at <span class="comma-list-item"> <strong>UCSF</strong></span> </small></p></div></div></li><li class="trials-list--trial card border trials-list--trial-joinable trials-list--trial-open-to-age-18-and-over trials-list--trial-open-to-sex-female trials-list--trial-open-to-sex-male trials-list--trial-institution-name-UCSF "><div class="card-body"><h2 class="h4 card-title"> <a href="https://clinicaltrials.ucbraid.org/trial/NCT05303467" class="stretched-link">Feasibility Study to Evaluate the Safety of the TheraSphere Glioblastoma (GBM) Device in Patients With Recurrent GBM</a> </h2><div class="trials-list--trial-details"><p class="h6 "> <i class="fa fa-user d-none d-md-inline" aria-hidden="true"></i> open to eligible people ages 18 years and up </p><div class="trials-list--trial-summary"><p>The FRONTIER Study is a prospective, interventional, single-arm, multi-center, study to assess the safety and technical feasibility of TheraSphere GBM in patients with recurrent GBM.</p></div><p class="comma-list text-right text-muted"><small> <i class="fa fa-map-marker fa-fw" aria-hidden="true"></i> at <span class="comma-list-item"> <strong>UCSF</strong></span> </small></p></div></div></li><li class="trials-list--trial card border trials-list--trial-joinable trials-list--trial-open-to-age-18-and-over trials-list--trial-open-to-sex-female trials-list--trial-open-to-sex-male trials-list--trial-institution-name-UCSF "><div class="card-body"><h2 class="h4 card-title"> <a href="https://clinicaltrials.ucbraid.org/trial/NCT05708352" class="stretched-link">Ketogenic Diet vs Standard Anti-cancer Diet Guidance for Patients With Glioblastoma in Combination With Standard-of-care Treatment</a> </h2><div class="trials-list--trial-details"><p class="h6 "> <i class="fa fa-user d-none d-md-inline" aria-hidden="true"></i> open to eligible people ages 18 years and up </p><div class="trials-list--trial-summary"><p>This is a Phase 2, randomized two-armed, multi-site study of 170 patients with newly diagnosed glioblastoma multiforme. Patients will be randomized 1:1 to receive Keto Diet, or Standard Anti-Cancer Diet. All patients will receive standard of care treatment for their glioblastoma. The Keto Diet intervention will be for an 18-week period and conducted by trained research dietitians. Daily ketone and glucose levels will be recorded to monitor Keto Diet adherence. This two-armed randomized multi-site study aims to provide evidence to support the hypothesis that a Keto Diet vs. Standard Anti-Cancer Diet improves overall survival in newly diagnosed glioblastoma multiforme patients who receive standard of care treatment.</p></div><p class="comma-list text-right text-muted"><small> <i class="fa fa-map-marker fa-fw" aria-hidden="true"></i> at <span class="comma-list-item"> <strong>UCSF</strong></span> </small></p></div></div></li><li class="trials-list--trial card border trials-list--trial-joinable trials-list--trial-open-to-age-18-and-over trials-list--trial-open-to-sex-female trials-list--trial-open-to-sex-male trials-list--trial-institution-name-UC%20Irvine "><div class="card-body"><h2 class="h4 card-title"> <a href="https://clinicaltrials.ucbraid.org/trial/NCT03862430" class="stretched-link">NanO2™ Combined With Radiation and Temozolomide in Patients With Newly Diagnosed GBM</a> </h2><div class="trials-list--trial-details"><p class="h6 "> <i class="fa fa-user d-none d-md-inline" aria-hidden="true"></i> open to eligible people ages 18 years and up </p><div class="trials-list--trial-summary"><p>This clinical trial is testing the safety and efficacy of NanO2TM administered via intravenous infusion in combination with standard radiation and chemotherapy. NanO2TM is being developed to increase the amount of oxygen delivered to tumors which is hoped to increase the effectiveness of radiation therapy.</p></div><p class="comma-list text-right text-muted"><small> <i class="fa fa-map-marker fa-fw" aria-hidden="true"></i> at <span class="comma-list-item"> <strong>UC Irvine</strong></span> </small></p></div></div></li><li class="trials-list--trial card border trials-list--trial-joinable trials-list--trial-open-to-age-under-18 trials-list--trial-open-to-age-18-and-over trials-list--trial-open-to-sex-female trials-list--trial-open-to-sex-male trials-list--trial-institution-name-UCSF "><div class="card-body"><h2 class="h4 card-title"> <a href="https://clinicaltrials.ucbraid.org/trial/NCT05099003" class="stretched-link">Drug Selinexor With Radiation Therapy in Patients With Newly-Diagnosed Diffuse Intrinsic Pontine (DIPG) Glioma and High-Grade Glioma (HGG)</a> </h2><div class="trials-list--trial-details"><p class="h6 "> <i class="fa fa-user d-none d-md-inline fa-small-icon" aria-hidden="true"></i> <i class="fa fa-user d-none d-md-inline" aria-hidden="true"></i> open to eligible people ages 12 months to 21 years </p><div class="trials-list--trial-summary"><p>This phase I/II trial tests the safety, side effects, and best dose of selinexor given in combination with standard radiation therapy in treating children and young adults with newly diagnosed diffuse intrinsic pontine glioma (DIPG) or high-grade glioma (HGG) with a genetic change called H3 K27M mutation. It also tests whether combination of selinexor and standard radiation therapy works to shrink tumors in this patient population. Glioma is a type of cancer that occurs in the brain or spine. Glioma is considered high risk (or high-grade) when it is growing and spreading quickly. The term, risk, refers to the chance of the cancer coming back after treatment. DIPG is a subtype of HGG that grows in the pons (a part of the brainstem that controls functions like breathing, swallowing, speaking, and eye movements). This trial has two parts. The only difference in treatment between the two parts is that some subjects treated in Part 1 may receive a different dose of selinexor than the subjects treated in Part 2. In Part 1 (also called the Dose-Finding Phase), investigators want to determine the dose of selinexor that can be given without causing side effects that are too severe. This dose is called the maximum tolerated dose (MTD). In Part 2 (also called the Efficacy Phase), investigators want to find out how effective the MTD of selinexor is against HGG or DIPG. Selinexor blocks a protein called CRM1, which may help keep cancer cells from growing and may kill them. It is a type of small molecule inhibitor called selective inhibitors of nuclear export (SINE). Radiation therapy uses high energy to kill tumor cells and shrink tumors. The combination of selinexor and radiation therapy may be effective in treating patients with newly-diagnosed DIPG and H3 K27M-Mutant HGG.</p></div><p class="comma-list text-right text-muted"><small> <i class="fa fa-map-marker fa-fw" aria-hidden="true"></i> at <span class="comma-list-item"> <strong>UCSF</strong></span> </small></p></div></div></li><li class="trials-list--trial card border trials-list--trial-joinable trials-list--trial-open-to-age-under-18 trials-list--trial-open-to-age-18-and-over trials-list--trial-open-to-sex-female trials-list--trial-open-to-sex-male trials-list--trial-institution-name-UCSF "><div class="card-body"><h2 class="h4 card-title"> <a href="https://clinicaltrials.ucbraid.org/trial/NCT03871257" class="stretched-link">Drugs Selumetinib Versus Carboplatin/Vincristine in Patients With Neurofibromatosis and Low-Grade Glioma</a> </h2><div class="trials-list--trial-details"><p class="h6 "> <i class="fa fa-user d-none d-md-inline fa-small-icon" aria-hidden="true"></i> <i class="fa fa-user d-none d-md-inline" aria-hidden="true"></i> open to eligible people ages 2-21 </p><div class="trials-list--trial-summary"><p>This phase III trial studies if selumetinib works just as well as the standard treatment with carboplatin/vincristine (CV) for subjects with NF1-associated low grade glioma (LGG), and to see if selumetinib is better than CV in improving vision in subjects with LGG of the optic pathway (vision nerves). Selumetinib is a drug that works by blocking some enzymes that low-grade glioma tumor cells need for their growth. This results in killing tumor cells. Drugs used as chemotherapy, such as carboplatin and vincristine, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. It is not yet known whether selumetinib works better in treating patients with NF1-associated low-grade glioma compared to standard therapy with carboplatin and vincristine.</p></div><p class="comma-list text-right text-muted"><small> <i class="fa fa-map-marker fa-fw" aria-hidden="true"></i> at <span class="comma-list-item"> <strong>UCSF</strong></span> </small></p></div></div></li><li class="trials-list--trial card border trials-list--trial-joinable trials-list--trial-open-to-age-under-18 trials-list--trial-open-to-age-18-and-over trials-list--trial-open-to-sex-female trials-list--trial-open-to-sex-male trials-list--trial-institution-name-UCLA trials-list--trial-institution-name-UCSF "><div class="card-body"><h2 class="h4 card-title"> <a href="https://clinicaltrials.ucbraid.org/trial/NCT04166409" class="stretched-link">Drugs Selumetinib vs. Carboplatin and Vincristine in Patients With Low-Grade Glioma</a> </h2><div class="trials-list--trial-details"><p class="h6 "> <i class="fa fa-user d-none d-md-inline fa-small-icon" aria-hidden="true"></i> <i class="fa fa-user d-none d-md-inline" aria-hidden="true"></i> open to eligible people ages 2-21 </p><div class="trials-list--trial-summary"><p>This phase III trial compares the effect of selumetinib versus the standard of care treatment with carboplatin and vincristine (CV) in treating patients with newly diagnosed or previously untreated low-grade glioma (LGG) that does not have a genetic abnormality called BRAFV600E mutation and is not associated with systemic neurofibromatosis type 1. Selumetinib works by blocking some of the enzymes needed for cell growth and may kill tumor cells. Carboplatin and vincristine are chemotherapy drugs that work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. The overall goal of this study is to see if selumetinib works just as well as the standard treatment of CV for patients with LGG. Another goal of this study is to compare the effects of selumetinib versus CV in subjects with LGG to find out which is better. Additionally, this trial will also examine if treatment with selumetinib improves the quality of life for subjects who take it.</p></div><p class="comma-list text-right text-muted"><small> <i class="fa fa-map-marker fa-fw" aria-hidden="true"></i> at <span class="comma-list-item"> <strong>UCLA</strong></span><span class="comma-list-item"> <strong>UCSF</strong></span> </small></p></div></div></li><li class="trials-list--trial card border trials-list--trial-joinable trials-list--trial-open-to-age-under-18 trials-list--trial-open-to-age-18-and-over trials-list--trial-open-to-sex-female trials-list--trial-open-to-sex-male trials-list--trial-institution-name-UCSF "><div class="card-body"><h2 class="h4 card-title"> <a href="https://clinicaltrials.ucbraid.org/trial/NCT04775485" class="stretched-link">DAY101 in Pediatric and Young Adult Patients With Relapsed or Progressive Low-Grade Glioma and Advance Solid Tumors</a> </h2><div class="trials-list--trial-details"><p class="h6 "> <i class="fa fa-user d-none d-md-inline fa-small-icon" aria-hidden="true"></i> <i class="fa fa-user d-none d-md-inline" aria-hidden="true"></i> open to eligible people ages 6 months to 25 years </p><div class="trials-list--trial-summary"><p>FIREFLY-1 is an ongoing, Phase 2, multi center, open-label study to evaluate the safety and efficacy of oral pan-RAF inhibitor DAY101 in pediatric, adolescent, and young adult patients with recurrent or progressive low-grade glioma or an advanced solid tumor harboring a known RAF alteration.</p></div><p class="comma-list text-right text-muted"><small> <i class="fa fa-map-marker fa-fw" aria-hidden="true"></i> at <span class="comma-list-item"> <strong>UCSF</strong></span> </small></p></div></div></li><li class="trials-list--trial card border trials-list--trial-joinable trials-list--trial-open-to-age-under-18 trials-list--trial-open-to-age-18-and-over trials-list--trial-open-to-sex-female trials-list--trial-open-to-sex-male trials-list--trial-institution-name-UCSD trials-list--trial-institution-name-UCSF "><div class="card-body"><h2 class="h4 card-title"> <a href="https://clinicaltrials.ucbraid.org/trial/NCT05503264" class="stretched-link">Pharmacodynamics Of Satralizumab In Patients With Anti-N-Methyl-D-Aspartic Acid Receptor (NMDAR) Or Anti-Leucine-Rich Glioma-Inactivated 1 (LGI1) Encephalitis</a> </h2><div class="trials-list--trial-details"><p class="h6 "> <i class="fa fa-user d-none d-md-inline fa-small-icon" aria-hidden="true"></i> <i class="fa fa-user d-none d-md-inline" aria-hidden="true"></i> open to eligible people ages 12 years and up </p><div class="trials-list--trial-summary"><p>The purpose of this study is to assess the efficacy, safety, pharmacokinetics, and pharmacodynamics of satralizumab in participants with anti-N-methyl-D-aspartic acid receptor (NMDAR) and anti-leucine-rich glioma-inactivated 1 (LGI1) encephalitis.</p></div><p class="comma-list text-right text-muted"><small> <i class="fa fa-map-marker fa-fw" aria-hidden="true"></i> at <span class="comma-list-item"> <strong>UCSD</strong></span><span class="comma-list-item"> <strong>UCSF</strong></span> </small></p></div></div></li><li class="trials-list--trial card border trials-list--trial-joinable trials-list--trial-open-to-age-18-and-over trials-list--trial-open-to-sex-female trials-list--trial-open-to-sex-male trials-list--trial-institution-name-UC%20Irvine "><div class="card-body"><h2 class="h4 card-title"> <a href="https://clinicaltrials.ucbraid.org/trial/NCT05916313" class="stretched-link">Test How Well Different Doses of BI 764532 Are Tolerated by People With a Tumour in the Brain That is Positive for DLL3</a> </h2><div class="trials-list--trial-details"><p class="h6 "> <i class="fa fa-user d-none d-md-inline" aria-hidden="true"></i> open to eligible people ages 18 years and up </p><div class="trials-list--trial-summary"><p>This study (1438-0003) is open to adults with a tumour in the brain that is positive for the tumour marker delta-like 3 (DLL3). This study is in people with advanced cancer for whom previous treatment was not successful. The purpose of this study is to find out the highest dose of BI 764532 that people with a brain tumour that is positive for DLL3 can tolerate. BI 764532 is an antibody-like molecule that can attach and link together the cancer cells and T-cells of the immune system (DLL3/CD3 bispecific). This may help the immune system fight cancer. Participants get BI 764532 infusions into a vein when starting treatment. If there is benefit for the participants and if they can tolerate it, the treatment is continued. During this time, participants visit the study site at regular intervals. The total number of visits depends on how they respond to and tolerate the treatment. The first study visits include staying to monitor participants' safety. Doctors record any unwanted effects and regularly check the general health of the participants.</p></div><p class="comma-list text-right text-muted"><small> <i class="fa fa-map-marker fa-fw" aria-hidden="true"></i> at <span class="comma-list-item"> <strong>UC Irvine</strong></span> </small></p></div></div></li><li class="trials-list--trial card border trials-list--trial-joinable trials-list--trial-open-to-age-18-and-over trials-list--trial-open-to-sex-female trials-list--trial-open-to-sex-male trials-list--trial-institution-name-UC%20Davis trials-list--trial-institution-name-UCLA "><div class="card-body"><h2 class="h4 card-title"> <a href="https://clinicaltrials.ucbraid.org/trial/NCT04678648" class="stretched-link">RSC-1255 for Treatment of Patients With Advanced Malignancies</a> </h2><div class="trials-list--trial-details"><p class="h6 "> <i class="fa fa-user d-none d-md-inline" aria-hidden="true"></i> open to eligible people ages 18 years and up </p><div class="trials-list--trial-summary"><p>RSC-101 is a Phase 1a/1b clinical trial of RSC-1255 in adult study participants with advanced solid tumor malignancies who are intolerant of existing therapies known to provide clinical benefit, have disease that has progressed after standard therapy, or have previously failed other therapies. The study has two phases. The purpose of Phase 1a (Dose Escalation) is to confirm the appropriate treatment dose and Phase 1b (Dose Expansion) is to characterize the safety and efficacy of RSC-1255.</p></div><p class="comma-list text-right text-muted"><small> <i class="fa fa-map-marker fa-fw" aria-hidden="true"></i> at <span class="comma-list-item"> <strong>UC Davis</strong></span><span class="comma-list-item"> <strong>UCLA</strong></span> </small></p></div></div></li><li class="trials-list--trial card border trials-list--trial-joinable trials-list--trial-open-to-age-18-and-over trials-list--trial-open-to-sex-female trials-list--trial-open-to-sex-male trials-list--trial-institution-name-UCLA trials-list--trial-institution-name-UCSD trials-list--trial-institution-name-UCSF "><div class="card-body"><h2 class="h4 card-title"> <a href="https://clinicaltrials.ucbraid.org/trial/NCT03970447" class="stretched-link">Evaluate Multiple Regimens in Newly Diagnosed and Recurrent Glioblastoma</a> </h2><div class="trials-list--trial-details"><p class="h6 "> <i class="fa fa-user d-none d-md-inline" aria-hidden="true"></i> open to eligible people ages 18 years and up </p><div class="trials-list--trial-summary"><p>Glioblastoma (GBM) adaptive, global, innovative learning environment (GBM AGILE) is an international, seamless Phase II/III response adaptive randomization platform trial designed to evaluate multiple therapies in newly diagnosed (ND) and recurrent GBM.</p></div><p class="comma-list text-right text-muted"><small> <i class="fa fa-map-marker fa-fw" aria-hidden="true"></i> at <span class="comma-list-item"> <strong>UCLA</strong></span><span class="comma-list-item"> <strong>UCSD</strong></span><span class="comma-list-item"> <strong>UCSF</strong></span> </small></p></div></div></li><li class="trials-list--trial card border trials-list--trial-joinable trials-list--trial-open-to-age-18-and-over trials-list--trial-open-to-sex-female trials-list--trial-open-to-sex-male trials-list--trial-institution-name-UCSF "><div class="card-body"><h2 class="h4 card-title"> <a href="https://clinicaltrials.ucbraid.org/trial/NCT04656535" class="stretched-link">AB154 Combined With AB122 for Recurrent Glioblastoma</a> </h2><div class="trials-list--trial-details"><p class="h6 "> <i class="fa fa-user d-none d-md-inline" aria-hidden="true"></i> open to eligible people ages 18 years and up </p><div class="trials-list--trial-summary"><p>This is a phase 0/I exploratory study. Patients at first or second recurrence of glioblastoma will be enrolled. The study will be divided into two cohorts: Cohort A (safety cohort) and Cohort B (surgical patient cohort). Cohort A: Eligible patients will be sequentially enrolled to receive intravenous AB154 combined with AB122 (N=6). AB154 will be given at a dose of 10 mg/kg and AB122 will be given at a dose of 240 mg (flat). Cohort B: Expansion surgical cohort. The purpose of cohort B is to provide an additional safety evaluation of AB154 + AB122 as well as tissue and blood for exploratory ancillary studies investigating the effects of AB154 + AB122 in the tumor and tumor microenvironment. A total of 40 patients will be enrolled in this cohort.</p></div><p class="comma-list text-right text-muted"><small> <i class="fa fa-map-marker fa-fw" aria-hidden="true"></i> at <span class="comma-list-item"> <strong>UCSF</strong></span> </small></p></div></div></li><li class="trials-list--trial card border trials-list--trial-joinable trials-list--trial-open-to-age-18-and-over trials-list--trial-open-to-sex-female trials-list--trial-open-to-sex-male trials-list--trial-institution-name-UCSF "><div class="card-body"><h2 class="h4 card-title"> <a href="https://clinicaltrials.ucbraid.org/trial/NCT06186401" class="stretched-link">Anti-EGFRvIII synNotch Receptor Induced Anti-EphA2/IL-13Ralpha2 CAR (E-SYNC) T Cells</a> </h2><div class="trials-list--trial-details"><p class="h6 "> <i class="fa fa-user d-none d-md-inline" aria-hidden="true"></i> open to eligible people ages 18 years and up </p><div class="trials-list--trial-summary"><p>This phase I trial tests the safety, side effects, and best dose of E-SYNC chimeric antigen receptor (CAR) T cells after lymphodepleting chemotherapy in treating patients with EGFRvIII positive (+) glioblastoma. Chimeric antigen receptor (CAR) T-cell therapy is a type of treatment in which a patient's T cells (a type of immune system cell) are changed in the laboratory so the CAR T cells will attack cancer cells. T cells are taken from a patient's blood. Then the gene for a special receptor that binds to a certain protein on the patient's cancer cells is added to the T cells in the laboratory. The special receptor is called a chimeric antigen receptor. Large numbers of the CAR T cells are grown in the laboratory and given to the patient by infusion for treatment of certain cancers. Lymphodepleting chemotherapy with cyclophosphamide and fludarabine before treatment with CAR T cells may make the CAR T cells more effective.</p></div><p class="comma-list text-right text-muted"><small> <i class="fa fa-map-marker fa-fw" aria-hidden="true"></i> at <span class="comma-list-item"> <strong>UCSF</strong></span> </small></p></div></div></li><li class="trials-list--trial card border trials-list--trial-joinable trials-list--trial-open-to-age-under-18 trials-list--trial-open-to-age-18-and-over trials-list--trial-open-to-sex-female trials-list--trial-open-to-sex-male trials-list--trial-institution-name-UCSF "><div class="card-body"><h2 class="h4 card-title"> <a href="https://clinicaltrials.ucbraid.org/trial/NCT03749187" class="stretched-link">BGB-290 and Temozolomide in Treating Isocitrate Dehydrogenase (IDH)1/2-Mutant Grade I-IV Gliomas</a> </h2><div class="trials-list--trial-details"><p class="h6 "> <i class="fa fa-user d-none d-md-inline fa-small-icon" aria-hidden="true"></i> <i class="fa fa-user d-none d-md-inline" aria-hidden="true"></i> open to eligible people ages 13-25 </p><div class="trials-list--trial-summary"><p>This phase I trial studies the side effects and best dose of BGB-290 and temozolomide in treating adolescents and young adults with IDH1/2-mutant grade I-IV glioma that is newly diagnosed or has come back. BGB-290 may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as temozolomide, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving BGB-290 and temozolomide may work better in treating adolescents and young adults with IDH1/2-mutant grade I-IV glioma.</p></div><p class="comma-list text-right text-muted"><small> <i class="fa fa-map-marker fa-fw" aria-hidden="true"></i> at <span class="comma-list-item"> <strong>UCSF</strong></span> </small></p></div></div></li><li class="trials-list--trial card border trials-list--trial-joinable trials-list--trial-open-to-age-18-and-over trials-list--trial-open-to-sex-female trials-list--trial-open-to-sex-male trials-list--trial-institution-name-UCLA "><div class="card-body"><h2 class="h4 card-title"> <a href="https://clinicaltrials.ucbraid.org/trial/NCT06059690" class="stretched-link">Biologic Association Between Metabolic Magnetic Resonance-positron Emission Tomograph (MR-PET) and Tissue Measures of Glycolysis in Brain Tumors of Infiltrating Glioblastoma Cells</a> </h2><div class="trials-list--trial-details"><p class="h6 "> <i class="fa fa-user d-none d-md-inline" aria-hidden="true"></i> open to eligible people ages 18 years and up </p><div class="trials-list--trial-summary"><p>The purpose of this project is to validate a new combined MRI and PET imaging technique as a biomarker or measure of glycolysis in brain tumors. To accomplish this, the investigators propose obtaining image-guided measures of tissue pH and biopsied tissue in tumor areas selected for bulk resection surgery. Investigators will then correlate the imaging measurements with pH, RNA expression, protein expression, and bioenergetics measurements of key glycolytic enzymes.</p></div><p class="comma-list text-right text-muted"><small> <i class="fa fa-map-marker fa-fw" aria-hidden="true"></i> at <span class="comma-list-item"> <strong>UCLA</strong></span> </small></p></div></div></li><li class="trials-list--trial card border trials-list--trial-joinable trials-list--trial-open-to-age-18-and-over trials-list--trial-open-to-sex-female trials-list--trial-open-to-sex-male trials-list--trial-institution-name-UCLA trials-list--trial-institution-name-UCSF "><div class="card-body"><h2 class="h4 card-title"> <a href="https://clinicaltrials.ucbraid.org/trial/NCT05383872" class="stretched-link">Blood-Brain Barrier Disruption (BBBD) for Liquid Biopsy in Subjects With GlioBlastoma Brain Tumors</a> </h2><div class="trials-list--trial-details"><p class="h6 "> <i class="fa fa-user d-none d-md-inline" aria-hidden="true"></i> open to eligible people ages 18-80 </p><div class="trials-list--trial-summary"><p>The purpose of this study is to evaluate the safety and efficacy of targeted blood brain barrier disruption with Exablate Model 4000 Type 2.0/2.1 for liquid biopsy in subjects with suspected Glioblastoma brain tumors</p></div><p class="comma-list text-right text-muted"><small> <i class="fa fa-map-marker fa-fw" aria-hidden="true"></i> at <span class="comma-list-item"> <strong>UCLA</strong></span><span class="comma-list-item"> <strong>UCSF</strong></span> </small></p></div></div></li><li class="trials-list--trial card border trials-list--trial-joinable trials-list--trial-open-to-age-under-18 trials-list--trial-open-to-age-18-and-over trials-list--trial-open-to-sex-female trials-list--trial-open-to-sex-male trials-list--trial-institution-name-UCSF "><div class="card-body"><h2 class="h4 card-title"> <a href="https://clinicaltrials.ucbraid.org/trial/NCT04870944" class="stretched-link">CBL0137 for the Treatment of Relapsed or Refractory Solid Tumors, Including CNS Tumors and Lymphoma</a> </h2><div class="trials-list--trial-details"><p class="h6 "> <i class="fa fa-user d-none d-md-inline fa-small-icon" aria-hidden="true"></i> <i class="fa fa-user d-none d-md-inline" aria-hidden="true"></i> open to eligible people ages 12 months to 30 years </p><div class="trials-list--trial-summary"><p>This phase I/II trial evaluates the best dose, side effects and possible benefit of CBL0137 in treating patients with solid tumors, including central nervous system (CNS) tumors or lymphoma that has come back (relapsed) or does not respond to treatment (refractory). Drugs, such as CBL0137, block signals passed from one molecule to another inside a cell. Blocking these signals can affect many functions of the cell, including cell division and cell death, and may kill cancer cells.</p></div><p class="comma-list text-right text-muted"><small> <i class="fa fa-map-marker fa-fw" aria-hidden="true"></i> at <span class="comma-list-item"> <strong>UCSF</strong></span> </small></p></div></div></li><li class="trials-list--trial card border trials-list--trial-joinable trials-list--trial-open-to-age-under-18 trials-list--trial-open-to-age-18-and-over trials-list--trial-open-to-sex-female trials-list--trial-open-to-sex-male trials-list--trial-institution-name-UCSD trials-list--trial-institution-name-UCSF "><div class="card-body"><h2 class="h4 card-title"> <a href="https://clinicaltrials.ucbraid.org/trial/NCT05009992" class="stretched-link">Combination Therapy for the Treatment of Diffuse Midline Gliomas</a> </h2><div class="trials-list--trial-details"><p class="h6 "> <i class="fa fa-user d-none d-md-inline fa-small-icon" aria-hidden="true"></i> <i class="fa fa-user d-none d-md-inline" aria-hidden="true"></i> open to eligible people ages 2-39 </p><div class="trials-list--trial-summary"><p>This phase II trial determines if the combination of ONC201 with different drugs, panobinostat or paxalisib, is effective for treating participants with diffuse midline gliomas (DMGs). Despite years of research, little to no progress has been made to improve outcomes for participants with DMGs, and there are few treatment options. ONC201, panobinostat, and paxalisib are all enzyme inhibitors that may stop the growth of tumor cells by clocking some of the enzymes needed for cell growth. This phase II trial assesses different combinations of these drugs for the treatment of DMGs.</p></div><p class="comma-list text-right text-muted"><small> <i class="fa fa-map-marker fa-fw" aria-hidden="true"></i> at <span class="comma-list-item"> <strong>UCSD</strong></span><span class="comma-list-item"> <strong>UCSF</strong></span> </small></p></div></div></li><li class="trials-list--trial card border trials-list--trial-joinable trials-list--trial-open-to-age-under-18 trials-list--trial-open-to-age-18-and-over trials-list--trial-open-to-sex-female trials-list--trial-open-to-sex-male trials-list--trial-institution-name-UC%20Davis trials-list--trial-institution-name-UCLA trials-list--trial-institution-name-UCSF "><div class="card-body"><h2 class="h4 card-title"> <a href="https://clinicaltrials.ucbraid.org/trial/NCT03919071" class="stretched-link">Dabrafenib Combined With Trametinib After Radiation Therapy in Treating Patients With Newly-Diagnosed High-Grade Glioma</a> </h2><div class="trials-list--trial-details"><p class="h6 "> <i class="fa fa-user d-none d-md-inline fa-small-icon" aria-hidden="true"></i> <i class="fa fa-user d-none d-md-inline" aria-hidden="true"></i> open to eligible people ages 3-25 </p><div class="trials-list--trial-summary"><p>This phase II trial studies how well the combination of dabrafenib and trametinib works after radiation therapy in children and young adults with high grade glioma who have a genetic change called BRAF V600 mutation. Radiation therapy uses high energy rays to kill tumor cells and reduce the size of tumors. Dabrafenib and trametinib may stop the growth of tumor cells by blocking BRAF and MEK, respectively, which are enzymes that tumor cells need for their growth. Giving dabrafenib with trametinib after radiation therapy may work better than treatments used in the past in patients with newly-diagnosed BRAF V600-mutant high-grade glioma.</p></div><p class="comma-list text-right text-muted"><small> <i class="fa fa-map-marker fa-fw" aria-hidden="true"></i> at <span class="comma-list-item"> <strong>UC Davis</strong></span><span class="comma-list-item"> <strong>UCLA</strong></span><span class="comma-list-item"> <strong>UCSF</strong></span> </small></p></div></div></li><li class="trials-list--trial card border trials-list--trial-joinable trials-list--trial-open-to-age-under-18 trials-list--trial-open-to-age-18-and-over trials-list--trial-open-to-sex-female trials-list--trial-open-to-sex-male trials-list--trial-institution-name-UCSF "><div class="card-body"><h2 class="h4 card-title"> <a href="https://clinicaltrials.ucbraid.org/trial/NCT05566795" class="stretched-link">DAY101 Vs. Standard of Care Chemotherapy in Pediatric Patients with Low-Grade Glioma Requiring First-Line Systemic Therapy (LOGGIC/FIREFLY-2)</a> </h2><div class="trials-list--trial-details"><p class="h6 "> <i class="fa fa-user d-none d-md-inline fa-small-icon" aria-hidden="true"></i> <i class="fa fa-user d-none d-md-inline" aria-hidden="true"></i> open to eligible people ages up to 25 years </p><div class="trials-list--trial-summary"><p>This is a 2-arm, randomized, open-label, multicenter, global, Phase 3 trial to evaluate the efficacy, safety, and tolerability of tovorafenib monotherapy versus standard of care (SoC) chemotherapy in patients with pediatric low-grade glioma (LGG) harboring an activating rapidly accelerated fibrosarcoma (RAF) alteration requiring front-line systemic therapy.</p></div><p class="comma-list text-right text-muted"><small> <i class="fa fa-map-marker fa-fw" aria-hidden="true"></i> at <span class="comma-list-item"> <strong>UCSF</strong></span> </small></p></div></div></li><li class="trials-list--trial card border trials-list--trial-joinable trials-list--trial-open-to-age-18-and-over trials-list--trial-open-to-sex-female trials-list--trial-open-to-sex-male trials-list--trial-institution-name-UC%20Irvine "><div class="card-body"><h2 class="h4 card-title"> <a href="https://clinicaltrials.ucbraid.org/trial/NCT03115333" class="stretched-link">DSC-MRI in Measuring rCBV for Early Response to Bevacizumab in Patients With Recurrent Glioblastoma</a> </h2><div class="trials-list--trial-details"><p class="h6 "> <i class="fa fa-user d-none d-md-inline" aria-hidden="true"></i> open to eligible people ages 18 years and up </p><div class="trials-list--trial-summary"><p>This phase II trial studies how well dynamic susceptibility contrast-enhanced magnetic resonance imaging (DSC-MRI) works in measuring relative cerebral blood volume (rCBV) for early response to bevacizumab in patients with glioblastoma that has come back. DSC-MRI may help evaluate changes in the blood vessels within the cancer to determine a patient?s response to treatment.</p></div><p class="comma-list text-right text-muted"><small> <i class="fa fa-map-marker fa-fw" aria-hidden="true"></i> at <span class="comma-list-item"> <strong>UC Irvine</strong></span> </small></p></div></div></li><li class="trials-list--trial card border trials-list--trial-joinable trials-list--trial-open-to-age-under-18 trials-list--trial-open-to-age-18-and-over trials-list--trial-open-to-sex-female trials-list--trial-open-to-sex-male trials-list--trial-institution-name-UC%20Davis trials-list--trial-institution-name-UCSF "><div class="card-body"><h2 class="h4 card-title"> <a href="https://clinicaltrials.ucbraid.org/trial/NCT03213652" class="stretched-link">Ensartinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With ALK or ROS1 Genomic Alterations (A Pediatric MATCH Treatment Trial)</a> </h2><div class="trials-list--trial-details"><p class="h6 "> <i class="fa fa-user d-none d-md-inline fa-small-icon" aria-hidden="true"></i> <i class="fa fa-user d-none d-md-inline" aria-hidden="true"></i> open to eligible people ages 12 months to 21 years </p><div class="trials-list--trial-summary"><p>This phase II Pediatric MATCH treatment trial studies how well ensartinib works in treating patients with solid tumors, non-Hodgkin lymphoma, or histiocytic disorders with ALK or ROS1 genomic alterations that have come back (recurrent) or does not respond to treatment (refractory) and may have spread from where it first started to nearby tissue, lymph nodes, or distant parts of the body (advanced). Ensartinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.</p></div><p class="comma-list text-right text-muted"><small> <i class="fa fa-map-marker fa-fw" aria-hidden="true"></i> at <span class="comma-list-item"> <strong>UC Davis</strong></span><span class="comma-list-item"> <strong>UCSF</strong></span> </small></p></div></div></li><li class="trials-list--trial card border trials-list--trial-joinable trials-list--trial-open-to-age-18-and-over trials-list--trial-open-to-sex-female trials-list--trial-open-to-sex-male trials-list--trial-institution-name-UCSD "><div class="card-body"><h2 class="h4 card-title"> <a href="https://clinicaltrials.ucbraid.org/trial/NCT05634707" class="stretched-link">Fluoxetine and Cytotoxic Lysosomal Stress in Glioma (FLIRT)</a> </h2><div class="trials-list--trial-details"><p class="h6 "> <i class="fa fa-user d-none d-md-inline" aria-hidden="true"></i> open to eligible people ages 24 years and up </p><div class="trials-list--trial-summary"><p>The purpose of this research study is to determine if fluoxetine increases lysosomal stress in patients with recurrent IDHwt glioma by evaluating LAMP1 expression in tumor samples obtained pre-resection via biopsy and during surgery. Lysosomes are organelles (structures in cells) that contain digestive enzymes (substances that break down chemicals) that help keep the cells free of extra or worn out cell parts. Fluoxetine, a drug approved by the FDA to treat problems like depression and anxiety, can cause changes to structures in cells called lysosomes that then improve how well the chemotherapy drug temozolomide (TMZ) kills cancer cells in the brain.</p></div><p class="comma-list text-right text-muted"><small> <i class="fa fa-map-marker fa-fw" aria-hidden="true"></i> at <span class="comma-list-item"> <strong>UCSD</strong></span> </small></p></div></div></li><li class="trials-list--trial card border trials-list--trial-joinable trials-list--trial-open-to-age-18-and-over trials-list--trial-open-to-sex-female trials-list--trial-open-to-sex-male trials-list--trial-institution-name-UCLA "><div class="card-body"><h2 class="h4 card-title"> <a href="https://clinicaltrials.ucbraid.org/trial/NCT02902757" class="stretched-link">FDG PET/CT in Monitoring Very Early Therapy Response in Patients With Glioblastoma</a> </h2><div class="trials-list--trial-details"><p class="h6 "> <i class="fa fa-user d-none d-md-inline" aria-hidden="true"></i> open to eligible people ages 18-99 </p><div class="trials-list--trial-summary"><p>This pilot clinical trial studies fluordeoxyglucose (fludeoxyglucose) F-18 (FDG) positron emission tomography (PET)/computed tomography (CT) in monitoring very early therapy response in patients with glioblastoma. Diagnostic procedures, such as FDG PET/CT, may help measure a patient's response to earlier treatment. Chemotherapy can induce very rapid changes to the tumor's glucose consumption which can be measured with imaging. FDG PET/CT shortly after the start of therapy may help identify very early therapy response in patients with glioblastoma.</p></div><p class="comma-list text-right text-muted"><small> <i class="fa fa-map-marker fa-fw" aria-hidden="true"></i> at <span class="comma-list-item"> <strong>UCLA</strong></span> </small></p></div></div></li><li class="trials-list--trial card border trials-list--trial-joinable trials-list--trial-open-to-age-18-and-over trials-list--trial-open-to-sex-female trials-list--trial-open-to-sex-male trials-list--trial-institution-name-UC%20Davis "><div class="card-body"><h2 class="h4 card-title"> <a href="https://clinicaltrials.ucbraid.org/trial/NCT05342883" class="stretched-link">GammaTile and Stupp in Newly Diagnosed GBM</a> </h2><div class="trials-list--trial-details"><p class="h6 "> <i class="fa fa-user d-none d-md-inline" aria-hidden="true"></i> open to eligible people ages 18 years and up </p><div class="trials-list--trial-summary"><p>In summary, standard of care postoperative chemoradiation for patients with newly diagnosed GBM does not routinely provide durable local control or prolonged overall survival. As discussed above it seems unlikely that patient outcomes will be significantly improved with radiation dose escalation given at the time of the EBRT boost. However, as most failures are local, improving LC could potentially improve the OS of patients. To do this, we propose a shift in the traditional radiation paradigm. This study will assess the feasibility and tolerability of adding GT radiation therapy as an upfront boost at the time of maximum safe resection, along with the backbone of the current standard of care approach, concomitant and adjuvant temozolomide +/- TTF, for patients with newly diagnosed GBM. GT, a novel brain brachytherapy device utilizing Cs-131 embedded in bioresorbable collagen tiles, offers a more sophisticated carrier and a shorter half-life radioisotope, Cs-131. Use of this device allows for radiation initiation at an earlier time point and a more rapid dose delivery and possibly more effective tumor control particularly for rapidly proliferating tumors such as GBM. Two prospective studies have demonstrated the safety and efficacy of re-irradiation with GT in patients with recurrent GBM. The overarching goal of this single-arm, open label phase 4 study is to determine the feasibility and tolerability of treating patients with GammaTile in combination with the Stupp Protocol and how to proceed with testing this treatment in a future, larger, randomized clinical study. The aims of the study are to demonstrate that the use of GammaTile at the time of surgery is well tolerated and does not delay the start of the Stupp protocol. Efficacy outcomes (e.g., LC, OS, PFS) will also be described.</p></div><p class="comma-list text-right text-muted"><small> <i class="fa fa-map-marker fa-fw" aria-hidden="true"></i> at <span class="comma-list-item"> <strong>UC Davis</strong></span> </small></p></div></div></li><li class="trials-list--trial card border trials-list--trial-joinable trials-list--trial-open-to-age-18-and-over trials-list--trial-open-to-sex-female trials-list--trial-open-to-sex-male trials-list--trial-institution-name-UCLA "><div class="card-body"><h2 class="h4 card-title"> <a href="https://clinicaltrials.ucbraid.org/trial/NCT04119024" class="stretched-link">Gene Modified Immune Cells (IL13Ralpha2 CAR T Cells) After Conditioning Regimen for the Treatment of Stage IIIC or IV Melanoma or Metastatic Solid Tumors</a> </h2><div class="trials-list--trial-details"><p class="h6 "> <i class="fa fa-user d-none d-md-inline" aria-hidden="true"></i> open to eligible people ages 18-70 </p><div class="trials-list--trial-summary"><p>This phase I trial studies the side effects and best dose of modified immune cells (IL13Ralpha2 CAR T cells) after a chemotherapy conditioning regimen for the treatment of patients with stage IIIC or IV melanoma or solid tumors that have spread to other places in the body (metastatic). The study agent is called IL13Ralpha2 CAR T cells. T cells are a special type of white blood cell (immune cells) that have the ability to kill tumor cells. The T cells are obtained from the patient's own blood, grown in a laboratory, and modified by adding the IL13Ralpha2 CAR gene. The IL13Ralpha2 CAR gene is inserted into T cells with a virus called a lentivirus. The lentivirus allows cells to make the IL13Ralpha2 CAR protein. This CAR has been designed to bind to a protein on the surface of tumor cells called IL13Ralpha2. This study is being done to determine the dose at which the gene-modified immune cells are safe, how long the cells stay in the body, and if the cells are able to attack the cancer.</p></div><p class="comma-list text-right text-muted"><small> <i class="fa fa-map-marker fa-fw" aria-hidden="true"></i> at <span class="comma-list-item"> <strong>UCLA</strong></span> </small></p></div></div></li><li class="trials-list--trial card border trials-list--trial-joinable trials-list--trial-open-to-age-under-18 trials-list--trial-open-to-age-18-and-over trials-list--trial-open-to-sex-female trials-list--trial-open-to-sex-male trials-list--trial-institution-name-UCSF "><div class="card-body"><h2 class="h4 card-title"> <a href="https://clinicaltrials.ucbraid.org/trial/NCT05478837" class="stretched-link">Genetically Modified Cells (KIND T Cells) for the Treatment of HLA-A*0201-Positive Patients With H3.3K27M-Mutated Glioma</a> </h2><div class="trials-list--trial-details"><p class="h6 "> <i class="fa fa-user d-none d-md-inline fa-small-icon" aria-hidden="true"></i> <i class="fa fa-user d-none d-md-inline" aria-hidden="true"></i> open to eligible people ages 3-25 </p><div class="trials-list--trial-summary"><p>This phase I, first-in-human trial tests the safety, side effects, and best dose of genetically modified cells called KIND T cells after lymphodepletion (a short dose of chemotherapy) in treating patients who are HLA-A*0201-positive and have H3.3K27M-mutated diffuse midline glioma. KIND T cells are a type of treatment in which a patient's T cells (a type of immune system cell) are changed in the laboratory into KIND T cells so they will recognize certain markers found in tumor cells. Drugs such as cyclophosphamide and fludarabine are chemotherapy drugs used to decrease the number of T cells in the body to make room for KIND T cells. Giving KIND T cells after cyclophosphamide and fludarabine may be more useful against cancer compared to the usual treatment for patients with H3.3K27M-mutated diffuse midline glioma (DMG).</p></div><p class="comma-list text-right text-muted"><small> <i class="fa fa-map-marker fa-fw" aria-hidden="true"></i> at <span class="comma-list-item"> <strong>UCSF</strong></span> </small></p></div></div></li><li class="trials-list--trial card border trials-list--trial-joinable trials-list--trial-open-to-age-18-and-over trials-list--trial-open-to-sex-female trials-list--trial-open-to-sex-male trials-list--trial-institution-name-UCSF "><div class="card-body"><h2 class="h4 card-title"> <a href="https://clinicaltrials.ucbraid.org/trial/NCT05851378" class="stretched-link">Hyperpolarized Carbon-13 Alpha-ketoglutarate Imaging in IDH Mutant Glioma</a> </h2><div class="trials-list--trial-details"><p class="h6 "> <i class="fa fa-user d-none d-md-inline" aria-hidden="true"></i> open to eligible people ages 18 years and up </p><div class="trials-list--trial-summary"><p>This study will investigate the use of hyperpolarized (HP) carbon-13 (13C) alpha-ketoglutarate (aKG) (HP 13C-aKG) to characterize tumor burden in patients with isocitrate dehydrogenase (IDH) mutant glioma.</p></div><p class="comma-list text-right text-muted"><small> <i class="fa fa-map-marker fa-fw" aria-hidden="true"></i> at <span class="comma-list-item"> <strong>UCSF</strong></span> </small></p></div></div></li><li class="trials-list--trial card border trials-list--trial-joinable trials-list--trial-open-to-age-18-and-over trials-list--trial-open-to-sex-female trials-list--trial-open-to-sex-male trials-list--trial-institution-name-UCSF "><div class="card-body"><h2 class="h4 card-title"> <a href="https://clinicaltrials.ucbraid.org/trial/NCT03739411" class="stretched-link">Hyperpolarized Imaging in Diagnosing Participants With Glioma</a> </h2><div class="trials-list--trial-details"><p class="h6 "> <i class="fa fa-user d-none d-md-inline" aria-hidden="true"></i> open to eligible people ages 19 years and up </p><div class="trials-list--trial-summary"><p>This pilot trial studies the side effects of hyperpolarized carbon C 13 pyruvate magnetic resonance imaging (MRI) in diagnosing participants with glioma. Diagnostic procedures, such as hyperpolarized carbon C 13 pyruvate MRI, may help find and diagnose glioma.</p></div><p class="comma-list text-right text-muted"><small> <i class="fa fa-map-marker fa-fw" aria-hidden="true"></i> at <span class="comma-list-item"> <strong>UCSF</strong></span> </small></p></div></div></li><li class="trials-list--trial card border trials-list--trial-joinable trials-list--trial-open-to-age-under-18 trials-list--trial-open-to-age-18-and-over trials-list--trial-open-to-sex-female trials-list--trial-open-to-sex-male trials-list--trial-institution-name-UCSF "><div class="card-body"><h2 class="h4 card-title"> <a href="https://clinicaltrials.ucbraid.org/trial/NCT04323046" class="stretched-link">Immunotherapy Before and After Surgery for Treatment of Recurrent or Progressive High Grade Glioma in Children and Young Adults</a> </h2><div class="trials-list--trial-details"><p class="h6 "> <i class="fa fa-user d-none d-md-inline fa-small-icon" aria-hidden="true"></i> <i class="fa fa-user d-none d-md-inline" aria-hidden="true"></i> open to eligible people ages 6 months to 25 years </p><div class="trials-list--trial-summary"><p>This phase I trial studies the side effects of nivolumab before and after surgery in treating children and young adults with high grade glioma that has come back (recurrent) or is increasing in scope or severity (progressive). Immunotherapy with monoclonal antibodies, such as nivolumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread.</p></div><p class="comma-list text-right text-muted"><small> <i class="fa fa-map-marker fa-fw" aria-hidden="true"></i> at <span class="comma-list-item"> <strong>UCSF</strong></span> </small></p></div></div></li><li class="trials-list--trial card border trials-list--trial-joinable trials-list--trial-open-to-age-18-and-over trials-list--trial-open-to-sex-female trials-list--trial-open-to-sex-male trials-list--trial-institution-name-UCLA "><div class="card-body"><h2 class="h4 card-title"> <a href="https://clinicaltrials.ucbraid.org/trial/NCT06090903" class="stretched-link">Magnetic Resonance Imaging for Improving Knowledge of Brain Tumor Biology in Patients With Resectable Glioblastoma</a> </h2><div class="trials-list--trial-details"><p class="h6 "> <i class="fa fa-user d-none d-md-inline" aria-hidden="true"></i> open to eligible people ages 18 years and up </p><div class="trials-list--trial-summary"><p>This clinical trial uses a type of imaging scan called magnetic resonance imaging (MRI) to study brain tumor biology in patients with glioblastoma that can be removed by surgery (resectable). Malignant gliomas are the second leading cause of cancer mortality in people under the age of 35 in the United States. Glioblastoma is a type of malignant glioma with very poor patient prognosis. There are currently only about 3 drugs approved by the Food and Drug Administration (FDA) for the treatment of glioblastoma, one of them being administration of bevacizumab, which is very expensive. It is the most widely used treatment for glioblastoma with dramatic results. However, previous clinical trials have not demonstrated an overall survival benefit across all patient populations with glioblastoma that has returned after treatment (recurrent). The study aims to identify which patients who will benefit from bevacizumab therapy by observing MRI images and corresponding imaging biomarkers.</p></div><p class="comma-list text-right text-muted"><small> <i class="fa fa-map-marker fa-fw" aria-hidden="true"></i> at <span class="comma-list-item"> <strong>UCLA</strong></span> </small></p></div></div></li><li class="trials-list--trial card border trials-list--trial-joinable trials-list--trial-open-to-age-under-18 trials-list--trial-open-to-age-18-and-over trials-list--trial-open-to-sex-female trials-list--trial-open-to-sex-male trials-list--trial-institution-name-UCSF "><div class="card-body"><h2 class="h4 card-title"> <a href="https://clinicaltrials.ucbraid.org/trial/NCT06000787" class="stretched-link">MCT for the Harvard/UCSF ROBIN Center</a> </h2><div class="trials-list--trial-details"><p class="h6 "> <i class="fa fa-user d-none d-md-inline fa-small-icon" aria-hidden="true"></i> <i class="fa fa-user d-none d-md-inline" aria-hidden="true"></i> open to all eligible people </p><div class="trials-list--trial-summary"><p>The goal of the Molecular Characterization Trial (MCT) is to obtain biological specimens and data resources from patients enrolled on prospective trials, to ensure that the Harvard/UCSF ROBIN Center accomplishes its key objective of advancing our understanding of the biological mechanisms that underlie how radiation treats tumors but also can cause unwanted side effects. The MCT focuses on collection of research biospecimens before, during, and after radiation. Also critical to the MCT is the deep annotation of these research biospecimens with elements that complement each other to provide a holistic, detailed view of each patient. Annotated elements include those used in the past such as clinical and biological features but extend to factors we have so far neglected but must incorporate in the future such as dosimetry (precise anatomical measurement of radiation dose), artificial intelligence, computational biology, and natural language processing.</p></div><p class="comma-list text-right text-muted"><small> <i class="fa fa-map-marker fa-fw" aria-hidden="true"></i> at <span class="comma-list-item"> <strong>UCSF</strong></span> </small></p></div></div></li><li class="trials-list--trial card border trials-list--trial-joinable trials-list--trial-open-to-age-under-18 trials-list--trial-open-to-age-18-and-over trials-list--trial-open-to-sex-female trials-list--trial-open-to-sex-male trials-list--trial-institution-name-UC%20Irvine trials-list--trial-institution-name-UCLA trials-list--trial-institution-name-UCSD trials-list--trial-institution-name-UCSF "><div class="card-body"><h2 class="h4 card-title"> <a href="https://clinicaltrials.ucbraid.org/trial/NCT05580562" class="stretched-link">ONC201 in H3 K27M-mutant Diffuse Glioma Following Radiotherapy (the ACTION Study)</a> </h2><div class="trials-list--trial-details"><p class="h6 "> <i class="fa fa-user d-none d-md-inline fa-small-icon" aria-hidden="true"></i> <i class="fa fa-user d-none d-md-inline" aria-hidden="true"></i> open to all eligible people </p><div class="trials-list--trial-summary"><p>This is a randomized, double-blind, placebo-controlled, parallel-group, international, Phase 3 study in patients with newly diagnosed H3 K27M-mutant diffuse glioma to assess whether treatment with ONC201 following frontline radiotherapy will extend overall survival and progression-free survival in this population. Eligible participants will have histologically diagnosed H3 K27M-mutant diffuse glioma and have completed standard frontline radiotherapy.</p></div><p class="comma-list text-right text-muted"><small> <i class="fa fa-map-marker fa-fw" aria-hidden="true"></i> at <span class="comma-list-item"> <strong>UC Irvine</strong></span><span class="comma-list-item"> <strong>UCLA</strong></span><span class="comma-list-item"> <strong>UCSD</strong></span><span class="comma-list-item"> <strong>UCSF</strong></span> </small></p></div></div></li><li class="trials-list--trial card border trials-list--trial-joinable trials-list--trial-open-to-age-under-18 trials-list--trial-open-to-age-18-and-over trials-list--trial-open-to-sex-female trials-list--trial-open-to-sex-male trials-list--trial-institution-name-UCSF "><div class="card-body"><h2 class="h4 card-title"> <a href="https://clinicaltrials.ucbraid.org/trial/NCT04732065" class="stretched-link">ONC206 for Treatment of Newly Diagnosed, Recurrent Diffuse Midline Gliomas, and Other Recurrent Malignant CNS Tumors</a> </h2><div class="trials-list--trial-details"><p class="h6 "> <i class="fa fa-user d-none d-md-inline fa-small-icon" aria-hidden="true"></i> <i class="fa fa-user d-none d-md-inline" aria-hidden="true"></i> open to eligible people ages 2-21 </p><div class="trials-list--trial-summary"><p>This phase I trial studies the effects and best dose of ONC206 alone or in combination with radiation therapy in treating patients with diffuse midline gliomas that is newly diagnosed or has come back (recurrent) or other recurrent primary malignant CNS tumors. ONC206 is a recently discovered compound that may stop cancer cells from growing. This drug has been shown in laboratory experiments to kill brain tumor cells by causing a so called "stress response" in tumor cells. This stress response causes cancer cells to die, but without affecting normal cells. ONC206 alone or in combination with radiation therapy may be effective in treating newly diagnosed or recurrent diffuse midline gliomas and other recurrent primary malignant CNS tumors.</p></div><p class="comma-list text-right text-muted"><small> <i class="fa fa-map-marker fa-fw" aria-hidden="true"></i> at <span class="comma-list-item"> <strong>UCSF</strong></span> </small></p></div></div></li><li class="trials-list--trial card border trials-list--trial-joinable trials-list--trial-open-to-age-18-and-over trials-list--trial-open-to-sex-female trials-list--trial-open-to-sex-male trials-list--trial-institution-name-UCLA "><div class="card-body"><h2 class="h4 card-title"> <a href="https://clinicaltrials.ucbraid.org/trial/NCT04201873" class="stretched-link">Pembrolizumab and a Vaccine (ATL-DC) for the Treatment of Surgically Accessible Recurrent Glioblastoma</a> </h2><div class="trials-list--trial-details"><p class="h6 "> <i class="fa fa-user d-none d-md-inline" aria-hidden="true"></i> open to eligible people ages 18 years and up </p><div class="trials-list--trial-summary"><p>This phase I trial studies the side effects and how well of pembrolizumab and a vaccine therapy (ATL-DC vaccine) work in treating patients with glioblastoma that has come back (recurrent) and can be removed by surgery (surgically accessible). Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Vaccines, such as ATL-DC vaccine, may help the body build an effective immune response to kill tumor cells. Giving pembrolizumab and ATL-DC vaccine may work better in treating patients with glioblastoma compared to ATL-DC alone.</p></div><p class="comma-list text-right text-muted"><small> <i class="fa fa-map-marker fa-fw" aria-hidden="true"></i> at <span class="comma-list-item"> <strong>UCLA</strong></span> </small></p></div></div></li><li class="trials-list--trial card border trials-list--trial-joinable trials-list--trial-open-to-age-18-and-over trials-list--trial-open-to-sex-female trials-list--trial-open-to-sex-male trials-list--trial-institution-name-UCSF "><div class="card-body"><h2 class="h4 card-title"> <a href="https://clinicaltrials.ucbraid.org/trial/NCT05557292" class="stretched-link">RMC-5552 Monotherapy in Adult Subjects With Recurrent Glioblastoma</a> </h2><div class="trials-list--trial-details"><p class="h6 "> <i class="fa fa-user d-none d-md-inline" aria-hidden="true"></i> open to eligible people ages 18 years and up </p><div class="trials-list--trial-summary"><p>This phase I/Ib trial tests the side effects, best dose, tolerability, and effectiveness of RMC-5552 in treating patients with glioblastoma that has come back (recurrent). RMC-5552 is a type of medicine called an mechanistic target of rapamycin (mTOR) inhibitor. These types of drugs prevent the formation of a specific group of proteins called mTOR. This protein controls cancer cell growth, and the study doctors believe stopping mTOR from forming may help to kill tumor cells.</p></div><p class="comma-list text-right text-muted"><small> <i class="fa fa-map-marker fa-fw" aria-hidden="true"></i> at <span class="comma-list-item"> <strong>UCSF</strong></span> </small></p></div></div></li><li class="trials-list--trial card border trials-list--trial-joinable trials-list--trial-open-to-age-18-and-over trials-list--trial-open-to-sex-female trials-list--trial-open-to-sex-male trials-list--trial-institution-name-UCSF "><div class="card-body"><h2 class="h4 card-title"> <a href="https://clinicaltrials.ucbraid.org/trial/NCT04540107" class="stretched-link">Serial MR Imaging and MR Spectroscopic Imaging for the Characterization of Lower Grade Glioma</a> </h2><div class="trials-list--trial-details"><p class="h6 "> <i class="fa fa-user d-none d-md-inline" aria-hidden="true"></i> open to eligible people ages 18 years and up </p><div class="trials-list--trial-summary"><p>This trial studies how well serial magnetic resonance (MR) imaging and MR spectroscopic imaging work in characterizing lower grade glioma. Diagnostic procedures, such as MR imaging and MR spectroscopic imaging, may detect serial changes in lower grade glioma. This study may help researchers learn more about practical ways of evaluating and standardizing treatment in patients with brain tumors.</p></div><p class="comma-list text-right text-muted"><small> <i class="fa fa-map-marker fa-fw" aria-hidden="true"></i> at <span class="comma-list-item"> <strong>UCSF</strong></span> </small></p></div></div></li><li class="trials-list--trial card border trials-list--trial-joinable trials-list--trial-open-to-age-18-and-over trials-list--trial-open-to-sex-female trials-list--trial-open-to-sex-male trials-list--trial-open-to-healthy trials-list--trial-institution-name-UCLA "><div class="card-body"><h2 class="h4 card-title"> <a href="https://clinicaltrials.ucbraid.org/trial/NCT05045027" class="stretched-link">Simultaneous Multinuclear Metabolic MRI in Newly Diagnosed or Recurrent Glioma</a> </h2><div class="trials-list--trial-details"><p class="h6 "> <i class="fa fa-user d-none d-md-inline" aria-hidden="true"></i> open to eligible people ages 18 years and up </p><div class="trials-list--trial-summary"><p>This clinical trial constructs and tests a novel multinuclear metabolic magnetic resonance imaging (MRI) sequence in patients with glioma (brain tumor) that is newly diagnosed or has come back (recurrent). This trial aims to develop new diagnostic imaging technology that may bridge gaps between early detection and diagnosis, prognosis, and treatment in brain cancer.</p></div><p class="comma-list text-right text-muted"><small> <i class="fa fa-map-marker fa-fw" aria-hidden="true"></i> at <span class="comma-list-item"> <strong>UCLA</strong></span> </small></p></div></div></li><li class="trials-list--trial card border trials-list--trial-joinable trials-list--trial-open-to-age-18-and-over trials-list--trial-open-to-sex-female trials-list--trial-open-to-sex-male trials-list--trial-institution-name-UCLA trials-list--trial-institution-name-UCSF "><div class="card-body"><h2 class="h4 card-title"> <a href="https://clinicaltrials.ucbraid.org/trial/NCT05484622" class="stretched-link">Vorasidenib and Pembrolizumab Combination in Recurrent or Progressive Enhancing IDH-1 Mutant Glioma</a> </h2><div class="trials-list--trial-details"><p class="h6 "> <i class="fa fa-user d-none d-md-inline" aria-hidden="true"></i> open to eligible people ages 18 years and up </p><div class="trials-list--trial-summary"><p>Vorasidenib in combination with pembrolizumab in participants with recurrent or progressive enhancing isocitrate dehydrogenase-1 (IDH-1) mutant Glioma.</p></div><p class="comma-list text-right text-muted"><small> <i class="fa fa-map-marker fa-fw" aria-hidden="true"></i> at <span class="comma-list-item"> <strong>UCLA</strong></span><span class="comma-list-item"> <strong>UCSF</strong></span> </small></p></div></div></li><li class="trials-list--trial card border trials-list--trial-joinable trials-list--trial-open-to-age-18-and-over trials-list--trial-open-to-sex-female trials-list--trial-open-to-sex-male trials-list--trial-institution-name-UC%20Irvine trials-list--trial-institution-name-UCLA trials-list--trial-institution-name-UCSD "><div class="card-body"><h2 class="h4 card-title"> <a href="https://clinicaltrials.ucbraid.org/trial/NCT03382977" class="stretched-link">Optimal Dose of Candidate GBM Vaccine VBI-1901 in Recurrent GBM Subjects</a> </h2><div class="trials-list--trial-details"><p class="h6 "> <i class="fa fa-user d-none d-md-inline" aria-hidden="true"></i> open to eligible people ages 18 years and up </p><div class="trials-list--trial-summary"><p>The purpose of this study is to assess the safety and tolerability of VBI-1901 in subjects with recurrent malignant gliomas (glioblastoma, or GBM).</p></div><p class="comma-list text-right text-muted"><small> <i class="fa fa-map-marker fa-fw" aria-hidden="true"></i> at <span class="comma-list-item"> <strong>UC Irvine</strong></span><span class="comma-list-item"> <strong>UCLA</strong></span><span class="comma-list-item"> <strong>UCSD</strong></span> </small></p></div></div></li><li class="trials-list--trial card border trials-list--trial-joinable trials-list--trial-open-to-age-under-18 trials-list--trial-open-to-age-18-and-over trials-list--trial-open-to-sex-female trials-list--trial-open-to-sex-male trials-list--trial-institution-name-UC%20Davis trials-list--trial-institution-name-UCLA trials-list--trial-institution-name-UCSF "><div class="card-body"><h2 class="h4 card-title"> <a href="https://clinicaltrials.ucbraid.org/trial/NCT03155620" class="stretched-link">Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphomas, or Histiocytic Disorders (The Pediatric MATCH Screening Trial)</a> </h2><div class="trials-list--trial-details"><p class="h6 "> <i class="fa fa-user d-none d-md-inline fa-small-icon" aria-hidden="true"></i> <i class="fa fa-user d-none d-md-inline" aria-hidden="true"></i> open to eligible people ages 12 months to 21 years </p><div class="trials-list--trial-summary"><p>This Pediatric MATCH screening and multi-sub-study phase II trial studies how well treatment that is directed by genetic testing works in pediatric patients with solid tumors, non-Hodgkin lymphomas, or histiocytic disorders that have progressed following at least one line of standard systemic therapy and/or for which no standard treatment exists that has been shown to prolong survival. Genetic tests look at the unique genetic material (genes) of patients' tumor cells. Patients with genetic changes or abnormalities (mutations) may benefit more from treatment which targets their tumor's particular genetic mutation, and may help doctors plan better treatment for patients with solid tumors or non-Hodgkin lymphomas.</p></div><p class="comma-list text-right text-muted"><small> <i class="fa fa-map-marker fa-fw" aria-hidden="true"></i> at <span class="comma-list-item"> <strong>UC Davis</strong></span><span class="comma-list-item"> <strong>UCLA</strong></span><span class="comma-list-item"> <strong>UCSF</strong></span> </small></p></div></div></li><li class="trials-list--trial card border trials-list--trial-joinable trials-list--trial-open-to-age-18-and-over trials-list--trial-open-to-sex-female trials-list--trial-open-to-sex-male trials-list--trial-institution-name-UC%20Davis trials-list--trial-institution-name-UCSD "><div class="card-body"><h2 class="h4 card-title"> <a href="https://clinicaltrials.ucbraid.org/trial/NCT05432804" class="stretched-link">Anti-cancer Drug, Selinexor, to the Usual Chemotherapy Treatment (Temozolomide) for Brain Tumors That Have Returned After Previous Treatment</a> </h2><div class="trials-list--trial-details"><p class="h6 "> <i class="fa fa-user d-none d-md-inline" aria-hidden="true"></i> open to eligible people ages 18 years and up </p><div class="trials-list--trial-summary"><p>This phase I/II trial tests the safety, side effects and best dose of selinexor given in combination with the usual chemotherapy (temozolomide) and compares the effect of this combination therapy vs. the usual chemotherapy alone (temozolomide) in treating patients with glioblastoma that has come back (recurrent). Selinexor is in a class of medications called selective inhibitors of nuclear export (SINE). It works by blocking a protein called CRM1, which may keep cancer cells from growing and may kill them. Temozolomide is in a class of medications called alkylating agents. It works by damaging the cell's DNA and may kill tumor cells and slow down or stop tumor growth. Giving selinexor in combination with usual chemotherapy (temozolomide) may shrink or stabilize the tumor better than the usual chemotherapy with temozolomide alone in patients with recurrent glioblastoma.</p></div><p class="comma-list text-right text-muted"><small> <i class="fa fa-map-marker fa-fw" aria-hidden="true"></i> at <span class="comma-list-item"> <strong>UC Davis</strong></span><span class="comma-list-item"> <strong>UCSD</strong></span> </small></p></div></div></li><li class="trials-list--trial card border trials-list--trial-joinable trials-list--trial-open-to-age-18-and-over trials-list--trial-open-to-sex-female trials-list--trial-open-to-sex-male trials-list--trial-institution-name-UC%20Irvine "><div class="card-body"><h2 class="h4 card-title"> <a href="https://clinicaltrials.ucbraid.org/trial/NCT05095376" class="stretched-link">Chemotherapy Drug Lomustine (Gleostine®) to the Usual Treatment (Temozolomide and Radiation Therapy) for Newly Diagnosed MGMT Methylated Glioblastoma</a> </h2><div class="trials-list--trial-details"><p class="h6 "> <i class="fa fa-user d-none d-md-inline" aria-hidden="true"></i> open to eligible people ages 18-70 </p><div class="trials-list--trial-summary"><p>This phase III trial compares the effect of adding lomustine to temozolomide and radiation therapy versus temozolomide and radiation therapy alone in shrinking or stabilizing newly diagnosed MGMT methylated glioblastoma. Chemotherapy drugs, such as lomustine and temozolomide, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Radiation therapy uses high energy photons to kill tumor cells and shrink tumors. Adding lomustine to usual treatment of temozolomide and radiation therapy may help shrink and stabilize glioblastoma.</p></div><p class="comma-list text-right text-muted"><small> <i class="fa fa-map-marker fa-fw" aria-hidden="true"></i> at <span class="comma-list-item"> <strong>UC Irvine</strong></span> </small></p></div></div></li><li class="trials-list--trial card border trials-list--trial-joinable trials-list--trial-open-to-age-under-18 trials-list--trial-open-to-age-18-and-over trials-list--trial-open-to-sex-female trials-list--trial-open-to-sex-male trials-list--trial-institution-name-UCSD trials-list--trial-institution-name-UCSF "><div class="card-body"><h2 class="h4 card-title"> <a href="https://clinicaltrials.ucbraid.org/trial/NCT04485559" class="stretched-link">Trametinib and Everolimus for Treatment of Pediatric and Young Adult Patients With Recurrent Gliomas (PNOC021)</a> </h2><div class="trials-list--trial-details"><p class="h6 "> <i class="fa fa-user d-none d-md-inline fa-small-icon" aria-hidden="true"></i> <i class="fa fa-user d-none d-md-inline" aria-hidden="true"></i> open to eligible people ages 1-25 </p><div class="trials-list--trial-summary"><p>This phase I trial studies the side effects and best dose of trametinib and everolimus in treating pediatric and young adult patients with gliomas that have come back (recurrent). Trametinib acts by targeting a protein in cells called MEK and disrupting tumor growth. Everolimus is a drug that may block another pathway in tumor cells that can help tumors grow. Giving trametinib and everolimus may work better to treat low and high grade gliomas compared to trametinib or everolimus alone.</p></div><p class="comma-list text-right text-muted"><small> <i class="fa fa-map-marker fa-fw" aria-hidden="true"></i> at <span class="comma-list-item"> <strong>UCSD</strong></span><span class="comma-list-item"> <strong>UCSF</strong></span> </small></p></div></div></li><li class="trials-list--trial card border trials-list--trial-joinable trials-list--trial-open-to-age-18-and-over trials-list--trial-open-to-sex-female trials-list--trial-open-to-sex-male trials-list--trial-institution-name-UCSD "><div class="card-body"><h2 class="h4 card-title"> <a href="https://clinicaltrials.ucbraid.org/trial/NCT05576103" class="stretched-link">Longitudinal Prospective Study of Neurocognition & Neuroimaging in Primary BT Patients</a> </h2><div class="trials-list--trial-details"><p class="h6 "> <i class="fa fa-user d-none d-md-inline" aria-hidden="true"></i> open to eligible people ages 18-99 </p><div class="trials-list--trial-summary"><p>In this proposal, the investigators introduce a novel, translational study to prospectively examine primary brain tumor patients undergoing fractionated radiation therapy to the brain. Quantitative neuroimaging, radiation dose information, and directed neurocognitive testing will be acquired through this study to improve understanding of cognitive changes associated with radiation dosage to non-targeted tissue, and will provide the basis for evidence-based cognitive- sparing brain radiotherapy.</p></div><p class="comma-list text-right text-muted"><small> <i class="fa fa-map-marker fa-fw" aria-hidden="true"></i> at <span class="comma-list-item"> <strong>UCSD</strong></span> </small></p></div></div></li><li class="trials-list--trial card border trials-list--trial-joinable trials-list--trial-open-to-age-under-18 trials-list--trial-open-to-age-18-and-over trials-list--trial-open-to-sex-female trials-list--trial-open-to-sex-male trials-list--trial-institution-name-UCSD "><div class="card-body"><h2 class="h4 card-title"> <a href="https://clinicaltrials.ucbraid.org/trial/NCT04427384" class="stretched-link">Registry of Patients With Brain Tumors Treated With STaRT (GammaTiles)</a> </h2><div class="trials-list--trial-details"><p class="h6 "> <i class="fa fa-user d-none d-md-inline fa-small-icon" aria-hidden="true"></i> <i class="fa fa-user d-none d-md-inline" aria-hidden="true"></i> open to all eligible people </p><div class="trials-list--trial-summary"><p>The objectives of this registry study are to evaluate real-world clinical outcomes and patient reported outcomes that measure the effectiveness and safety of STaRT.</p></div><p class="comma-list text-right text-muted"><small> <i class="fa fa-map-marker fa-fw" aria-hidden="true"></i> at <span class="comma-list-item"> <strong>UCSD</strong></span> </small></p></div></div></li><li class="trials-list--trial card border trials-list--trial-joinable trials-list--trial-open-to-age-18-and-over trials-list--trial-open-to-sex-female trials-list--trial-open-to-sex-male trials-list--trial-institution-name-UCSF "><div class="card-body"><h2 class="h4 card-title"> <a href="https://clinicaltrials.ucbraid.org/trial/NCT06146738" class="stretched-link">PALSUR-study: Palliative Care Versus Surgery in High-grade Glioma Patients (ENCRAM 2203)</a> </h2><div class="trials-list--trial-details"><p class="h6 "> <i class="fa fa-user d-none d-md-inline" aria-hidden="true"></i> open to eligible people ages 18-90 </p><div class="trials-list--trial-summary"><p>There is no consensus on the optimal treatment of patients with high-grade glioma, especially when patients have limited functioning performance at presentation (KPS ≤70). Therefore, there are varied practice patterns around pursuing biopsy, resection, or palliation (best supportive care). This study aims to characterize the impact of palliative care versus biopsy versus resection on survival and quality of life in these patients. Also, it will aim to determine if there is a subset of patients that benefit the most from resection or biopsy, for which outcome, and how they could be identified preoperatively. This study is an international, multicenter, prospective, 3-arm cohort study of observational nature. Consecutive HGG patients will be treated with palliative care, biopsy, or resection at a 1:3:3 ratio. Primary endpoints are: 1) overall survival, and 2) quality of life at 6 weeks, 3 months and 6 months after initial presentation based on the EQ-5D, EORTC QLQ C30 and EORTC BN 20 questionnaires. Total duration of the study is 5 years. Patient inclusion is 4 years, follow-up is 1 year.</p></div><p class="comma-list text-right text-muted"><small> <i class="fa fa-map-marker fa-fw" aria-hidden="true"></i> at <span class="comma-list-item"> <strong>UCSF</strong></span> </small></p></div></div></li><li class="trials-list--trial card border trials-list--trial-joinable trials-list--trial-open-to-age-under-18 trials-list--trial-open-to-age-18-and-over trials-list--trial-open-to-sex-female trials-list--trial-open-to-sex-male trials-list--trial-institution-name-UCSF "><div class="card-body"><h2 class="h4 card-title"> <a href="https://clinicaltrials.ucbraid.org/trial/NCT06273176" class="stretched-link">RECMAP-study: Resection With or Without Intraoperative Mapping for Recurrent Glioblastoma</a> </h2><div class="trials-list--trial-details"><p class="h6 "> <i class="fa fa-user d-none d-md-inline fa-small-icon" aria-hidden="true"></i> <i class="fa fa-user d-none d-md-inline" aria-hidden="true"></i> open to eligible people ages up to 90 years </p><div class="trials-list--trial-summary"><p>Resection of glioblastoma in or near functional brain tissue is challenging because of the proximity of important structures to the tumor site. To pursue maximal resection in a safe manner, mapping methods have been developed to test for motor and language function during the operation. Previous evidence suggests that these techniques are beneficial for maximum safe resection in newly diagnosed grade 2-4 astrocytoma, grade 2-3 oligodendroglioma, and recently, glioblastoma. However, their effects in recurrent glioblastoma are still poorly understood. The aim of this study, therefore, is to compare the effects of awake mapping and asleep mapping with no mapping in resections for recurrent glioblastoma. This study is an international, multicenter, prospective 3-arm cohort study of observational nature. Recurrent glioblastoma patients will be operated with mapping or no mapping techniques with a 1:1 ratio. Primary endpoints are: 1) proportion of patients with NIHSS (National Institute of Health Stroke Scale) deterioration at 6 weeks, 3 months, and 6 months after surgery and 2) residual tumor volume of the contrast-enhancing and non-contrast-enhancing part as assessed by a neuroradiologist on postoperative contrast MRI scans. Secondary endpoints are: 1) overall survival (OS), 2) progression-free survival (PFS), 4) health-related quality of life (HRQoL) at 6 weeks, 3 months, and 6 months after surgery, and 4) frequency and severity of Serious Adverse Events (SAEs) in each arm. Estimated total duration of the study is 5 years. Patient inclusion is 4 years, follow-up is 1 year. The study will be carried out by the centers affiliated with the European and North American Consortium and Registry for Intraoperative Mapping (ENCRAM).</p></div><p class="comma-list text-right text-muted"><small> <i class="fa fa-map-marker fa-fw" aria-hidden="true"></i> at <span class="comma-list-item"> <strong>UCSF</strong></span> </small></p></div></div></li><li class="trials-list--trial card border trials-list--trial-joinable trials-list--trial-open-to-age-18-and-over trials-list--trial-open-to-sex-female trials-list--trial-open-to-sex-male trials-list--trial-institution-name-UCSF "><div class="card-body"><h2 class="h4 card-title"> <a href="https://clinicaltrials.ucbraid.org/trial/NCT06283927" class="stretched-link">RECSUR-study: Resection Versus Best Oncological Treatment for Recurrent Glioblastoma (ENCRAM 2302)</a> </h2><div class="trials-list--trial-details"><p class="h6 "> <i class="fa fa-user d-none d-md-inline" aria-hidden="true"></i> open to eligible people ages 18-90 </p><div class="trials-list--trial-summary"><p>Previous evidence has indicated that resection for recurrent glioblastoma might benefit the prognosis of these patients in terms of overall survival. However, the demonstrated safety profile of this approach is contradictory in the literature and the specific benefits in distinct clinical and molecular patient subgroups remains ill-defined. The aim of this study, therefore, is to compare the effects of resection and best oncological treatment for recurrent glioblastoma as a whole and in clinically important subgroups. This study is an international, multicenter, prospective observational cohort study. Recurrent glioblastoma patients will undergo tumor resection or best oncological treatment at a 1:1 ratio as decided by the tumor board. Primary endpoints are: 1) proportion of patients with NIHSS (National Institute of Health Stroke Scale) deterioration at 6 weeks after surgery and 2) overall survival. Secondary endpoints are: 1) progression-free survival (PFS), 2) NIHSS deterioration at 3 months and 6 months after surgery, 3) health-related quality of life (HRQoL) at 6 weeks, 3 months, and 6 months after surgery, and 4) frequency and severity of Serious Adverse Events (SAEs) in each arm. Estimated total duration of the study is 5 years. Patient inclusion is 4 years, follow-up is 1 year. The study has been approved by the Medical Ethics Committee (METC Zuid-West Holland/Erasmus Medical Center; MEC-2020-0812). The results will be published in peer-reviewed academic journals and disseminated to patient organisations and media.</p></div><p class="comma-list text-right text-muted"><small> <i class="fa fa-map-marker fa-fw" aria-hidden="true"></i> at <span class="comma-list-item"> <strong>UCSF</strong></span> </small></p></div></div></li><li class="trials-list--trial card border trials-list--trial-joinable trials-list--trial-open-to-age-18-and-over trials-list--trial-open-to-sex-female trials-list--trial-open-to-sex-male trials-list--trial-institution-name-UCSF "><div class="card-body"><h2 class="h4 card-title"> <a href="https://clinicaltrials.ucbraid.org/trial/NCT06146725" class="stretched-link">RESBIOP-study: Resection Versus Biopsy in High-grade Glioma Patients (ENCRAM 2202)</a> </h2><div class="trials-list--trial-details"><p class="h6 "> <i class="fa fa-user d-none d-md-inline" aria-hidden="true"></i> open to eligible people ages 18-90 </p><div class="trials-list--trial-summary"><p>There are no guidelines or prospective studies defining the optimal surgical treatment for gliomas of older patients (≥70 years) or those with limited functioning performance at presentation (KPS ≤70). Therefore, the decision between resection and biopsy is varied, amongst neurosurgeons internationally and at times even within an instiutition. This study aims to compare the effects of maximal tumor resection versus tissue biopsy on survival, functional, neurological, and quality of life outcomes in these patient subgroups. Furthermore, it evaluates which modality would maximize the potential to undergo adjuvant treatment. This study is an international, multicenter, prospective, 2-arm cohort study of observational nature. Consecutive HGG patients will be treated with resection or biopsy at a 3:1 ratio. Primary endpoints are: 1) overall survival (OS) and 2) proportion of patients that have received adjuvant treatment with chemotherapy and radiotherapy. Secondary endpoints are 1) proportion of patients with NIHSS (National Institute of Health Stroke Scale) deterioration at 6 weeks, 3 months and 6 months after surgery 2) progression-free survival (PFS); 3) quality of life at 6 weeks, 3 months and 6 months after surgery and 4) frequency and severity of Serious Adverse Events (SAEs). Total duration of the study is 5 years. Patient inclusion is 4 years, follow-up is 1 year.</p></div><p class="comma-list text-right text-muted"><small> <i class="fa fa-map-marker fa-fw" aria-hidden="true"></i> at <span class="comma-list-item"> <strong>UCSF</strong></span> </small></p></div></div></li><li class="trials-list--trial card border trials-list--trial-joinable trials-list--trial-open-to-age-18-and-over trials-list--trial-open-to-sex-female trials-list--trial-open-to-sex-male trials-list--trial-institution-name-UCSF "><div class="card-body"><h2 class="h4 card-title"> <a href="https://clinicaltrials.ucbraid.org/trial/NCT06118723" class="stretched-link">SUPRAMAX Study: Supramaximal Resection Versus Maximal Resection for High-Grade Glioma Patients (ENCRAM 2201)</a> </h2><div class="trials-list--trial-details"><p class="h6 "> <i class="fa fa-user d-none d-md-inline" aria-hidden="true"></i> open to eligible people ages 18-90 </p><div class="trials-list--trial-summary"><p>A greater extent of resection of the contrast-enhancing (CE) tumor part has been associated with improved outcomes in high-grade glioma patients. Recent results suggest that resection of the non-contrast-enhancing (NCE) part might yield even better survival outcomes (supramaximal resection, SMR). Therefore, this study evaluates the efficacy and safety of SMR with and without mapping techniques in HGG patients in terms of survival, functional, neurological, cognitive, and quality of life outcomes. Furthermore, it evaluates which patients benefit the most from SMR, and how they could be identified preoperatively. This study is an international, multicenter, prospective, 2-arm cohort study of observational nature. Consecutive HGG patients will be operated with supramaximal resection or maximal resection at a 1:3 ratio. Primary endpoints are: 1) overall survival and 2) proportion of patients with NIHSS (National Institute of Health Stroke Scale) deterioration at 6 weeks, 3 months, and 6 months postoperatively. Secondary endpoints are 1) residual CE and NCE tumor volume on postoperative T1-contrast and FLAIR MRI scans 2) progression-free survival; 3) onco-functional outcome, and 4) quality of life at 6 weeks, 3 months, and 6 months postoperatively. The study will be carried out by the centers affiliated with the European and North American Consortium and Registry for Intraoperative Mapping (ENCRAM).</p></div><p class="comma-list text-right text-muted"><small> <i class="fa fa-map-marker fa-fw" aria-hidden="true"></i> at <span class="comma-list-item"> <strong>UCSF</strong></span> </small></p></div></div></li><li class="trials-list--trial card border trials-list--trial-not-joinable trials-list--trial-open-to-age-18-and-over trials-list--trial-open-to-sex-female trials-list--trial-open-to-sex-male trials-list--trial-institution-name-UC%20Irvine trials-list--trial-institution-name-UCSF "><div class="card-body"><h2 class="h4 card-title"> <a href="https://clinicaltrials.ucbraid.org/trial/NCT03678883" class="stretched-link">9-ING-41 in Patients with Advanced Cancers</a> </h2><div class="trials-list--trial-details"><p class="h6 text-danger"> <i class="fa fa-ban" aria-hidden="true"></i> <span class="sr-only">Sorry, </span> in progress, not accepting new patients </p><div class="trials-list--trial-summary"><p>GSK-3β is a potentially important therapeutic target in human malignancies. The Actuate 1801 Phase 1/2 study is designed to evaluate the safety and efficacy of 9-ING-41, a potent GSK-3β inhibitor, as a single agent and in combination with cytotoxic agents, in patients with refractory cancers.</p></div><p class="comma-list text-right text-muted"><small> <i class="fa fa-map-marker fa-fw" aria-hidden="true"></i> at <span class="comma-list-item"> <strong>UC Irvine</strong></span><span class="comma-list-item"> <strong>UCSF</strong></span> </small></p></div></div></li><li class="trials-list--trial card border trials-list--trial-not-joinable trials-list--trial-open-to-age-18-and-over trials-list--trial-open-to-sex-female trials-list--trial-open-to-sex-male trials-list--trial-institution-name-UCSF "><div class="card-body"><h2 class="h4 card-title"> <a href="https://clinicaltrials.ucbraid.org/trial/NCT04478279" class="stretched-link">Phase 1-2 Study of ST101 in Patients With Advanced Solid Tumors</a> </h2><div class="trials-list--trial-details"><p class="h6 text-danger"> <i class="fa fa-ban" aria-hidden="true"></i> <span class="sr-only">Sorry, </span> in progress, not accepting new patients </p><div class="trials-list--trial-summary"><p>This is an open-label, two-part, phase 1-2 dose-finding study designed to determine the safety, tolerability, PK, PD, and proof-of-concept efficacy of ST101 administered IV in patients with advanced solid tumors. The study consists of two phases: a phase 1 dose escalation/regimen exploration phase and a phase 2 expansion phase.</p></div><p class="comma-list text-right text-muted"><small> <i class="fa fa-map-marker fa-fw" aria-hidden="true"></i> at <span class="comma-list-item"> <strong>UCSF</strong></span> </small></p></div></div></li><li class="trials-list--trial card border trials-list--trial-not-joinable trials-list--trial-open-to-age-under-18 trials-list--trial-open-to-age-18-and-over trials-list--trial-open-to-sex-female trials-list--trial-open-to-sex-male trials-list--trial-institution-name-UCLA "><div class="card-body"><h2 class="h4 card-title"> <a href="https://clinicaltrials.ucbraid.org/trial/NCT02586857" class="stretched-link">ACP-196 in Subjects With Recurrent Glioblastoma Multiforme (GBM)</a> </h2><div class="trials-list--trial-details"><p class="h6 text-danger"> <i class="fa fa-ban" aria-hidden="true"></i> <span class="sr-only">Sorry, </span> in progress, not accepting new patients </p><div class="trials-list--trial-summary"><p>A Phase 1b/2, Multicenter, Open-Label Study of ACP-196 in Subjects with Recurrent Glioblastoma Multiforme (GBM)</p></div><p class="comma-list text-right text-muted"><small> <i class="fa fa-map-marker fa-fw" aria-hidden="true"></i> at <span class="comma-list-item"> <strong>UCLA</strong></span> </small></p></div></div></li><li class="trials-list--trial card border trials-list--trial-not-joinable trials-list--trial-open-to-age-under-18 trials-list--trial-open-to-age-18-and-over trials-list--trial-open-to-sex-female trials-list--trial-open-to-sex-male trials-list--trial-institution-name-UCSF "><div class="card-body"><h2 class="h4 card-title"> <a href="https://clinicaltrials.ucbraid.org/trial/NCT05123534" class="stretched-link">Sonodynamic Therapy Using SONALA-001 and Exablate 4000 Type 2.0 in Patients with DIPG</a> </h2><div class="trials-list--trial-details"><p class="h6 text-danger"> <i class="fa fa-ban" aria-hidden="true"></i> <span class="sr-only">Sorry, </span> currently not accepting new patients, but might later </p><div class="trials-list--trial-summary"><p>The primary objectives of this trial are to evaluate the safety and tolerability of sonodynamic therapy (SDT) using SONALA-001 and Exablate Type 2.0 device and to determine the maximum tolerated dose (MTD) or recommended phase 2 dose (RP2D) of MR-Guided Focused Ultrasound (MRgFUS) energy in combination with SONALA-001 in subjects with diffuse intrinsic pontine glioma Funding Source - FDA OOPD</p></div><p class="comma-list text-right text-muted"><small> <i class="fa fa-map-marker fa-fw" aria-hidden="true"></i> at <span class="comma-list-item"> <strong>UCSF</strong></span> </small></p></div></div></li><li class="trials-list--trial card border trials-list--trial-not-joinable trials-list--trial-open-to-age-18-and-over trials-list--trial-open-to-sex-female trials-list--trial-open-to-sex-male trials-list--trial-institution-name-UCLA "><div class="card-body"><h2 class="h4 card-title"> <a href="https://clinicaltrials.ucbraid.org/trial/NCT05187624" class="stretched-link">Anti-tumor Activity of RO7428731 in Participants With Glioblastoma</a> </h2><div class="trials-list--trial-details"><p class="h6 text-danger"> <i class="fa fa-ban" aria-hidden="true"></i> <span class="sr-only">Sorry, </span> in progress, not accepting new patients </p><div class="trials-list--trial-summary"><p>This is an open-label, multicenter study to assess safety, tolerability, pharmacokinetics (PK), immunogenicity, pharmacodynamics (PD), and preliminary efficacy of RO7428731 administered as a monotherapy in participants with newly diagnosed or recurrent epidermal growth factor receptor variant III (EGFRvIII)-positive glioblastoma (GBM).</p></div><p class="comma-list text-right text-muted"><small> <i class="fa fa-map-marker fa-fw" aria-hidden="true"></i> at <span class="comma-list-item"> <strong>UCLA</strong></span> </small></p></div></div></li><li class="trials-list--trial card border trials-list--trial-not-joinable trials-list--trial-open-to-age-18-and-over trials-list--trial-open-to-sex-female trials-list--trial-open-to-sex-male trials-list--trial-institution-name-UCLA trials-list--trial-institution-name-UCSF "><div class="card-body"><h2 class="h4 card-title"> <a href="https://clinicaltrials.ucbraid.org/trial/NCT02981940" class="stretched-link">Abemaciclib in Recurrent Glioblastoma</a> </h2><div class="trials-list--trial-details"><p class="h6 text-danger"> <i class="fa fa-ban" aria-hidden="true"></i> <span class="sr-only">Sorry, </span> in progress, not accepting new patients </p><div class="trials-list--trial-summary"><p>This research study is studying a targeted therapy as a possible treatment for recurrent glioblastoma (GBM). The following intervention will be used in this study: -Abemaciclib</p></div><p class="comma-list text-right text-muted"><small> <i class="fa fa-map-marker fa-fw" aria-hidden="true"></i> at <span class="comma-list-item"> <strong>UCLA</strong></span><span class="comma-list-item"> <strong>UCSF</strong></span> </small></p></div></div></li><li class="trials-list--trial card border trials-list--trial-not-joinable trials-list--trial-open-to-age-18-and-over trials-list--trial-open-to-sex-female trials-list--trial-open-to-sex-male trials-list--trial-institution-name-UC%20Irvine trials-list--trial-institution-name-UCSD trials-list--trial-institution-name-UCSF "><div class="card-body"><h2 class="h4 card-title"> <a href="https://clinicaltrials.ucbraid.org/trial/NCT04762069" class="stretched-link">Berubicin in Adult Subjects With Recurrent Glioblastoma Multiforme</a> </h2><div class="trials-list--trial-details"><p class="h6 text-danger"> <i class="fa fa-ban" aria-hidden="true"></i> <span class="sr-only">Sorry, </span> in progress, not accepting new patients </p><div class="trials-list--trial-summary"><p>This is an open-label, multicenter, randomized, parallel, 2-arm, efficacy and safety study. Patients with GBM after failure of standard first line therapy will be randomized in a 2:1 ratio to receive berubicin or lomustine for the evaluation of OS. Additional endpoints will include response and progression outcomes evaluated by a blinded central reviewer for each patient according to RANO criteria. A pre-planned, non-binding futility analysis will be performed after approximately 30 to 50% of all planned patients have completed the primary endpoint at 6 months. This review will include additional evaluation of safety as well as secondary efficacy endpoints. Enrollment will not be paused during this interim analysis.</p></div><p class="comma-list text-right text-muted"><small> <i class="fa fa-map-marker fa-fw" aria-hidden="true"></i> at <span class="comma-list-item"> <strong>UC Irvine</strong></span><span class="comma-list-item"> <strong>UCSD</strong></span><span class="comma-list-item"> <strong>UCSF</strong></span> </small></p></div></div></li><li class="trials-list--trial card border trials-list--trial-not-joinable trials-list--trial-open-to-age-18-and-over trials-list--trial-open-to-sex-female trials-list--trial-open-to-sex-male trials-list--trial-institution-name-UC%20Davis trials-list--trial-institution-name-UC%20Irvine trials-list--trial-institution-name-UCSD "><div class="card-body"><h2 class="h4 card-title"> <a href="https://clinicaltrials.ucbraid.org/trial/NCT00887146" class="stretched-link">Radiation Therapy With Concomitant and Adjuvant Temozolomide Versus Radiation Therapy With Adjuvant PCV Chemotherapy in Patients With Anaplastic Glioma or Low Grade Glioma</a> </h2><div class="trials-list--trial-details"><p class="h6 text-danger"> <i class="fa fa-ban" aria-hidden="true"></i> <span class="sr-only">Sorry, </span> in progress, not accepting new patients </p><div class="trials-list--trial-summary"><p>Radiation therapy uses high-energy x-rays to kill tumor cells. Drugs used in chemotherapy, such as temozolomide, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. It is not yet known whether giving radiation with concomitant and adjuvant temozolomide versus radiation with adjuvant PCV is more effective in treating anaplastic glioma or low grade glioma.</p></div><p class="comma-list text-right text-muted"><small> <i class="fa fa-map-marker fa-fw" aria-hidden="true"></i> at <span class="comma-list-item"> <strong>UC Davis</strong></span><span class="comma-list-item"> <strong>UC Irvine</strong></span><span class="comma-list-item"> <strong>UCSD</strong></span> </small></p></div></div></li><li class="trials-list--trial card border trials-list--trial-not-joinable trials-list--trial-open-to-age-18-and-over trials-list--trial-open-to-sex-female trials-list--trial-open-to-sex-male trials-list--trial-institution-name-UC%20Davis trials-list--trial-institution-name-UCSD "><div class="card-body"><h2 class="h4 card-title"> <a href="https://clinicaltrials.ucbraid.org/trial/NCT04145115" class="stretched-link">Testing the Effect of Immunotherapy (Ipilimumab and Nivolumab) in Patients With Recurrent Glioma With Elevated Mutational Burden</a> </h2><p class="h5" id="trials-list--trial-tagline">“Volunteer for research and contribute to discoveries that may improve health care for you, your family, and your community!”</p><div class="trials-list--trial-details"><p class="h6 text-danger"> <i class="fa fa-ban" aria-hidden="true"></i> <span class="sr-only">Sorry, </span> currently not accepting new patients, but might later </p><div class="trials-list--trial-summary"><p>This phase II trial studies the effect of immunotherapy drugs (ipilimumab and nivolumab) in treating patients with glioma that has come back (recurrent) and carries a high number of mutations (mutational burden). Cancer is caused by changes (mutations) to genes that control the way cells function. Tumors with high number of mutations may respond well to immunotherapy. Immunotherapy with monoclonal antibodies such as ipilimumab and nivolumab may help the body's immune system attack the cancer and may interfere with the ability of tumor cells to grow and spread. Giving ipilimumab and nivolumab may lower the chance of recurrent glioblastoma with high number of mutations from growing or spreading compared to usual care (surgery or chemotherapy).</p></div><p class="comma-list text-right text-muted"><small> <i class="fa fa-map-marker fa-fw" aria-hidden="true"></i> at <span class="comma-list-item"> <strong>UC Davis</strong></span><span class="comma-list-item"> <strong>UCSD</strong></span> </small></p></div></div></li><li class="trials-list--trial card border trials-list--trial-not-joinable trials-list--trial-open-to-age-18-and-over trials-list--trial-open-to-sex-female trials-list--trial-open-to-sex-male trials-list--trial-institution-name-UCLA "><div class="card-body"><h2 class="h4 card-title"> <a href="https://clinicaltrials.ucbraid.org/trial/NCT05222802" class="stretched-link">ERAS-801 in Patients With Recurrent Glioblastoma (THUNDERBBOLT-1)</a> </h2><div class="trials-list--trial-details"><p class="h6 text-danger"> <i class="fa fa-ban" aria-hidden="true"></i> <span class="sr-only">Sorry, </span> in progress, not accepting new patients </p><div class="trials-list--trial-summary"><p>- To evaluate the safety and tolerability of escalating doses of ERAS-801 in study participants with recurrent glioblastoma multiforme (GBM). - To determine the Maximum Tolerated Dose (MTD) and/or Recommended Dose (RD) of ERAS-801. - To evaluate the antitumor activity of ERAS-801. - To evaluate the PK profile of ERAS-801.</p></div><p class="comma-list text-right text-muted"><small> <i class="fa fa-map-marker fa-fw" aria-hidden="true"></i> at <span class="comma-list-item"> <strong>UCLA</strong></span> </small></p></div></div></li><li class="trials-list--trial card border trials-list--trial-not-joinable trials-list--trial-open-to-age-18-and-over trials-list--trial-open-to-sex-female trials-list--trial-open-to-sex-male trials-list--trial-institution-name-UCLA "><div class="card-body"><h2 class="h4 card-title"> <a href="https://clinicaltrials.ucbraid.org/trial/NCT06342908" class="stretched-link">Vaccine (Neoantigen-Targeted ppDC) for the Treatment of H3 G34-mutant Diffuse Hemispheric Glioma</a> </h2><div class="trials-list--trial-details"><p class="h6 text-danger"> <i class="fa fa-ban" aria-hidden="true"></i> <span class="sr-only">Sorry, </span> not yet accepting patients </p><div class="trials-list--trial-summary"><p>This phase I trial tests the safety and side effects, and best dose of a vaccine (neoantigen-target ppDC) in treating patients with H3 G34-mutant diffuse hemispheric glioma. Vaccines made from the patient's own white blood cells and peptide-pulsed dendritic cells may help the body build an effective immune response to kill tumor cells. Giving neoantigen-targeted ppDC may be safe, tolerable and/or effective in treating patients with diffuse hemispheric glioma with a H3 G34 mutation.</p></div><p class="comma-list text-right text-muted"><small> <i class="fa fa-map-marker fa-fw" aria-hidden="true"></i> at <span class="comma-list-item"> <strong>UCLA</strong></span> </small></p></div></div></li><li class="trials-list--trial card border trials-list--trial-not-joinable trials-list--trial-open-to-age-18-and-over trials-list--trial-open-to-sex-female trials-list--trial-open-to-sex-male trials-list--trial-institution-name-UCLA trials-list--trial-institution-name-UCSF "><div class="card-body"><h2 class="h4 card-title"> <a href="https://clinicaltrials.ucbraid.org/trial/NCT01849146" class="stretched-link">Adavosertib, Radiation Therapy, and Temozolomide in Treating Patients With Newly Diagnosed or Recurrent Glioblastoma</a> </h2><div class="trials-list--trial-details"><p class="h6 text-danger"> <i class="fa fa-ban" aria-hidden="true"></i> <span class="sr-only">Sorry, </span> in progress, not accepting new patients </p><div class="trials-list--trial-summary"><p>This phase I trial studies the side effects and best dose of adavosertib when given together with radiation therapy and temozolomide in treating patients with glioblastoma that is newly diagnosed or has come back. Adavosertib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Radiation therapy uses high energy x-rays to kill tumor cells and shrink tumors. Drugs used in chemotherapy, such as temozolomide, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving adavosertib, radiation therapy, and temozolomide may work better in treating patients with newly diagnosed or recurrent glioblastoma compared to radiation therapy and temozolomide alone.</p></div><p class="comma-list text-right text-muted"><small> <i class="fa fa-map-marker fa-fw" aria-hidden="true"></i> at <span class="comma-list-item"> <strong>UCLA</strong></span><span class="comma-list-item"> <strong>UCSF</strong></span> </small></p></div></div></li><li class="trials-list--trial card border trials-list--trial-not-joinable trials-list--trial-open-to-age-18-and-over trials-list--trial-open-to-sex-female trials-list--trial-open-to-sex-male trials-list--trial-institution-name-UCLA trials-list--trial-institution-name-UCSF "><div class="card-body"><h2 class="h4 card-title"> <a href="https://clinicaltrials.ucbraid.org/trial/NCT03175224" class="stretched-link">APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors</a> </h2><div class="trials-list--trial-details"><p class="h6 text-danger"> <i class="fa fa-ban" aria-hidden="true"></i> <span class="sr-only">Sorry, </span> not currently recruiting here </p><div class="trials-list--trial-summary"><p>To assess: - efficacy of APL-101 as monotherapy for the treatment of NSCLC harboring MET Exon 14 skipping mutations, NSCLC harboring MET amplification, solid tumors harboring MET amplification, solid tumors harboring MET fusion, primary CNS tumors harboring MET alterations, solid tumors harboring wild-type MET with overexpression of HGF and MET - efficacy of APL-101 as an add-on therapy to EGFR inhibitor for the treatment of NSCLC harboring EGFR activating mutations and developed acquired resistance with MET amplification and disease progression after documented CR or PR with 1st line EGFR inhibitors (EGFR-I)</p></div><p class="comma-list text-right text-muted"><small> <i class="fa fa-map-marker fa-fw" aria-hidden="true"></i> at <span class="comma-list-item"> <strong>UCLA</strong></span><span class="comma-list-item"> <strong>UCSF</strong></span> </small></p></div></div></li><li class="trials-list--trial card border trials-list--trial-not-joinable trials-list--trial-open-to-age-18-and-over trials-list--trial-open-to-sex-female trials-list--trial-open-to-sex-male trials-list--trial-institution-name-UCSD "><div class="card-body"><h2 class="h4 card-title"> <a href="https://clinicaltrials.ucbraid.org/trial/NCT02974621" class="stretched-link">Cediranib Maleate and Olaparib Compared to Bevacizumab in Treating Patients With Recurrent Glioblastoma</a> </h2><div class="trials-list--trial-details"><p class="h6 text-danger"> <i class="fa fa-ban" aria-hidden="true"></i> <span class="sr-only">Sorry, </span> in progress, not accepting new patients </p><div class="trials-list--trial-summary"><p>This randomized phase II trial studies how well cediranib maleate and olaparib work compared to bevacizumab in treating patients with glioblastoma that has come back (recurrent). Cediranib maleate and olaparib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Immunotherapy with monoclonal antibodies, such as bevacizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread.</p></div><p class="comma-list text-right text-muted"><small> <i class="fa fa-map-marker fa-fw" aria-hidden="true"></i> at <span class="comma-list-item"> <strong>UCSD</strong></span> </small></p></div></div></li><li class="trials-list--trial card border trials-list--trial-not-joinable trials-list--trial-open-to-age-under-18 trials-list--trial-open-to-age-18-and-over trials-list--trial-open-to-sex-female trials-list--trial-open-to-sex-male trials-list--trial-institution-name-UCSD trials-list--trial-institution-name-UCSF "><div class="card-body"><h2 class="h4 card-title"> <a href="https://clinicaltrials.ucbraid.org/trial/NCT03739372" class="stretched-link">Clinical Benefit of Using Molecular Profiling to Determine an Individualized Treatment Plan for Patients With High Grade Glioma</a> </h2><div class="trials-list--trial-details"><p class="h6 text-danger"> <i class="fa fa-ban" aria-hidden="true"></i> <span class="sr-only">Sorry, </span> in progress, not accepting new patients </p><div class="trials-list--trial-summary"><p>This is a 2 strata pilot trial within the Pacific Pediatric Neuro-Oncology Consortium (PNOC). The study will use a new treatment approach based on each patient's tumor gene expression, whole-exome sequencing (WES), targeted panel profile (UCSF 500 gene panel), and RNA-Seq. The current study will test the efficacy of such an approach in children with High-grade gliomas HGG.</p></div><p class="comma-list text-right text-muted"><small> <i class="fa fa-map-marker fa-fw" aria-hidden="true"></i> at <span class="comma-list-item"> <strong>UCSD</strong></span><span class="comma-list-item"> <strong>UCSF</strong></span> </small></p></div></div></li><li class="trials-list--trial card border trials-list--trial-not-joinable trials-list--trial-open-to-age-under-18 trials-list--trial-open-to-age-18-and-over trials-list--trial-open-to-sex-female trials-list--trial-open-to-sex-male trials-list--trial-institution-name-UCSD trials-list--trial-institution-name-UCSF "><div class="card-body"><h2 class="h4 card-title"> <a href="https://clinicaltrials.ucbraid.org/trial/NCT03429803" class="stretched-link">DAY101 In Gliomas and Other Tumors</a> </h2><div class="trials-list--trial-details"><p class="h6 text-danger"> <i class="fa fa-ban" aria-hidden="true"></i> <span class="sr-only">Sorry, </span> in progress, not accepting new patients </p><div class="trials-list--trial-summary"><p>This research study is studying a drug Tovorafenib/DAY101 (formerly TAK-580, MLN2480) as a possible treatment a low-grade glioma that has not responded to other treatments. The name of the study drug involved in this study is: • Tovorafenib/DAY101 (formerly TAK-580, MLN2480)</p></div><p class="comma-list text-right text-muted"><small> <i class="fa fa-map-marker fa-fw" aria-hidden="true"></i> at <span class="comma-list-item"> <strong>UCSD</strong></span><span class="comma-list-item"> <strong>UCSF</strong></span> </small></p></div></div></li><li class="trials-list--trial card border trials-list--trial-not-joinable trials-list--trial-open-to-age-18-and-over trials-list--trial-open-to-sex-female trials-list--trial-open-to-sex-male trials-list--trial-institution-name-UCSF "><div class="card-body"><h2 class="h4 card-title"> <a href="https://clinicaltrials.ucbraid.org/trial/NCT06504381" class="stretched-link">DB107-RRV, DB107-FC, and Radiation Therapy With or Without Temozolomide (TMZ) for High Grade Glioma</a> </h2><div class="trials-list--trial-details"><p class="h6 text-danger"> <i class="fa fa-ban" aria-hidden="true"></i> <span class="sr-only">Sorry, </span> not yet accepting patients </p><div class="trials-list--trial-summary"><p>This is a multicenter, open-label study of DB107-RRV (formerly Toca 511) and DB107-FC (formerly Toca FC) when administered following surgical resection in newly diagnosed High Grade Glioma (HGG) patients. The study is designed to evaluate whether treatment with DB107-RRV in combination with DB107-FC when added to standard of care provides clinical benefit to newly diagnosed HGG when compared to historical performance previously determined in well controlled clinical trials published in the peer reviewed literature. This study is going to be conducted in newly diagnosed HGG patients receiving with maximum surgical resection treatment followed by radiation and temozolomide treatment using the established Stupp Protocol for O6-methylguanine-DNA methyl-transferase (MGMT) methylated patients or radiation therapy for MGMT unmethylated patients.</p></div><p class="comma-list text-right text-muted"><small> <i class="fa fa-map-marker fa-fw" aria-hidden="true"></i> at <span class="comma-list-item"> <strong>UCSF</strong></span> </small></p></div></div></li><li class="trials-list--trial card border trials-list--trial-not-joinable trials-list--trial-open-to-age-18-and-over trials-list--trial-open-to-sex-female trials-list--trial-open-to-sex-male trials-list--trial-institution-name-UC%20Davis trials-list--trial-institution-name-UC%20Irvine "><div class="card-body"><h2 class="h4 card-title"> <a href="https://clinicaltrials.ucbraid.org/trial/NCT02179086" class="stretched-link">Dose-Escalated Photon IMRT or Proton Beam Radiation Therapy Versus Standard-Dose Radiation Therapy and Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma</a> </h2><div class="trials-list--trial-details"><p class="h6 text-danger"> <i class="fa fa-ban" aria-hidden="true"></i> <span class="sr-only">Sorry, </span> in progress, not accepting new patients </p><div class="trials-list--trial-summary"><p>This randomized phase II trial studies how well dose-escalated photon intensity-modulated radiation therapy (IMRT) or proton beam radiation therapy works compared with standard-dose radiation therapy when given with temozolomide in patients with newly diagnosed glioblastoma. Radiation therapy uses high-energy x-rays and other types of radiation to kill tumor cells and shrink tumors. Specialized radiation therapy that delivers a high dose of radiation directly to the tumor may kill more tumor cells and cause less damage to normal tissue. Drugs, such as temozolomide, may make tumor cells more sensitive to radiation therapy. It is not yet known whether dose-escalated photon IMRT or proton beam radiation therapy is more effective than standard-dose radiation therapy with temozolomide in treating glioblastoma.</p></div><p class="comma-list text-right text-muted"><small> <i class="fa fa-map-marker fa-fw" aria-hidden="true"></i> at <span class="comma-list-item"> <strong>UC Davis</strong></span><span class="comma-list-item"> <strong>UC Irvine</strong></span> </small></p></div></div></li><li class="trials-list--trial card border trials-list--trial-not-joinable trials-list--trial-open-to-age-under-18 trials-list--trial-open-to-age-18-and-over trials-list--trial-open-to-sex-female trials-list--trial-open-to-sex-male trials-list--trial-institution-name-UC%20Davis trials-list--trial-institution-name-UCSF "><div class="card-body"><h2 class="h4 card-title"> <a href="https://clinicaltrials.ucbraid.org/trial/NCT03210714" class="stretched-link">Erdafitinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With FGFR Mutations (A Pediatric MATCH Treatment Trial)</a> </h2><div class="trials-list--trial-details"><p class="h6 text-danger"> <i class="fa fa-ban" aria-hidden="true"></i> <span class="sr-only">Sorry, </span> in progress, not accepting new patients </p><div class="trials-list--trial-summary"><p>This phase II Pediatric MATCH trial studies how well erdafitinib works in treating patients with solid tumors, non-Hodgkin lymphoma, or histiocytic disorders with FGFR mutations that have spread to other places in the body and have come back or do not respond to treatment. Erdafitinib may stop the growth of cancer cells with FGFR mutations by blocking some of the enzymes needed for cell growth.</p></div><p class="comma-list text-right text-muted"><small> <i class="fa fa-map-marker fa-fw" aria-hidden="true"></i> at <span class="comma-list-item"> <strong>UC Davis</strong></span><span class="comma-list-item"> <strong>UCSF</strong></span> </small></p></div></div></li><li class="trials-list--trial card border trials-list--trial-not-joinable trials-list--trial-open-to-age-18-and-over trials-list--trial-open-to-sex-female trials-list--trial-open-to-sex-male trials-list--trial-institution-name-UCSF "><div class="card-body"><h2 class="h4 card-title"> <a href="https://clinicaltrials.ucbraid.org/trial/NCT03681028" class="stretched-link">Individualized Therapy for Recurrent Glioblastoma</a> </h2><div class="trials-list--trial-details"><p class="h6 text-danger"> <i class="fa fa-ban" aria-hidden="true"></i> <span class="sr-only">Sorry, </span> in progress, not accepting new patients </p><div class="trials-list--trial-summary"><p>The current study will test the ability and likelihood of successfully implementing individualized combination treatment recommendations for adult patients with surgically-resectable recurrent glioblastoma in a timely fashion. Collected tumor tissue and blood will be examined using a new diagnostic testing called University of California, San Francisco (UCSF) 500 Cancer Gene Panel which is done at the UCSF Clinical Cancer Genomics Laboratory. The UCSF 500 Cancer Gene Panel will help identify genetic changes in the DNA of a patient's cancer, which helps oncologists improve treatment by identifying targeted therapies.</p></div><p class="comma-list text-right text-muted"><small> <i class="fa fa-map-marker fa-fw" aria-hidden="true"></i> at <span class="comma-list-item"> <strong>UCSF</strong></span> </small></p></div></div></li><li class="trials-list--trial card border trials-list--trial-not-joinable trials-list--trial-open-to-age-under-18 trials-list--trial-open-to-age-18-and-over trials-list--trial-open-to-sex-female trials-list--trial-open-to-sex-male trials-list--trial-institution-name-UCSF "><div class="card-body"><h2 class="h4 card-title"> <a href="https://clinicaltrials.ucbraid.org/trial/NCT03893487" class="stretched-link">Fimepinostat in Treating Brain Tumors in Children and Young Adults</a> </h2><div class="trials-list--trial-details"><p class="h6 text-danger"> <i class="fa fa-ban" aria-hidden="true"></i> <span class="sr-only">Sorry, </span> in progress, not accepting new patients </p><div class="trials-list--trial-summary"><p>This trial studies how well fimepinostat works in treating patients with newly diagnosed diffuse intrinsic pontine glioma, or medulloblastoma, or high-grade glioma that have come back. Fimepinostat may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.</p></div><p class="comma-list text-right text-muted"><small> <i class="fa fa-map-marker fa-fw" aria-hidden="true"></i> at <span class="comma-list-item"> <strong>UCSF</strong></span> </small></p></div></div></li><li class="trials-list--trial card border trials-list--trial-not-joinable trials-list--trial-open-to-age-18-and-over trials-list--trial-open-to-sex-female trials-list--trial-open-to-sex-male trials-list--trial-institution-name-UCLA "><div class="card-body"><h2 class="h4 card-title"> <a href="https://clinicaltrials.ucbraid.org/trial/NCT03576612" class="stretched-link">GMCI, Nivolumab, and Radiation Therapy in Treating Patients With Newly Diagnosed High-Grade Gliomas</a> </h2><div class="trials-list--trial-details"><p class="h6 text-danger"> <i class="fa fa-ban" aria-hidden="true"></i> <span class="sr-only">Sorry, </span> in progress, not accepting new patients </p><div class="trials-list--trial-summary"><p>The purpose of this phase I trial is to test the safety of combining GMCI, an immunostimulator, plus nivolumab, an immune checkpoint inhibitor (ICI), with standard of care radiation therapy, and temozolomide in treating patients with newly diagnosed high-grade gliomas. Gene Mediated Cytotoxic Immunotherapy (GMCI) involves the use of aglatimagene besadenovec (AdV-tk) injection into the tumor site and oral valacyclovir to kill tumor cells and stimulate the immune system. Nivolumab is an immune checkpoint inhibitor that may also stimulate the immune system by blocking the PD-1 immune suppressive pathway. Radiation therapy uses high energy x-rays to kill tumor cells and shrink tumors and temozolomide is a chemotherapy drug that kills tumor cells. Giving GMCI, nivolumab, radiation therapy, and temozolomide may work better in treating patients with high-grade gliomas</p></div><p class="comma-list text-right text-muted"><small> <i class="fa fa-map-marker fa-fw" aria-hidden="true"></i> at <span class="comma-list-item"> <strong>UCLA</strong></span> </small></p></div></div></li><li class="trials-list--trial card border trials-list--trial-not-joinable trials-list--trial-open-to-age-18-and-over trials-list--trial-open-to-sex-female trials-list--trial-open-to-sex-male trials-list--trial-institution-name-UCSF "><div class="card-body"><h2 class="h4 card-title"> <a href="https://clinicaltrials.ucbraid.org/trial/NCT04019002" class="stretched-link">Hyperpolarized Carbon-13 (13C) Pyruvate Imaging in Patients With Glioblastoma</a> </h2><div class="trials-list--trial-details"><p class="h6 text-danger"> <i class="fa fa-ban" aria-hidden="true"></i> <span class="sr-only">Sorry, </span> in progress, not accepting new patients </p><div class="trials-list--trial-summary"><p>The purpose of this study is to evaluate whether new metabolic imaging will be useful to physicians and patients with glioblastoma for making treatment decisions and seeing how well various types of treatment work. The goal is to improve the way patient care is managed in the future. If you chose to be in this study, you will be receiving novel magnetic resonance (MR) metabolic imaging with standard MR imaging. The research component includes an injection of an investigational agent, called hyperpolarized 13C pyruvate, to obtain dynamic metabolic imaging.</p></div><p class="comma-list text-right text-muted"><small> <i class="fa fa-map-marker fa-fw" aria-hidden="true"></i> at <span class="comma-list-item"> <strong>UCSF</strong></span> </small></p></div></div></li><li class="trials-list--trial card border trials-list--trial-not-joinable trials-list--trial-open-to-age-under-18 trials-list--trial-open-to-age-18-and-over trials-list--trial-open-to-sex-female trials-list--trial-open-to-sex-male trials-list--trial-institution-name-UCLA "><div class="card-body"><h2 class="h4 card-title"> <a href="https://clinicaltrials.ucbraid.org/trial/NCT04374305" class="stretched-link">Innovative Trial for Understanding the Impact of Targeted Therapies in NF2-Related Schwannomatosis (INTUITT-NF2)</a> </h2><div class="trials-list--trial-details"><p class="h6 text-danger"> <i class="fa fa-ban" aria-hidden="true"></i> <span class="sr-only">Sorry, </span> in progress, not accepting new patients </p><div class="trials-list--trial-summary"><p>This is a multi-arm phase II platform-basket screening study designed to test multiple experimental therapies simultaneously in patients with NF2-related schwannomatosis (NF2-SWN, formerly known as neurofibromatosis type 2) with associated progressive tumors of vestibular schwannomas (VS), non-vestibular schwannomas (non-VS), meningiomas, and ependymomas. This Master Study is being conducted as a "basket" study that may allow people with multiple tumor types associated with NF2-SWN to receive new drugs throughout this study. Embedded within the Master Study are individual drug substudies. - Investigational Drug Sub-study A: Brigatinib - Investigational Drug Sub-study B: Neratinib</p></div><p class="comma-list text-right text-muted"><small> <i class="fa fa-map-marker fa-fw" aria-hidden="true"></i> at <span class="comma-list-item"> <strong>UCLA</strong></span> </small></p></div></div></li><li class="trials-list--trial card border trials-list--trial-not-joinable trials-list--trial-open-to-age-18-and-over trials-list--trial-open-to-sex-female trials-list--trial-open-to-sex-male trials-list--trial-institution-name-UCSF "><div class="card-body"><h2 class="h4 card-title"> <a href="https://clinicaltrials.ucbraid.org/trial/NCT03491683" class="stretched-link">INO-5401 and INO-9012 Delivered by Electroporation (EP) in Combination With Cemiplimab (REGN2810) in Newly-Diagnosed Glioblastoma (GBM)</a> </h2><div class="trials-list--trial-details"><p class="h6 text-danger"> <i class="fa fa-ban" aria-hidden="true"></i> <span class="sr-only">Sorry, </span> in progress, not accepting new patients </p><div class="trials-list--trial-summary"><p>Phase 1/2 trial to evaluate safety, immunogenicity and preliminary efficacy of INO-5401 and INO-9012 in combination with cemiplimab (REGN2810), with radiation and chemotherapy, in subjects with newly-diagnosed glioblastoma (GBM).</p></div><p class="comma-list text-right text-muted"><small> <i class="fa fa-map-marker fa-fw" aria-hidden="true"></i> at <span class="comma-list-item"> <strong>UCSF</strong></span> </small></p></div></div></li><li class="trials-list--trial card border trials-list--trial-not-joinable trials-list--trial-open-to-age-under-18 trials-list--trial-open-to-age-18-and-over trials-list--trial-open-to-sex-female trials-list--trial-open-to-sex-male trials-list--trial-institution-name-UC%20Davis trials-list--trial-institution-name-UCLA trials-list--trial-institution-name-UCSF "><div class="card-body"><h2 class="h4 card-title"> <a href="https://clinicaltrials.ucbraid.org/trial/NCT04195555" class="stretched-link">Ivosidenib in Treating Patients With Advanced Solid Tumors, Lymphoma, or Histiocytic Disorders With IDH1 Mutations (A Pediatric MATCH Treatment Trial)</a> </h2><div class="trials-list--trial-details"><p class="h6 text-danger"> <i class="fa fa-ban" aria-hidden="true"></i> <span class="sr-only">Sorry, </span> in progress, not accepting new patients </p><div class="trials-list--trial-summary"><p>This phase II Pediatric MATCH trial studies how well ivosidenib works in treating patients with solid tumors that have spread to other places in the body (advanced), lymphoma, or histiocytic disorders that have IDH1 genetic alterations (mutations). Ivosidenib may block the growth of cancer cells that have specific genetic changes in an important signaling pathway called the IDH pathway.</p></div><p class="comma-list text-right text-muted"><small> <i class="fa fa-map-marker fa-fw" aria-hidden="true"></i> at <span class="comma-list-item"> <strong>UC Davis</strong></span><span class="comma-list-item"> <strong>UCLA</strong></span><span class="comma-list-item"> <strong>UCSF</strong></span> </small></p></div></div></li><li class="trials-list--trial card border trials-list--trial-not-joinable trials-list--trial-open-to-age-under-18 trials-list--trial-open-to-age-18-and-over trials-list--trial-open-to-sex-female trials-list--trial-open-to-sex-male trials-list--trial-institution-name-UC%20Davis trials-list--trial-institution-name-UCSF "><div class="card-body"><h2 class="h4 card-title"> <a href="https://clinicaltrials.ucbraid.org/trial/NCT03213704" class="stretched-link">Larotrectinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With NTRK Fusions (A Pediatric MATCH Treatment Trial)</a> </h2><div class="trials-list--trial-details"><p class="h6 text-danger"> <i class="fa fa-ban" aria-hidden="true"></i> <span class="sr-only">Sorry, </span> in progress, not accepting new patients </p><div class="trials-list--trial-summary"><p>This phase II Pediatric MATCH trial studies how well larotrectinib works in treating patients with solid tumors, non-Hodgkin lymphoma, or histiocytic disorders with NTRK fusions that may have spread from where it first started to nearby tissue, lymph nodes, or distant parts of the body (advanced) and have come back (relapased) or does not respond to treatment (refractory). Larotrectinib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth.</p></div><p class="comma-list text-right text-muted"><small> <i class="fa fa-map-marker fa-fw" aria-hidden="true"></i> at <span class="comma-list-item"> <strong>UC Davis</strong></span><span class="comma-list-item"> <strong>UCSF</strong></span> </small></p></div></div></li><li class="trials-list--trial card border trials-list--trial-not-joinable trials-list--trial-open-to-age-under-18 trials-list--trial-open-to-age-18-and-over trials-list--trial-open-to-sex-female trials-list--trial-open-to-sex-male trials-list--trial-institution-name-UC%20Davis trials-list--trial-institution-name-UCSF "><div class="card-body"><h2 class="h4 card-title"> <a href="https://clinicaltrials.ucbraid.org/trial/NCT01096368" class="stretched-link">Maintenance Chemotherapy or Observation Following Induction Chemotherapy and Radiation Therapy in Treating Patients With Newly Diagnosed Ependymoma</a> </h2><div class="trials-list--trial-details"><p class="h6 text-danger"> <i class="fa fa-ban" aria-hidden="true"></i> <span class="sr-only">Sorry, </span> in progress, not accepting new patients </p><div class="trials-list--trial-summary"><p>The primary aim of this randomized phase III trial was to study whether the addition of maintenance chemotherapy delivered after surgical resection and focal radiation would be better than surgery and focal radiation alone. The trial also studied if patients who received induction chemotherapy and then either achieved a complete response or went on to have a complete resection would also benefit from maintenance chemotherapy. Children ages 1-21 years with newly diagnosed intracranial ependymoma were included. There were 2 arms that were not randomized. One arm studied patients with Grade II tumors located in the supratentorial compartment that were completely resected. One arm studied patients with residual tumor and those patients all received maintenance chemotherapy after focal radiation. Chemotherapy drugs, such as vincristine sulfate, carboplatin, cyclophosphamide, etoposide, and cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving more than one drug (combination chemotherapy) may kill more tumor cells. Radiation therapy uses high-energy x-rays to kill tumor cells. Specialized radiation therapy that delivers a high dose of radiation directly to the tumor may kill more tumor cells and cause less damage to normal tissue. Giving chemotherapy in combination with radiation therapy may kill more tumor cells and allow doctors to save the part of the body where the cancer started.</p></div><p class="comma-list text-right text-muted"><small> <i class="fa fa-map-marker fa-fw" aria-hidden="true"></i> at <span class="comma-list-item"> <strong>UC Davis</strong></span><span class="comma-list-item"> <strong>UCSF</strong></span> </small></p></div></div></li><li class="trials-list--trial card border trials-list--trial-not-joinable trials-list--trial-open-to-age-18-and-over trials-list--trial-open-to-sex-female trials-list--trial-open-to-sex-male trials-list--trial-institution-name-UCSF "><div class="card-body"><h2 class="h4 card-title"> <a href="https://clinicaltrials.ucbraid.org/trial/NCT02549833" class="stretched-link">Neo-adjuvant Evaluation of Glioma Lysate Vaccines in WHO Grade II Glioma</a> </h2><div class="trials-list--trial-details"><p class="h6 text-danger"> <i class="fa fa-ban" aria-hidden="true"></i> <span class="sr-only">Sorry, </span> in progress, not accepting new patients </p><div class="trials-list--trial-summary"><p>This is a pilot neoadjuvant vaccine study in adults with WHO grade II glioma, for which surgical resection of the tumor is clinically indicated. Co-primary objectives are to determine: 1) the safety and feasibility of the neoadjuvant approach; and 2) whether the regimen increases the level of type-1 chemokine CXCL10 and vaccine-specific (i.e., reactive to GBM6-AD) CD8+ T-cells in tumor-infiltrating leukocytes (TILs) in the surgically resected glioma.</p></div><p class="comma-list text-right text-muted"><small> <i class="fa fa-map-marker fa-fw" aria-hidden="true"></i> at <span class="comma-list-item"> <strong>UCSF</strong></span> </small></p></div></div></li><li class="trials-list--trial card border trials-list--trial-not-joinable trials-list--trial-open-to-age-18-and-over trials-list--trial-open-to-sex-female trials-list--trial-open-to-sex-male trials-list--trial-institution-name-UC%20Davis trials-list--trial-institution-name-UC%20Irvine trials-list--trial-institution-name-UCSD "><div class="card-body"><h2 class="h4 card-title"> <a href="https://clinicaltrials.ucbraid.org/trial/NCT02834013" class="stretched-link">Nivolumab and Ipilimumab in Treating Patients With Rare Tumors</a> </h2><div class="trials-list--trial-details"><p class="h6 text-danger"> <i class="fa fa-ban" aria-hidden="true"></i> <span class="sr-only">Sorry, </span> in progress, not accepting new patients </p><div class="trials-list--trial-summary"><p>This phase II trial studies nivolumab and ipilimumab in treating patients with rare tumors. Immunotherapy with monoclonal antibodies, such as nivolumab and ipilimumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. This trial enrolls participants for the following cohorts based on condition: 1. Epithelial tumors of nasal cavity, sinuses, nasopharynx: A) Squamous cell carcinoma with variants of nasal cavity, sinuses, and nasopharynx and trachea (excluding laryngeal, nasopharyngeal cancer [NPC], and squamous cell carcinoma of the head and neck [SCCHN]) B) Adenocarcinoma and variants of nasal cavity, sinuses, and nasopharynx (closed to accrual 07/27/2018) 2. Epithelial tumors of major salivary glands (closed to accrual 03/20/2018) 3. Salivary gland type tumors of head and neck, lip, esophagus, stomach, trachea and lung, breast and other location (closed to accrual) 4. Undifferentiated carcinoma of gastrointestinal (GI) tract 5. Adenocarcinoma with variants of small intestine (closed to accrual 05/10/2018) 6. Squamous cell carcinoma with variants of GI tract (stomach small intestine, colon, rectum, pancreas) (closed to accrual 10/17/2018) 7. Fibromixoma and low grade mucinous adenocarcinoma (pseudomixoma peritonei) of the appendix and ovary (closed to accrual 03/20/2018) 8. Rare pancreatic tumors including acinar cell carcinoma, mucinous cystadenocarcinoma or serous cystadenocarcinoma. Pancreatic adenocarcinoma is not eligible (closed to accrual) 9. Intrahepatic cholangiocarcinoma (closed to accrual 03/20/2018) 10. Extrahepatic cholangiocarcinoma and bile duct tumors (closed to accrual 03/20/2018) 11. Sarcomatoid carcinoma of lung 12. Bronchoalveolar carcinoma lung. This condition is now also referred to as adenocarcinoma in situ, minimally invasive adenocarcinoma, lepidic predominant adenocarcinoma, or invasive mucinous adenocarcinoma 13. Non-epithelial tumors of the ovary: A) Germ cell tumor of ovary B) Mullerian mixed tumor and adenosarcoma (closed to accrual 03/30/2018) 14. Trophoblastic tumor: A) Choriocarcinoma (closed to accrual) 15. Transitional cell carcinoma other than that of the renal, pelvis, ureter, or bladder (closed to accrual) 16. Cell tumor of the testes and extragonadal germ tumors: A) Seminoma and testicular sex cord cancer B) Non seminomatous tumor C) Teratoma with malignant transformation (closed to accrual) 17. Epithelial tumors of penis - squamous adenocarcinoma cell carcinoma with variants of penis (closed to accrual) 18. Squamous cell carcinoma variants of the genitourinary (GU) system 19. Spindle cell carcinoma of kidney, pelvis, ureter 20. Adenocarcinoma with variants of GU system (excluding prostate cancer) (closed to accrual 07/27/2018) 21. Odontogenic malignant tumors 22. Pancreatic neuroendocrine tumor (PNET) (formerly named: Endocrine carcinoma of pancreas and digestive tract.) (closed to accrual) 23. Neuroendocrine carcinoma including carcinoid of the lung (closed to accrual 12/19/2017) 24. Pheochromocytoma, malignant (closed to accrual) 25. Paraganglioma (closed to accrual 11/29/2018) 26. Carcinomas of pituitary gland, thyroid gland parathyroid gland and adrenal cortex (closed to accrual) 27. Desmoid tumors 28. Peripheral nerve sheath tumors and NF1-related tumors (closed to accrual 09/19/2018) 29. Malignant giant cell tumors 30. Chordoma (closed to accrual 11/29/2018) 31. Adrenal cortical tumors (closed to accrual 06/27/2018) 32. Tumor of unknown primary (Cancer of Unknown Primary; CuP) (closed to accrual 12/22/2017) 33. Not Otherwise Categorized (NOC) Rare Tumors [To obtain permission to enroll in the NOC cohort, contact: S1609SC@swog.org] (closed to accrual 03/15/2019) 34. Adenoid cystic carcinoma (closed to accrual 02/06/2018) 35. Vulvar cancer (closed to accrual) 36. MetaPLASTIC carcinoma (of the breast) (closed to accrual) 37. Gastrointestinal stromal tumor (GIST) (closed to accrual 09/26/2018) 38. Perivascular epithelioid cell tumor (PEComa) 39. Apocrine tumors/extramammary Paget's disease (closed to accrual) 40. Peritoneal mesothelioma 41. Basal cell carcinoma (temporarily closed to accrual 04/29/2020) 42. Clear cell cervical cancer 43. Esthenioneuroblastoma (closed to accrual) 44. Endometrial carcinosarcoma (malignant mixed Mullerian tumors) (closed to accrual) 45. Clear cell endometrial cancer 46. Clear cell ovarian cancer (closed to accrual) 47. Gestational trophoblastic disease (GTD) 48. Gallbladder cancer 49. Small cell carcinoma of the ovary, hypercalcemic type 50. PD-L1 amplified tumors 51. Angiosarcoma 52. High-grade neuroendocrine carcinoma (pancreatic neuroendocrine tumor [PNET] should be enrolled in Cohort 22; prostatic neuroendocrine carcinomas should be enrolled into Cohort 53). Small cell lung cancer is not eligible (closed to accrual) 53. Treatment-emergent small-cell neuroendocrine prostate cancer (t-SCNC)</p></div><p class="comma-list text-right text-muted"><small> <i class="fa fa-map-marker fa-fw" aria-hidden="true"></i> at <span class="comma-list-item"> <strong>UC Davis</strong></span><span class="comma-list-item"> <strong>UC Irvine</strong></span><span class="comma-list-item"> <strong>UCSD</strong></span> </small></p></div></div></li><li class="trials-list--trial card border trials-list--trial-not-joinable trials-list--trial-open-to-age-18-and-over trials-list--trial-open-to-sex-female trials-list--trial-open-to-sex-male trials-list--trial-institution-name-UC%20Davis trials-list--trial-institution-name-UC%20Irvine "><div class="card-body"><h2 class="h4 card-title"> <a href="https://clinicaltrials.ucbraid.org/trial/NCT03212274" class="stretched-link">Olaparib in Treating Patients With Advanced Glioma, Cholangiocarcinoma, or Solid Tumors With IDH1 or IDH2 Mutations</a> </h2><div class="trials-list--trial-details"><p class="h6 text-danger"> <i class="fa fa-ban" aria-hidden="true"></i> <span class="sr-only">Sorry, </span> in progress, not accepting new patients </p><div class="trials-list--trial-summary"><p>This phase II trial studies how well olaparib works in treating patients with glioma, cholangiocarcinoma, or solid tumors with IDH1 or IDH2 mutations that has spread from where it first started (primary site) to other places in the body (metastatic) and that does not respond to treatment (refractory). Olaparib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.</p></div><p class="comma-list text-right text-muted"><small> <i class="fa fa-map-marker fa-fw" aria-hidden="true"></i> at <span class="comma-list-item"> <strong>UC Davis</strong></span><span class="comma-list-item"> <strong>UC Irvine</strong></span> </small></p></div></div></li><li class="trials-list--trial card border trials-list--trial-not-joinable trials-list--trial-open-to-age-18-and-over trials-list--trial-open-to-sex-female trials-list--trial-open-to-sex-male trials-list--trial-institution-name-UCSF "><div class="card-body"><h2 class="h4 card-title"> <a href="https://clinicaltrials.ucbraid.org/trial/NCT03295396" class="stretched-link">ONC201 in Adults With Recurrent H3 K27M-mutant Glioma</a> </h2><div class="trials-list--trial-details"><p class="h6 text-danger"> <i class="fa fa-ban" aria-hidden="true"></i> <span class="sr-only">Sorry, </span> in progress, not accepting new patients </p><div class="trials-list--trial-summary"><p>The primary objective of this phase II trial is to determine the efficacy and safety of ONC201, an oral small molecule imipridone DRD2 antagonist, in adult subjects with recurrent high-grade glioma. This study will test the research hypothesis that histone H3 K27M mutation sensitizes to oral administration of ONC201 in gliomas.</p></div><p class="comma-list text-right text-muted"><small> <i class="fa fa-map-marker fa-fw" aria-hidden="true"></i> at <span class="comma-list-item"> <strong>UCSF</strong></span> </small></p></div></div></li><li class="trials-list--trial card border trials-list--trial-not-joinable trials-list--trial-open-to-age-under-18 trials-list--trial-open-to-sex-female trials-list--trial-open-to-sex-male trials-list--trial-institution-name-UCSF "><div class="card-body"><h2 class="h4 card-title"> <a href="https://clinicaltrials.ucbraid.org/trial/NCT03416530" class="stretched-link">ONC201 in Pediatric H3 K27M Gliomas</a> </h2><div class="trials-list--trial-details"><p class="h6 text-danger"> <i class="fa fa-ban" aria-hidden="true"></i> <span class="sr-only">Sorry, </span> in progress, not accepting new patients </p><div class="trials-list--trial-summary"><p>This is a multicenter, open-label, seven arm, dose escalation, phase I study of oral ONC201 in pediatric patients with newly diagnosed Diffuse Intrinsic Pontine Glioma (DIPG) and recurrent/refractory H3 K27M gliomas. Arm A will define the RP2D for single agent ONC201 in pediatric patients with glioma who are positive for the H3 K27M mutation (positive testing in CLIA laboratory) and have completed at least one line of prior therapy. This will allow for recurrent patients and also patients who have not yet recurred, but have completed radiation and will inevitably recur based on prior clinical experience and the literature. Arm B will define the RP2D for ONC201 in combination with radiation in pediatric patients with newly diagnosed DIPG. Arm C will determine intratumoral drug concentrations and biomarker expression in pediatric patients with midline gliomas. Arm D will determine H3 K27M DNA levels and drug concentrations in the CSF of pediatric H3 K27M-mutant glioma patients. Arm E will determine the RP2D for single agent ONC201 administered as a liquid formulation in Ora-Sweet to patients with DIPG and/or H3 K27M glioma. Arm F is a dose expansion cohort to confirm the safety and estimate the efficacy in recurrent H3 K27M-mutant glioma population at the RP2D. Arm G will define the RP2D for single agent ONC201 given on two consecutive days of each week in pediatric patients with glioma who are positive for the H3 K27M mutation and have completed at least one line of prior therapy.</p></div><p class="comma-list text-right text-muted"><small> <i class="fa fa-map-marker fa-fw" aria-hidden="true"></i> at <span class="comma-list-item"> <strong>UCSF</strong></span> </small></p></div></div></li><li class="trials-list--trial card border trials-list--trial-not-joinable trials-list--trial-open-to-age-under-18 trials-list--trial-open-to-age-18-and-over trials-list--trial-open-to-sex-female trials-list--trial-open-to-sex-male trials-list--trial-institution-name-UCLA "><div class="card-body"><h2 class="h4 card-title"> <a href="https://clinicaltrials.ucbraid.org/trial/NCT02525692" class="stretched-link">Oral ONC201 in Recurrent GBM, H3 K27M Glioma, and Midline Glioma</a> </h2><div class="trials-list--trial-details"><p class="h6 text-danger"> <i class="fa fa-ban" aria-hidden="true"></i> <span class="sr-only">Sorry, </span> in progress, not accepting new patients </p><div class="trials-list--trial-summary"><p>ONC201 is a new drug candidate that kills cancer cells but not normal cells in laboratory studies and has been previously evaluated in a phase I clinical trial in advanced cancer patients. This clinical trial will enroll patients with recurrent glioblastoma or recurrent WHO Grade IV gliomas with the H3 K27M mutation.</p></div><p class="comma-list text-right text-muted"><small> <i class="fa fa-map-marker fa-fw" aria-hidden="true"></i> at <span class="comma-list-item"> <strong>UCLA</strong></span> </small></p></div></div></li><li class="trials-list--trial card border trials-list--trial-not-joinable trials-list--trial-open-to-age-18-and-over trials-list--trial-open-to-sex-female trials-list--trial-open-to-sex-male trials-list--trial-institution-name-UCLA trials-list--trial-institution-name-UCSF "><div class="card-body"><h2 class="h4 card-title"> <a href="https://clinicaltrials.ucbraid.org/trial/NCT02658279" class="stretched-link">Pembrolizumab (MK-3475) in Patients With Recurrent Malignant Glioma With a Hypermutator Phenotype</a> </h2><div class="trials-list--trial-details"><p class="h6 text-danger"> <i class="fa fa-ban" aria-hidden="true"></i> <span class="sr-only">Sorry, </span> in progress, not accepting new patients </p><div class="trials-list--trial-summary"><p>The purpose of this study is to test if the study drug called pembrolizumab could control the growth or shrink the cancer but it could also cause side effects. Researchers hope to learn if the study drug will shrink the cancer by half, or prevent it from growing for at least 6 months. Pembrolizumab is an antibody that targets the immune system and activates it to stop cancer growth and/or kill cancer cells.</p></div><p class="comma-list text-right text-muted"><small> <i class="fa fa-map-marker fa-fw" aria-hidden="true"></i> at <span class="comma-list-item"> <strong>UCLA</strong></span><span class="comma-list-item"> <strong>UCSF</strong></span> </small></p></div></div></li><li class="trials-list--trial card border trials-list--trial-not-joinable trials-list--trial-open-to-age-under-18 trials-list--trial-open-to-age-18-and-over trials-list--trial-open-to-sex-female trials-list--trial-open-to-sex-male trials-list--trial-institution-name-UCLA "><div class="card-body"><h2 class="h4 card-title"> <a href="https://clinicaltrials.ucbraid.org/trial/NCT05457959" class="stretched-link">Peptide-Pulsed Dendritic Cell Vaccination in Combination With Nivolumab and Ipilimumab for the Treatment of Recurrent and/or Progressive Diffuse Hemispheric Glioma, H3 G34-mutant</a> </h2><div class="trials-list--trial-details"><p class="h6 text-danger"> <i class="fa fa-ban" aria-hidden="true"></i> <span class="sr-only">Sorry, </span> not yet accepting patients </p><div class="trials-list--trial-summary"><p>This phase I trial tests peptide-pulsed dendritic cell vaccination in combination with immunotherapy nivolumab and ipilimumab for the treatment diffuse hemispheric glioma with a H3 G34 mutation that has come back (recurrent) and/or is growing, spreading, or getting worse (progressive). Vaccines made from the patient's own white blood cells and peptide-pulsed dendritic cells may help the body build an effective immune response to kill tumor cells. Immunotherapy with monoclonal antibodies, such as nivolumab and ipilimumab, also may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Together, the vaccine and immunotherapy drugs given before and after surgical resection (the removal of tumor cells through surgery) may improve stimulation of anti-tumor immunity to help fight the cancer.</p></div><p class="comma-list text-right text-muted"><small> <i class="fa fa-map-marker fa-fw" aria-hidden="true"></i> at <span class="comma-list-item"> <strong>UCLA</strong></span> </small></p></div></div></li><li class="trials-list--trial card border trials-list--trial-not-joinable trials-list--trial-open-to-age-18-and-over trials-list--trial-open-to-sex-female trials-list--trial-open-to-sex-male trials-list--trial-institution-name-UCLA "><div class="card-body"><h2 class="h4 card-title"> <a href="https://clinicaltrials.ucbraid.org/trial/NCT06176066" class="stretched-link">PH Sensitive MRI Based Resections of Glioblastoma</a> </h2><div class="trials-list--trial-details"><p class="h6 text-danger"> <i class="fa fa-ban" aria-hidden="true"></i> <span class="sr-only">Sorry, </span> not yet accepting patients </p><div class="trials-list--trial-summary"><p>Standard of care therapy and all FDA approved adjuvant therapy for glioblastoma continue to provide < 12-month progression free survival (PFS) and < 24-month overall survival (OS). Standard of care therapy continues to be defined by the volume of tumor that enhances with gadolinium on standard magnetic resonance imaging (MRI). The investigators have identified a significant tumor burden in non-enhancing (NE) regions beyond the contrast-enhancing (CE) portion of tumor. Furthermore, the investigators have adapted a pH-sensitive technique called amine chemical exchange saturation transfer (CEST) MRI to identify tumor cells in NE regions with high sensitivity and specificity. This study is a randomized trial of CEST based resections versus standard of care in newly diagnosed glioblastoma with primary endpoint of progression free survival and secondary endpoints of overall survival and quality of life metrics. The hypothesis being tested is whether surgical resection of infiltrating tumor cells visualized by CEST MRI contributes to survival in glioblastoma patients.</p></div><p class="comma-list text-right text-muted"><small> <i class="fa fa-map-marker fa-fw" aria-hidden="true"></i> at <span class="comma-list-item"> <strong>UCLA</strong></span> </small></p></div></div></li><li class="trials-list--trial card border trials-list--trial-not-joinable trials-list--trial-open-to-age-18-and-over trials-list--trial-open-to-sex-female trials-list--trial-open-to-sex-male trials-list--trial-institution-name-UCLA "><div class="card-body"><h2 class="h4 card-title"> <a href="https://clinicaltrials.ucbraid.org/trial/NCT06448286" class="stretched-link">PH Weighted Chemical Exchange Saturation Transfer MRI-Based Surgical Resection to Improve Survival in Patients With Glioblastoma</a> </h2><div class="trials-list--trial-details"><p class="h6 text-danger"> <i class="fa fa-ban" aria-hidden="true"></i> <span class="sr-only">Sorry, </span> not yet accepting patients </p><div class="trials-list--trial-summary"><p>This phase III trial compares pH weighted chemical exchange saturation transfer (CEST) magnetic resonance imaging (MRI)-based surgical resections to standard of care surgical resections for the treatment of patients with glioblastoma. Standard of care therapy for glioblastoma is surgery to remove tumor tissue that enhances on standard MRI imaging, however, it has been shown that significant tumor burden exists in the region around the tumor tissue that does not enhance with standard MRI. MRI is a procedure in which radio waves and a powerful magnet linked to a computer are used to create detailed pictures of areas inside the body. These pictures can show the difference between normal and tumor tissue. CEST MRI is a technique that uses differences in the tissue environment, like protein concentration or intracellular pH, to generate contrast differences. CEST MRI may identify tumor tissue that does not enhance with standard of care MRI. PH weighted CEST MRI based surgical resection may be more effective compared to standard of care surgical resection in treating patients with glioblastoma.</p></div><p class="comma-list text-right text-muted"><small> <i class="fa fa-map-marker fa-fw" aria-hidden="true"></i> at <span class="comma-list-item"> <strong>UCLA</strong></span> </small></p></div></div></li><li class="trials-list--trial card border trials-list--trial-not-joinable trials-list--trial-open-to-age-18-and-over trials-list--trial-open-to-sex-female trials-list--trial-open-to-sex-male trials-list--trial-institution-name-UC%20Irvine trials-list--trial-institution-name-UCSD "><div class="card-body"><h2 class="h4 card-title"> <a href="https://clinicaltrials.ucbraid.org/trial/NCT02546102" class="stretched-link">ICT-107 in Glioblastoma</a> </h2><div class="trials-list--trial-details"><p class="h6 text-danger"> <i class="fa fa-ban" aria-hidden="true"></i> <span class="sr-only">Sorry, </span> currently not accepting new patients, but might later </p><div class="trials-list--trial-summary"><p>ICT-107 consists of dendritic cells, prepared from autologous mononuclear cells that are pulsed with six synthetic peptides that were derived from tumor associated antigens (TAA) present on glioblastoma tumor cells. This is a Phase 3 study to evaluate ICT-107 in patients with newly diagnosed glioblastoma. Subjects will be randomized to receive standard of care chemoradiation (temozolomide (TMZ) with either ICT-107 or a blinded control. Reinfusion with the pulsed dendritic cells should stimulate cytotoxic T cells to specifically target glioblastoma tumour cells.</p></div><p class="comma-list text-right text-muted"><small> <i class="fa fa-map-marker fa-fw" aria-hidden="true"></i> at <span class="comma-list-item"> <strong>UC Irvine</strong></span><span class="comma-list-item"> <strong>UCSD</strong></span> </small></p></div></div></li><li class="trials-list--trial card border trials-list--trial-not-joinable trials-list--trial-open-to-age-18-and-over trials-list--trial-open-to-sex-female trials-list--trial-open-to-sex-male trials-list--trial-institution-name-UCSF "><div class="card-body"><h2 class="h4 card-title"> <a href="https://clinicaltrials.ucbraid.org/trial/NCT00626990" class="stretched-link">Anaplastic Glioma Without 1p/19q Loss of Heterozygosity (LOH)</a> </h2><div class="trials-list--trial-details"><p class="h6 text-danger"> <i class="fa fa-ban" aria-hidden="true"></i> <span class="sr-only">Sorry, </span> in progress, not accepting new patients </p><div class="trials-list--trial-summary"><p>RATIONALE: Radiation therapy uses high-energy x-rays to kill tumor cells. Drugs used in chemotherapy, such as temozolomide, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving radiation therapy together with temozolomide may kill more tumor cells. It is not yet known whether giving temozolomide during and/or after radiation therapy is more effective than radiation therapy alone in treating anaplastic glioma. PURPOSE: This randomized phase III trial is studying giving temozolomide during and/or after radiation therapy to see how well it works compared to radiation therapy alone in treating patients with anaplastic glioma.</p></div><p class="comma-list text-right text-muted"><small> <i class="fa fa-map-marker fa-fw" aria-hidden="true"></i> at <span class="comma-list-item"> <strong>UCSF</strong></span> </small></p></div></div></li><li class="trials-list--trial card border trials-list--trial-not-joinable trials-list--trial-open-to-age-18-and-over trials-list--trial-open-to-sex-female trials-list--trial-open-to-sex-male trials-list--trial-institution-name-UC%20Irvine "><div class="card-body"><h2 class="h4 card-title"> <a href="https://clinicaltrials.ucbraid.org/trial/NCT03935685" class="stretched-link">Mirtazapine for the Dual Tx of Depression and CINV in High-Grade Glioma Pts on TMZ</a> </h2><div class="trials-list--trial-details"><p class="h6 text-danger"> <i class="fa fa-ban" aria-hidden="true"></i> <span class="sr-only">Sorry, </span> in progress, not accepting new patients </p><div class="trials-list--trial-summary"><p>The purpose of the study is to estimate the ability of mirtazapine to reduce depression, nausea, and vomiting, and maintain weight in depressed glioma patients undergoing Temozolomide (TMZ) therapy. Of equal importance, the investigators will monitor the tolerability of Mirtazapine in these patients over the course of the study.</p></div><p class="comma-list text-right text-muted"><small> <i class="fa fa-map-marker fa-fw" aria-hidden="true"></i> at <span class="comma-list-item"> <strong>UC Irvine</strong></span> </small></p></div></div></li><li class="trials-list--trial card border trials-list--trial-not-joinable trials-list--trial-open-to-age-18-and-over trials-list--trial-open-to-sex-female trials-list--trial-open-to-sex-male trials-list--trial-institution-name-UC%20Irvine trials-list--trial-institution-name-UCSD trials-list--trial-institution-name-UCSF "><div class="card-body"><h2 class="h4 card-title"> <a href="https://clinicaltrials.ucbraid.org/trial/NCT04471844" class="stretched-link">Pivotal, Randomized, Open-label Study of Optune® (Tumor Treating Fields) Concomitant with RT & TMZ for the Treatment of Newly Diagnosed GBM</a> </h2><div class="trials-list--trial-details"><p class="h6 text-danger"> <i class="fa fa-ban" aria-hidden="true"></i> <span class="sr-only">Sorry, </span> in progress, not accepting new patients </p><div class="trials-list--trial-summary"><p>To test the effectiveness and safety of Optune® given concomitantly with radiation therapy (RT) and temozolomide (TMZ) in newly diagnosed GBM patients, compared to radiation therapy and temozolomide alone. In both arms, Optune® and maintenance temozolomide are continued following radiation therapy.</p></div><p class="comma-list text-right text-muted"><small> <i class="fa fa-map-marker fa-fw" aria-hidden="true"></i> at <span class="comma-list-item"> <strong>UC Irvine</strong></span><span class="comma-list-item"> <strong>UCSD</strong></span><span class="comma-list-item"> <strong>UCSF</strong></span> </small></p></div></div></li><li class="trials-list--trial card border trials-list--trial-not-joinable trials-list--trial-open-to-age-18-and-over trials-list--trial-open-to-sex-female trials-list--trial-open-to-sex-male trials-list--trial-institution-name-UCSF "><div class="card-body"><h2 class="h4 card-title"> <a href="https://clinicaltrials.ucbraid.org/trial/NCT02986178" class="stretched-link">PVSRIPO in Recurrent Malignant Glioma</a> </h2><div class="trials-list--trial-details"><p class="h6 text-danger"> <i class="fa fa-ban" aria-hidden="true"></i> <span class="sr-only">Sorry, </span> in progress, not accepting new patients </p><div class="trials-list--trial-summary"><p>This is a phase 2 study of oncolytic polio/rhinovirus recombinant (PVSRIPO) in adult patients with recurrent World Health Organization (WHO) grade IV malignant glioma.</p></div><p class="comma-list text-right text-muted"><small> <i class="fa fa-map-marker fa-fw" aria-hidden="true"></i> at <span class="comma-list-item"> <strong>UCSF</strong></span> </small></p></div></div></li><li class="trials-list--trial card border trials-list--trial-not-joinable trials-list--trial-open-to-age-18-and-over trials-list--trial-open-to-sex-female trials-list--trial-open-to-sex-male trials-list--trial-institution-name-UC%20Irvine trials-list--trial-institution-name-UCSD "><div class="card-body"><h2 class="h4 card-title"> <a href="https://clinicaltrials.ucbraid.org/trial/NCT00978458" class="stretched-link">Radiation Therapy With or Without Temozolomide in Treating Patients With Low-Grade Glioma</a> </h2><div class="trials-list--trial-details"><p class="h6 text-danger"> <i class="fa fa-ban" aria-hidden="true"></i> <span class="sr-only">Sorry, </span> in progress, not accepting new patients </p><div class="trials-list--trial-summary"><p>RATIONALE: Radiation therapy uses high-energy x-rays to kill tumor cells. Specialized radiation therapy that delivers a high dose of radiation directly to the tumor may kill more tumor cells and cause less damage to normal tissue. Drugs used in chemotherapy, such as temozolomide, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. It is not yet known whether radiation therapy is more effective when given together with or without temozolomide in treating patients with low-grade glioma. PURPOSE: This randomized phase III trial is studying radiation therapy so see how well it works when given together with or without temozolomide in treating patients with low-grade glioma.</p></div><p class="comma-list text-right text-muted"><small> <i class="fa fa-map-marker fa-fw" aria-hidden="true"></i> at <span class="comma-list-item"> <strong>UC Irvine</strong></span><span class="comma-list-item"> <strong>UCSD</strong></span> </small></p></div></div></li><li class="trials-list--trial card border trials-list--trial-not-joinable trials-list--trial-open-to-age-18-and-over trials-list--trial-open-to-sex-female trials-list--trial-open-to-sex-male trials-list--trial-institution-name-UCSF "><div class="card-body"><h2 class="h4 card-title"> <a href="https://clinicaltrials.ucbraid.org/trial/NCT03948490" class="stretched-link">Rehabilitation and Longitudinal Follow-up of Cognition in Adult Lower Grade Gliomas</a> </h2><div class="trials-list--trial-details"><p class="h6 text-danger"> <i class="fa fa-ban" aria-hidden="true"></i> <span class="sr-only">Sorry, </span> in progress, not accepting new patients </p><div class="trials-list--trial-summary"><p>Patients with glial brain tumors have increasingly improved outcomes, with median survival of 5-15 years. However, the treatments, including surgery, radiation, and chemotherapy, often lead to impaired attention, working memory, and other cognitive functions. These cognitive deficits frequently have significant impact on patient quality of life. Although currently, there is no established standard of care to treat cognitive deficits in brain tumor patients, standard cognitive rehabilitative treatments have been developed for those with traumatic brain injury and stroke. However, the feasibility and efficacy of these cognitive treatments in individuals with brain tumors remains unclear.</p></div><p class="comma-list text-right text-muted"><small> <i class="fa fa-map-marker fa-fw" aria-hidden="true"></i> at <span class="comma-list-item"> <strong>UCSF</strong></span> </small></p></div></div></li><li class="trials-list--trial card border trials-list--trial-not-joinable trials-list--trial-open-to-age-18-and-over trials-list--trial-open-to-sex-female trials-list--trial-open-to-sex-male trials-list--trial-institution-name-UC%20Davis "><div class="card-body"><h2 class="h4 card-title"> <a href="https://clinicaltrials.ucbraid.org/trial/NCT01638533" class="stretched-link">Romidepsin in Treating Patients With Lymphoma, Chronic Lymphocytic Leukemia, or Solid Tumors With Liver Dysfunction</a> </h2><div class="trials-list--trial-details"><p class="h6 text-danger"> <i class="fa fa-ban" aria-hidden="true"></i> <span class="sr-only">Sorry, </span> in progress, not accepting new patients </p><div class="trials-list--trial-summary"><p>This phase I trial studies the side effects and best dose of romidepsin in treating patients with lymphoma, chronic lymphocytic leukemia, or solid tumors with liver dysfunction. Romidepsin may stop the growth of cancer cells by entering the cancer cells and by blocking the activity of proteins that are important for the cancer's growth and survival.</p></div><p class="comma-list text-right text-muted"><small> <i class="fa fa-map-marker fa-fw" aria-hidden="true"></i> at <span class="comma-list-item"> <strong>UC Davis</strong></span> </small></p></div></div></li><li class="trials-list--trial card border trials-list--trial-not-joinable trials-list--trial-open-to-age-under-18 trials-list--trial-open-to-age-18-and-over trials-list--trial-open-to-sex-female trials-list--trial-open-to-sex-male trials-list--trial-institution-name-UC%20Davis trials-list--trial-institution-name-UCLA trials-list--trial-institution-name-UCSF "><div class="card-body"><h2 class="h4 card-title"> <a href="https://clinicaltrials.ucbraid.org/trial/NCT03213678" class="stretched-link">Samotolisib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With TSC or PI3K/MTOR Mutations (A Pediatric MATCH Treatment Trial)</a> </h2><div class="trials-list--trial-details"><p class="h6 text-danger"> <i class="fa fa-ban" aria-hidden="true"></i> <span class="sr-only">Sorry, </span> in progress, not accepting new patients </p><div class="trials-list--trial-summary"><p>This phase II Pediatric MATCH trial studies how well samotolisib works in treating patients with solid tumors, non-Hodgkin lymphoma, or histiocytic disorders with TSC or PI3K/MTOR mutations that have spread to other places in the body (metastatic) and have come back (recurrent) or do not respond to treatment (refractory). Samotolisib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth.</p></div><p class="comma-list text-right text-muted"><small> <i class="fa fa-map-marker fa-fw" aria-hidden="true"></i> at <span class="comma-list-item"> <strong>UC Davis</strong></span><span class="comma-list-item"> <strong>UCLA</strong></span><span class="comma-list-item"> <strong>UCSF</strong></span> </small></p></div></div></li><li class="trials-list--trial card border trials-list--trial-not-joinable trials-list--trial-open-to-age-under-18 trials-list--trial-open-to-age-18-and-over trials-list--trial-open-to-sex-female trials-list--trial-open-to-sex-male trials-list--trial-institution-name-UCSF "><div class="card-body"><h2 class="h4 card-title"> <a href="https://clinicaltrials.ucbraid.org/trial/NCT02323880" class="stretched-link">Selinexor in Treating Younger Patients With Recurrent or Refractory Solid Tumors or High-Grade Gliomas</a> </h2><div class="trials-list--trial-details"><p class="h6 text-danger"> <i class="fa fa-ban" aria-hidden="true"></i> <span class="sr-only">Sorry, </span> in progress, not accepting new patients </p><div class="trials-list--trial-summary"><p>This phase I trial studies the side effects and best dose of selinexor in treating younger patients with solid tumors or central nervous system (CNS) tumors that have come back (recurrent) or do not respond to treatment (refractory). Drugs used in chemotherapy, such as selinexor, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading.</p></div><p class="comma-list text-right text-muted"><small> <i class="fa fa-map-marker fa-fw" aria-hidden="true"></i> at <span class="comma-list-item"> <strong>UCSF</strong></span> </small></p></div></div></li><li class="trials-list--trial card border trials-list--trial-not-joinable trials-list--trial-open-to-age-under-18 trials-list--trial-open-to-age-18-and-over trials-list--trial-open-to-sex-female trials-list--trial-open-to-sex-male trials-list--trial-institution-name-UC%20Davis trials-list--trial-institution-name-UCLA trials-list--trial-institution-name-UCSF "><div class="card-body"><h2 class="h4 card-title"> <a href="https://clinicaltrials.ucbraid.org/trial/NCT04320888" class="stretched-link">Selpercatinib for the Treatment of Advanced Solid Tumors, Lymphomas, or Histiocytic Disorders With Activating RET Gene Alterations, a Pediatric MATCH Treatment Trial</a> </h2><div class="trials-list--trial-details"><p class="h6 text-danger"> <i class="fa fa-ban" aria-hidden="true"></i> <span class="sr-only">Sorry, </span> in progress, not accepting new patients </p><div class="trials-list--trial-summary"><p>This phase II pediatric MATCH treatment trial studies how well selpercatinib works in treating patients with solid tumors that may have spread from where they first started to nearby tissue, lymph nodes, or distant parts of the body (advanced), lymphomas, or histiocytic disorders that have activating RET gene alterations. Selpercatinib may block the growth of cancer cells that have specific genetic changes in an important signaling pathway (called the RET pathway) and may reduce tumor size.</p></div><p class="comma-list text-right text-muted"><small> <i class="fa fa-map-marker fa-fw" aria-hidden="true"></i> at <span class="comma-list-item"> <strong>UC Davis</strong></span><span class="comma-list-item"> <strong>UCLA</strong></span><span class="comma-list-item"> <strong>UCSF</strong></span> </small></p></div></div></li><li class="trials-list--trial card border trials-list--trial-not-joinable trials-list--trial-open-to-age-under-18 trials-list--trial-open-to-age-18-and-over trials-list--trial-open-to-sex-female trials-list--trial-open-to-sex-male trials-list--trial-institution-name-UCSF "><div class="card-body"><h2 class="h4 card-title"> <a href="https://clinicaltrials.ucbraid.org/trial/NCT01089101" class="stretched-link">Selumetinib in Treating Young Patients With Recurrent or Refractory Low Grade Glioma</a> </h2><div class="trials-list--trial-details"><p class="h6 text-danger"> <i class="fa fa-ban" aria-hidden="true"></i> <span class="sr-only">Sorry, </span> in progress, not accepting new patients </p><div class="trials-list--trial-summary"><p>This phase I/II trial studies the side effects and the best dose of selumetinib and how well it works in treating or re-treating young patients with low grade glioma that has come back (recurrent) or does not respond to treatment (refractory). Selumetinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.</p></div><p class="comma-list text-right text-muted"><small> <i class="fa fa-map-marker fa-fw" aria-hidden="true"></i> at <span class="comma-list-item"> <strong>UCSF</strong></span> </small></p></div></div></li><li class="trials-list--trial card border trials-list--trial-not-joinable trials-list--trial-open-to-age-18-and-over trials-list--trial-open-to-sex-female trials-list--trial-open-to-sex-male trials-list--trial-institution-name-UCSF "><div class="card-body"><h2 class="h4 card-title"> <a href="https://clinicaltrials.ucbraid.org/trial/NCT03343197" class="stretched-link">AG-120 and AG-881 in Subjects With Low Grade Glioma</a> </h2><div class="trials-list--trial-details"><p class="h6 text-danger"> <i class="fa fa-ban" aria-hidden="true"></i> <span class="sr-only">Sorry, </span> in progress, not accepting new patients </p><div class="trials-list--trial-summary"><p>Study to evaluate the suppression of 2-HG (2-hydroxyglutarate) in IDH-1 mutant gliomas in resected tumor tissue following pre-surgical treatment with AG-120 or AG-881.</p></div><p class="comma-list text-right text-muted"><small> <i class="fa fa-map-marker fa-fw" aria-hidden="true"></i> at <span class="comma-list-item"> <strong>UCSF</strong></span> </small></p></div></div></li><li class="trials-list--trial card border trials-list--trial-not-joinable trials-list--trial-open-to-age-18-and-over trials-list--trial-open-to-sex-female trials-list--trial-open-to-sex-male trials-list--trial-institution-name-UCSF "><div class="card-body"><h2 class="h4 card-title"> <a href="https://clinicaltrials.ucbraid.org/trial/NCT05023551" class="stretched-link">DSP-0390 in Patients with Recurrent High-Grade Glioma</a> </h2><div class="trials-list--trial-details"><p class="h6 text-danger"> <i class="fa fa-ban" aria-hidden="true"></i> <span class="sr-only">Sorry, </span> in progress, not accepting new patients </p><div class="trials-list--trial-summary"><p>This is a study of DSP-0390 in patients with recurrent high grade glioma.</p></div><p class="comma-list text-right text-muted"><small> <i class="fa fa-map-marker fa-fw" aria-hidden="true"></i> at <span class="comma-list-item"> <strong>UCSF</strong></span> </small></p></div></div></li><li class="trials-list--trial card border trials-list--trial-not-joinable trials-list--trial-open-to-age-18-and-over trials-list--trial-open-to-sex-female trials-list--trial-open-to-sex-male trials-list--trial-institution-name-UCSF "><div class="card-body"><h2 class="h4 card-title"> <a href="https://clinicaltrials.ucbraid.org/trial/NCT04521686" class="stretched-link">LY3410738 Administered to Patients With Advanced Solid Tumors With IDH1 or IDH2 Mutations</a> </h2><div class="trials-list--trial-details"><p class="h6 text-danger"> <i class="fa fa-ban" aria-hidden="true"></i> <span class="sr-only">Sorry, </span> in progress, not accepting new patients </p><div class="trials-list--trial-summary"><p>This is an open-label, multicenter Phase 1 study to evaluate safety, tolerability and preliminary efficacy of oral LY3410738 in patients with isocitrate dehydrogenase 1 (IDH1) arginine 132 (R132)-mutant advanced solid tumors, including but not limited to cholangiocarcinoma, chondrosarcoma, and glioma or isocitrate dehydrogenase 2 (IDH2) arginine 140 (R140) or arginine 172 (R172) mutant cholangiocarcinoma.</p></div><p class="comma-list text-right text-muted"><small> <i class="fa fa-map-marker fa-fw" aria-hidden="true"></i> at <span class="comma-list-item"> <strong>UCSF</strong></span> </small></p></div></div></li><li class="trials-list--trial card border trials-list--trial-not-joinable trials-list--trial-open-to-age-18-and-over trials-list--trial-open-to-sex-female trials-list--trial-open-to-sex-male trials-list--trial-institution-name-UCLA "><div class="card-body"><h2 class="h4 card-title"> <a href="https://clinicaltrials.ucbraid.org/trial/NCT04913337" class="stretched-link">NGM707 As Monotherapy and in Combination with Pembrolizumab in Advanced or Metastatic Solid Tumor Malignancies</a> </h2><div class="trials-list--trial-details"><p class="h6 text-danger"> <i class="fa fa-ban" aria-hidden="true"></i> <span class="sr-only">Sorry, </span> in progress, not accepting new patients </p><div class="trials-list--trial-summary"><p>Study of NGM707 as Monotherapy and in Combination with Pembrolizumab in Advanced or Metastatic Solid Tumor Malignancies</p></div><p class="comma-list text-right text-muted"><small> <i class="fa fa-map-marker fa-fw" aria-hidden="true"></i> at <span class="comma-list-item"> <strong>UCLA</strong></span> </small></p></div></div></li><li class="trials-list--trial card border trials-list--trial-not-joinable trials-list--trial-open-to-age-18-and-over trials-list--trial-open-to-sex-female trials-list--trial-open-to-sex-male trials-list--trial-institution-name-UC%20Irvine "><div class="card-body"><h2 class="h4 card-title"> <a href="https://clinicaltrials.ucbraid.org/trial/NCT03450850" class="stretched-link">NOVOTTF-200A In Bevacizumab-Naive Subjects With Recurrent Grade III Malignant Astrocytoma</a> </h2><div class="trials-list--trial-details"><p class="h6 text-danger"> <i class="fa fa-ban" aria-hidden="true"></i> <span class="sr-only">Sorry, </span> in progress, not accepting new patients </p><div class="trials-list--trial-summary"><p>This is a Phase 2 study in subjects with WHO Grade III Anaplastic Astrocytoma (G3 astrocytoma) who had progressive disease during first or second line treatment and who have not previously received any BEV or any experimental agents.</p></div><p class="comma-list text-right text-muted"><small> <i class="fa fa-map-marker fa-fw" aria-hidden="true"></i> at <span class="comma-list-item"> <strong>UC Irvine</strong></span> </small></p></div></div></li><li class="trials-list--trial card border trials-list--trial-not-joinable trials-list--trial-open-to-age-under-18 trials-list--trial-open-to-age-18-and-over trials-list--trial-open-to-sex-female trials-list--trial-open-to-sex-male trials-list--trial-institution-name-UCSF "><div class="card-body"><h2 class="h4 card-title"> <a href="https://clinicaltrials.ucbraid.org/trial/NCT03709680" class="stretched-link">Palbociclib Combined With Chemotherapy In Pediatric Patients With Recurrent/Refractory Solid Tumors</a> </h2><div class="trials-list--trial-details"><p class="h6 text-danger"> <i class="fa fa-ban" aria-hidden="true"></i> <span class="sr-only">Sorry, </span> in progress, not accepting new patients </p><div class="trials-list--trial-summary"><p>A study to learn about safety and find out maximum tolerable dose of palbociclib given in combination with chemotherapy (temozolomide with irinotecan or topotecan with cyclophosphamide) in children, adolescents and young adults with recurrent or refractory solid tumors (phase 1). Neuroblastoma tumor specific cohort to further evaluate antitumor activity of palbociclib in combination with topotecan and cyclophosphamide in children, adolescents, and young adults with recurrent or refractory neuroblastoma. Phase 2 to learn about the efficacy of palbociclib in combination with irinotecan and temozolomide when compared with irinotecan and temozolomide alone in the treatment of children, adolescents, and young adults with recurrent or refractory Ewing sarcoma (EWS).</p></div><p class="comma-list text-right text-muted"><small> <i class="fa fa-map-marker fa-fw" aria-hidden="true"></i> at <span class="comma-list-item"> <strong>UCSF</strong></span> </small></p></div></div></li><li class="trials-list--trial card border trials-list--trial-not-joinable trials-list--trial-open-to-age-under-18 trials-list--trial-open-to-age-18-and-over trials-list--trial-open-to-sex-female trials-list--trial-open-to-sex-male trials-list--trial-institution-name-UC%20Irvine trials-list--trial-institution-name-UCLA trials-list--trial-institution-name-UCSD trials-list--trial-institution-name-UCSF "><div class="card-body"><h2 class="h4 card-title"> <a href="https://clinicaltrials.ucbraid.org/trial/NCT04164901" class="stretched-link">Vorasidenib (AG-881) in Participants With Residual or Recurrent Grade 2 Glioma With an IDH1 or IDH2 Mutation (INDIGO)</a> </h2><div class="trials-list--trial-details"><p class="h6 text-danger"> <i class="fa fa-ban" aria-hidden="true"></i> <span class="sr-only">Sorry, </span> in progress, not accepting new patients </p><div class="trials-list--trial-summary"><p>Study AG881-C-004 is a phase 3, multicenter, randomized, double-blind, placebo-controlled study comparing the efficacy of vorasidenib to placebo in participants with residual or recurrent Grade 2 glioma with an IDH1 or IDH2 mutation who have undergone surgery as their only treatment. Participants will be required to have central confirmation of IDH mutation status prior to randomization. Approximately 340 participants are planned to be randomized 1:1 to receive orally administered vorasidenib 40 mg QD or placebo.</p></div><p class="comma-list text-right text-muted"><small> <i class="fa fa-map-marker fa-fw" aria-hidden="true"></i> at <span class="comma-list-item"> <strong>UC Irvine</strong></span><span class="comma-list-item"> <strong>UCLA</strong></span><span class="comma-list-item"> <strong>UCSD</strong></span><span class="comma-list-item"> <strong>UCSF</strong></span> </small></p></div></div></li><li class="trials-list--trial card border trials-list--trial-not-joinable trials-list--trial-open-to-age-18-and-over trials-list--trial-open-to-sex-female trials-list--trial-open-to-sex-male trials-list--trial-institution-name-UCSF "><div class="card-body"><h2 class="h4 card-title"> <a href="https://clinicaltrials.ucbraid.org/trial/NCT05267106" class="stretched-link">Pemigatinib in Participants With Previously Treated Glioblastoma or Other Primary Central Nervous System Tumors Harboring Activating FGFR1-3 Alterations</a> </h2><div class="trials-list--trial-details"><p class="h6 text-danger"> <i class="fa fa-ban" aria-hidden="true"></i> <span class="sr-only">Sorry, </span> in progress, not accepting new patients </p><div class="trials-list--trial-summary"><p>This is an open-label, monotherapy study of pemigatinib in participants with recurrent glioblastoma (GBM) or other recurrent gliomas, circumscribed astrocytic gliomas, and glioneuronal and neuronal tumors with an activating FGFR1-3 mutation or fusion/rearrangement. This study consists of 2 cohorts, Cohorts A, and B, and will enroll approximately 82 participants into each cohort. Participants will receive pemigatinib 13.5 mg QD on a 2-week on-therapy and 1-week off-therapy schedule as long as they are receiving benefit and have not met any criteria for study withdrawal.</p></div><p class="comma-list text-right text-muted"><small> <i class="fa fa-map-marker fa-fw" aria-hidden="true"></i> at <span class="comma-list-item"> <strong>UCSF</strong></span> </small></p></div></div></li><li class="trials-list--trial card border trials-list--trial-not-joinable trials-list--trial-open-to-age-18-and-over trials-list--trial-open-to-sex-female trials-list--trial-open-to-sex-male trials-list--trial-institution-name-UCLA "><div class="card-body"><h2 class="h4 card-title"> <a href="https://clinicaltrials.ucbraid.org/trial/NCT04606316" class="stretched-link">Surgical Nivolumab And Ipilimumab For Recurrent GBM</a> </h2><div class="trials-list--trial-details"><p class="h6 text-danger"> <i class="fa fa-ban" aria-hidden="true"></i> <span class="sr-only">Sorry, </span> in progress, not accepting new patients </p><div class="trials-list--trial-summary"><p>This research trial is studying the safety and effectiveness of nivolumab in combination with ipilimumab and surgery when used in the treatment of recurrent glioblastoma. The names of the study drugs involved in this study are: - Nivolumab - Ipilimumab - Placebo (IV solution with no medicine) - Zr-89 Crefmirlimab berdoxam (optional sub-study)</p></div><p class="comma-list text-right text-muted"><small> <i class="fa fa-map-marker fa-fw" aria-hidden="true"></i> at <span class="comma-list-item"> <strong>UCLA</strong></span> </small></p></div></div></li><li class="trials-list--trial card border trials-list--trial-not-joinable trials-list--trial-open-to-age-18-and-over trials-list--trial-open-to-sex-female trials-list--trial-open-to-sex-male trials-list--trial-institution-name-UCSF "><div class="card-body"><h2 class="h4 card-title"> <a href="https://clinicaltrials.ucbraid.org/trial/NCT05163080" class="stretched-link">SurVaxM Plus Adjuvant Temozolomide for Newly Diagnosed Glioblastoma (SURVIVE)</a> </h2><div class="trials-list--trial-details"><p class="h6 text-danger"> <i class="fa fa-ban" aria-hidden="true"></i> <span class="sr-only">Sorry, </span> in progress, not accepting new patients </p><div class="trials-list--trial-summary"><p>The main purpose of this study is to determine whether adding SurVaxM to standard-of-care temozolomide chemotherapy is better than temozolomide treatment alone for patients with newly diagnosed glioblastoma. This study is designed to compare the length of survival in patients with newly diagnosed glioblastoma who receive temozolomide plus SurVaxM to that of patients treated with standard-of-care temozolomide plus placebo. This study aims to discover what effects, both good and bad, this combination of drugs may have on you and to see if the study drug (SurVaxM) can create an immune response in your blood that is directed against your cancer cells. This study also aims to determine whether treatment with SurVaxM plus temozolomide improves the survival of glioblastoma patients like yourself compared to treatment with temozolomide alone.</p></div><p class="comma-list text-right text-muted"><small> <i class="fa fa-map-marker fa-fw" aria-hidden="true"></i> at <span class="comma-list-item"> <strong>UCSF</strong></span> </small></p></div></div></li><li class="trials-list--trial card border trials-list--trial-not-joinable trials-list--trial-open-to-age-18-and-over trials-list--trial-open-to-sex-female trials-list--trial-open-to-sex-male trials-list--trial-institution-name-UC%20Davis trials-list--trial-institution-name-UC%20Irvine trials-list--trial-institution-name-UCSD "><div class="card-body"><h2 class="h4 card-title"> <a href="https://clinicaltrials.ucbraid.org/trial/NCT02465060" class="stretched-link">Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)</a> </h2><p class="h5" id="trials-list--trial-tagline">“Will identifying genetic abnormalities in tumor cells help doctors plan better, more personalized treatment for cancer patients?”</p><div class="trials-list--trial-details"><p class="h6 text-danger"> <i class="fa fa-ban" aria-hidden="true"></i> <span class="sr-only">Sorry, </span> in progress, not accepting new patients </p><div class="trials-list--trial-summary"><p>This phase II MATCH screening and multi-sub-trial studies how well treatment that is directed by genetic testing works in patients with solid tumors, lymphomas, or multiple myelomas that may have spread from where it first started to nearby tissue, lymph nodes, or distant parts of the body (advanced) and does not respond to treatment (refractory). Patients must have progressed following at least one line of standard treatment or for which no agreed upon treatment approach exists. Genetic tests look at the unique genetic material (genes) of patients' tumor cells. Patients with genetic abnormalities (such as mutations, amplifications, or translocations) may benefit more from treatment which targets their tumor's particular genetic abnormality. Identifying these genetic abnormalities first may help doctors plan better treatment for patients with solid tumors, lymphomas, or multiple myeloma.</p></div><p class="comma-list text-right text-muted"><small> <i class="fa fa-map-marker fa-fw" aria-hidden="true"></i> at <span class="comma-list-item"> <strong>UC Davis</strong></span><span class="comma-list-item"> <strong>UC Irvine</strong></span><span class="comma-list-item"> <strong>UCSD</strong></span> </small></p></div></div></li><li class="trials-list--trial card border trials-list--trial-not-joinable trials-list--trial-open-to-age-under-18 trials-list--trial-open-to-age-18-and-over trials-list--trial-open-to-sex-female trials-list--trial-open-to-sex-male trials-list--trial-institution-name-UCLA trials-list--trial-institution-name-UCSF "><div class="card-body"><h2 class="h4 card-title"> <a href="https://clinicaltrials.ucbraid.org/trial/NCT03213665" class="stretched-link">Tazemetostat in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With EZH2, SMARCB1, or SMARCA4 Gene Mutations (A Pediatric MATCH Treatment Trial)</a> </h2><div class="trials-list--trial-details"><p class="h6 text-danger"> <i class="fa fa-ban" aria-hidden="true"></i> <span class="sr-only">Sorry, </span> in progress, not accepting new patients </p><div class="trials-list--trial-summary"><p>This phase II Pediatric MATCH trial studies how well tazemetostat works in treating patients with brain tumors, solid tumors, non-Hodgkin lymphoma, or histiocytic disorders that have come back (relapsed) or do not respond to treatment (refractory) and have EZH2, SMARCB1, or SMARCA4 gene mutations. Tazemetostat may stop the growth of tumor cells by blocking EZH2 and its relation to some of the pathways needed for cell proliferation.</p></div><p class="comma-list text-right text-muted"><small> <i class="fa fa-map-marker fa-fw" aria-hidden="true"></i> at <span class="comma-list-item"> <strong>UCLA</strong></span><span class="comma-list-item"> <strong>UCSF</strong></span> </small></p></div></div></li><li class="trials-list--trial card border trials-list--trial-not-joinable trials-list--trial-open-to-age-under-18 trials-list--trial-open-to-age-18-and-over trials-list--trial-open-to-sex-female trials-list--trial-open-to-sex-male trials-list--trial-institution-name-UC%20Irvine trials-list--trial-institution-name-UCSD "><div class="card-body"><h2 class="h4 card-title"> <a href="https://clinicaltrials.ucbraid.org/trial/NCT03528642" class="stretched-link">Telaglenastat With Radiation Therapy and Temozolomide in Treating Patients With IDH-Mutated Diffuse Astrocytoma or Anaplastic Astrocytoma</a> </h2><div class="trials-list--trial-details"><p class="h6 text-danger"> <i class="fa fa-ban" aria-hidden="true"></i> <span class="sr-only">Sorry, </span> in progress, not accepting new patients </p><div class="trials-list--trial-summary"><p>This phase 1b trial studies the side effects and best dose of telaglenastat in combination with radiation therapy and temozolomide in treating patients with IDH-mutated diffuse or anaplastic astrocytoma. Telaglenastat may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Radiation therapy uses high energy x-rays to kill tumor cells and shrink tumors. Chemotherapy drugs, such as temozolomide, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving telaglenastat with radiation therapy and temozolomide may work better than surgery, radiation therapy, and temozolomide in treating patients with IDH-mutated diffuse astrocytoma or anaplastic astrocytoma.</p></div><p class="comma-list text-right text-muted"><small> <i class="fa fa-map-marker fa-fw" aria-hidden="true"></i> at <span class="comma-list-item"> <strong>UC Irvine</strong></span><span class="comma-list-item"> <strong>UCSD</strong></span> </small></p></div></div></li><li class="trials-list--trial card border trials-list--trial-not-joinable trials-list--trial-open-to-age-18-and-over trials-list--trial-open-to-sex-female trials-list--trial-open-to-sex-male trials-list--trial-institution-name-UC%20Davis trials-list--trial-institution-name-UCSD trials-list--trial-institution-name-UCSF "><div class="card-body"><h2 class="h4 card-title"> <a href="https://clinicaltrials.ucbraid.org/trial/NCT02152982" class="stretched-link">Temozolomide With or Without Veliparib in Treating Patients With Newly Diagnosed Glioblastoma Multiforme</a> </h2><div class="trials-list--trial-details"><p class="h6 text-danger"> <i class="fa fa-ban" aria-hidden="true"></i> <span class="sr-only">Sorry, </span> in progress, not accepting new patients </p><div class="trials-list--trial-summary"><p>This randomized phase II/III trial studies how well temozolomide and veliparib work compared to temozolomide alone in treating patients with newly diagnosed glioblastoma multiforme. Drugs used in chemotherapy, such as temozolomide, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Veliparib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. It is not yet known whether temozolomide is more effective with or without veliparib in treating glioblastoma multiforme.</p></div><p class="comma-list text-right text-muted"><small> <i class="fa fa-map-marker fa-fw" aria-hidden="true"></i> at <span class="comma-list-item"> <strong>UC Davis</strong></span><span class="comma-list-item"> <strong>UCSD</strong></span><span class="comma-list-item"> <strong>UCSF</strong></span> </small></p></div></div></li><li class="trials-list--trial card border trials-list--trial-not-joinable trials-list--trial-open-to-age-18-and-over trials-list--trial-open-to-sex-female trials-list--trial-open-to-sex-male trials-list--trial-institution-name-UCLA "><div class="card-body"><h2 class="h4 card-title"> <a href="https://clinicaltrials.ucbraid.org/trial/NCT03107780" class="stretched-link">Testing the Ability of AMG 232 (KRT 232) to Get Into the Tumor in Patients With Brain Cancer</a> </h2><div class="trials-list--trial-details"><p class="h6 text-danger"> <i class="fa fa-ban" aria-hidden="true"></i> <span class="sr-only">Sorry, </span> currently not accepting new patients, but might later </p><div class="trials-list--trial-summary"><p>This phase I trial studies the side effects and best dose of navtemadlin in treating patients with glioblastoma (brain cancer) that is newly diagnosed or has come back (recurrent). Navtemadlin may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.</p></div><p class="comma-list text-right text-muted"><small> <i class="fa fa-map-marker fa-fw" aria-hidden="true"></i> at <span class="comma-list-item"> <strong>UCLA</strong></span> </small></p></div></div></li><li class="trials-list--trial card border trials-list--trial-not-joinable trials-list--trial-open-to-age-18-and-over trials-list--trial-open-to-sex-female trials-list--trial-open-to-sex-male trials-list--trial-institution-name-UC%20Davis trials-list--trial-institution-name-UC%20Irvine "><div class="card-body"><h2 class="h4 card-title"> <a href="https://clinicaltrials.ucbraid.org/trial/NCT04729959" class="stretched-link">Immune Therapy Drugs, Tocilizumab and Atezolizumab, to Radiation Therapy for Recurrent Glioblastoma</a> </h2><div class="trials-list--trial-details"><p class="h6 text-danger"> <i class="fa fa-ban" aria-hidden="true"></i> <span class="sr-only">Sorry, </span> in progress, not accepting new patients </p><div class="trials-list--trial-summary"><p>This phase II trial studies the best dose and effect of tocilizumab in combination with atezolizumab and stereotactic radiation therapy in treating glioblastoma patients whose tumor has come back after initial treatment (recurrent). Tocilizumab is a monoclonal antibody that binds to receptors for a protein called interleukin-6 (IL-6), which is made by white blood cells and other cells in the body as well as certain types of cancer. This may help lower the body's immune response and reduce inflammation. Immunotherapy with monoclonal antibodies, such as atezolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Fractionated stereotactic radiation therapy uses special equipment to precisely deliver multiple, smaller doses of radiation spread over several treatment sessions to the tumor. The goal of this study is to change a tumor that is unresponsive to cancer therapy into a more responsive one. Therapy with fractionated stereotactic radiotherapy in combination with tocilizumab may suppress the inhibitory effect of immune cells surrounding the tumor and consequently allow an immunotherapy treatment by atezolizumab to activate the immune response against the tumor. Combination therapy with tocilizumab, atezolizumab and fractionated stereotactic radiation therapy may shrink or stabilize the cancer better than radiation therapy alone in patients with recurrent glioblastoma.</p></div><p class="comma-list text-right text-muted"><small> <i class="fa fa-map-marker fa-fw" aria-hidden="true"></i> at <span class="comma-list-item"> <strong>UC Davis</strong></span><span class="comma-list-item"> <strong>UC Irvine</strong></span> </small></p></div></div></li><li class="trials-list--trial card border trials-list--trial-not-joinable trials-list--trial-open-to-age-18-and-over trials-list--trial-open-to-sex-female trials-list--trial-open-to-sex-male trials-list--trial-institution-name-UC%20Davis trials-list--trial-institution-name-UC%20Irvine trials-list--trial-institution-name-UCSD "><div class="card-body"><h2 class="h4 card-title"> <a href="https://clinicaltrials.ucbraid.org/trial/NCT04396860" class="stretched-link">Testing the Use of the Immunotherapy Drugs Ipilimumab and Nivolumab Plus Radiation Therapy Compared to the Usual Treatment (Temozolomide and Radiation Therapy) for Newly Diagnosed MGMT Unmethylated Glioblastoma</a> </h2><div class="trials-list--trial-details"><p class="h6 text-danger"> <i class="fa fa-ban" aria-hidden="true"></i> <span class="sr-only">Sorry, </span> in progress, not accepting new patients </p><div class="trials-list--trial-summary"><p>This phase II/III trial compares the usual treatment with radiation therapy and temozolomide to radiation therapy in combination with immunotherapy with ipilimumab and nivolumab in treating patients with newly diagnosed MGMT unmethylated glioblastoma. Radiation therapy uses high energy photons to kill tumor and shrink tumors. Chemotherapy drugs, such as temozolomide, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Temozolomide, may not work as well for the treatment of tumors that have the unmethylated MGMT. Immunotherapy with monoclonal antibodies called immune checkpoint inhibitors, such as ipilimumab and nivolumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. It is possible that immune checkpoint inhibitors may work better at time of first diagnosis as opposed to when tumor comes back. Giving radiation therapy with ipilimumab and nivolumab may lengthen the time without brain tumor returning or growing and may extend patients' life compared to usual treatment with radiation therapy and temozolomide.</p></div><p class="comma-list text-right text-muted"><small> <i class="fa fa-map-marker fa-fw" aria-hidden="true"></i> at <span class="comma-list-item"> <strong>UC Davis</strong></span><span class="comma-list-item"> <strong>UC Irvine</strong></span><span class="comma-list-item"> <strong>UCSD</strong></span> </small></p></div></div></li><li class="trials-list--trial card border trials-list--trial-not-joinable trials-list--trial-open-to-age-under-18 trials-list--trial-open-to-age-18-and-over trials-list--trial-open-to-sex-female trials-list--trial-open-to-sex-male trials-list--trial-institution-name-UC%20Davis trials-list--trial-institution-name-UCLA trials-list--trial-institution-name-UCSF "><div class="card-body"><h2 class="h4 card-title"> <a href="https://clinicaltrials.ucbraid.org/trial/NCT04284774" class="stretched-link">Tipifarnib for the Treatment of Advanced Solid Tumors, Lymphoma, or Histiocytic Disorders With HRAS Gene Alterations, a Pediatric MATCH Treatment Trial</a> </h2><div class="trials-list--trial-details"><p class="h6 text-danger"> <i class="fa fa-ban" aria-hidden="true"></i> <span class="sr-only">Sorry, </span> in progress, not accepting new patients </p><div class="trials-list--trial-summary"><p>This phase II pediatric MATCH trial studies how well tipifarnib works in treating patients with solid tumors that have recurred or spread to other places in the body (advanced), lymphoma, or histiocytic disorders, that have a genetic alteration in the gene HRAS. Tipifarnib may block the growth of cancer cells that have specific genetic changes in a gene called HRAS and may reduce tumor size.</p></div><p class="comma-list text-right text-muted"><small> <i class="fa fa-map-marker fa-fw" aria-hidden="true"></i> at <span class="comma-list-item"> <strong>UC Davis</strong></span><span class="comma-list-item"> <strong>UCLA</strong></span><span class="comma-list-item"> <strong>UCSF</strong></span> </small></p></div></div></li><li class="trials-list--trial card border trials-list--trial-not-joinable trials-list--trial-open-to-age-18-and-over trials-list--trial-open-to-sex-female trials-list--trial-open-to-sex-male trials-list--trial-institution-name-UCSF "><div class="card-body"><h2 class="h4 card-title"> <a href="https://clinicaltrials.ucbraid.org/trial/NCT02655601" class="stretched-link">Newly Diagnosed High Grade Glioma Treated With Concurrent Radiation Therapy, Temozolomide and BMX-001</a> </h2><div class="trials-list--trial-details"><p class="h6 text-danger"> <i class="fa fa-ban" aria-hidden="true"></i> <span class="sr-only">Sorry, </span> in progress, not accepting new patients </p><div class="trials-list--trial-summary"><p>This is a Phase 2 study of newly diagnosed patients with high grade glioma (HGG) undergoing standard radiation therapy and temozolomide treatment. BMX-001 added to radiation therapy and temozolomide has the potential not only to benefit the survival of high grade glioma patients but also to protect against deterioration of cognition and impairment of quality of life. BMX-001 will be given subcutaneously first with a loading dose zero to four days prior to the start of chemoradiation and followed by twice a week doses at one-half of the loading dose for the duration of radiation therapy plus two weeks. Both safety and efficacy of BMX-001 will be evaluated. Impact on cognition will also be assessed. Eighty patients will be randomized to the treatment arm that will receive BMX-001 while undergoing chemoradiation and 80 patients randomized to receive chemoradiation alone. The sponsor hypothesizes that BMX-001 when added to standard radiation therapy and temozolomide will be safe at pharmacologically relevant doses in patients with newly diagnosed high grade glioma. The sponsor also hypothesizes that the addition of BMX-001 will positively impact the overall survival and improve objective measures of cognition in newly diagnosed high grade glioma patients.</p></div><p class="comma-list text-right text-muted"><small> <i class="fa fa-map-marker fa-fw" aria-hidden="true"></i> at <span class="comma-list-item"> <strong>UCSF</strong></span> </small></p></div></div></li><li class="trials-list--trial card border trials-list--trial-not-joinable trials-list--trial-open-to-age-18-and-over trials-list--trial-open-to-sex-female trials-list--trial-open-to-sex-male trials-list--trial-institution-name-UCSF "><div class="card-body"><h2 class="h4 card-title"> <a href="https://clinicaltrials.ucbraid.org/trial/NCT05076513" class="stretched-link">Niraparib in Participants With Newly-diagnosed Glioblastoma and Recurrent Glioma</a> </h2><div class="trials-list--trial-details"><p class="h6 text-danger"> <i class="fa fa-ban" aria-hidden="true"></i> <span class="sr-only">Sorry, </span> not currently recruiting here </p><div class="trials-list--trial-summary"><p>This is an open-label, multi-center Phase 0 study with an expansion phase that will enroll up to 24 participants with newly-diagnosed glioblastoma and up to 18 recurrent glioma participants with IDH mutation and ATRX loss. The trial will be composed of a Phase 0 component (subdivided into Arm A and B) and a therapeutic expansion phase. Patients with tumors demonstrating a positive PK Response (in Arm A) or a positive PD Response (in Arm B) of the Phase 0 component of the study will graduate to a therapeutic expansion phase that combines therapeutic dosing of niraparib plus standard-of-care fractionated radiotherapy (in Arm A) or niraparib monotherapy (in Arm B) until progression of disease.</p></div><p class="comma-list text-right text-muted"><small> <i class="fa fa-map-marker fa-fw" aria-hidden="true"></i> at <span class="comma-list-item"> <strong>UCSF</strong></span> </small></p></div></div></li><li class="trials-list--trial card border trials-list--trial-not-joinable trials-list--trial-open-to-age-under-18 trials-list--trial-open-to-age-18-and-over trials-list--trial-open-to-sex-female trials-list--trial-open-to-sex-male trials-list--trial-institution-name-UCLA trials-list--trial-institution-name-UCSF "><div class="card-body"><h2 class="h4 card-title"> <a href="https://clinicaltrials.ucbraid.org/trial/NCT03698994" class="stretched-link">Ulixertinib in Treating Patients With Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With MAPK Pathway Mutations (A Pediatric MATCH Treatment Trial)</a> </h2><div class="trials-list--trial-details"><p class="h6 text-danger"> <i class="fa fa-ban" aria-hidden="true"></i> <span class="sr-only">Sorry, </span> in progress, not accepting new patients </p><div class="trials-list--trial-summary"><p>This phase II Pediatric MATCH trial studies how well ulixertinib works in treating patients with solid tumors that have spread to other places in the body (advanced), non-Hodgkin lymphoma, or histiocytic disorders that have a genetic alteration (mutation) in a signaling pathway called MAPK. A signaling pathway consists of a group of molecules in a cell that control one or more cell functions. Genes in the MAPK pathway are frequently mutated in many types of cancers. Ulixertinib may stop the growth of cancer cells that have mutations in the MAPK pathway.</p></div><p class="comma-list text-right text-muted"><small> <i class="fa fa-map-marker fa-fw" aria-hidden="true"></i> at <span class="comma-list-item"> <strong>UCLA</strong></span><span class="comma-list-item"> <strong>UCSF</strong></span> </small></p></div></div></li><li class="trials-list--trial card border trials-list--trial-not-joinable trials-list--trial-open-to-age-under-18 trials-list--trial-open-to-age-18-and-over trials-list--trial-open-to-sex-female trials-list--trial-open-to-sex-male trials-list--trial-institution-name-UCLA trials-list--trial-institution-name-UCSF "><div class="card-body"><h2 class="h4 card-title"> <a href="https://clinicaltrials.ucbraid.org/trial/NCT03581292" class="stretched-link">Veliparib, Radiation Therapy, and Temozolomide in Treating Patients With Newly Diagnosed Malignant Glioma Without H3 K27M or BRAFV600 Mutations</a> </h2><div class="trials-list--trial-details"><p class="h6 text-danger"> <i class="fa fa-ban" aria-hidden="true"></i> <span class="sr-only">Sorry, </span> in progress, not accepting new patients </p><div class="trials-list--trial-summary"><p>This phase II trial studies how well veliparib, radiation therapy, and temozolomide work in treating patients with newly diagnosed malignant glioma without H3 K27M or BRAFV600 mutations. Poly adenosine diphosphate (ADP) ribose polymerases (PARPs) are proteins that help repair DNA mutations. PARP inhibitors, such as veliparib, can keep PARP from working, so tumor cells can't repair themselves, and they may stop growing. Radiation therapy uses high energy x-rays to kill tumor cells and shrink tumors. Drugs used in chemotherapy, such as temozolomide, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving veliparib, radiation therapy, and temozolomide may work better in treating patients with newly diagnosed malignant glioma without H3 K27M or BRAFV600 mutations compared to radiation therapy and temozolomide alone.</p></div><p class="comma-list text-right text-muted"><small> <i class="fa fa-map-marker fa-fw" aria-hidden="true"></i> at <span class="comma-list-item"> <strong>UCLA</strong></span><span class="comma-list-item"> <strong>UCSF</strong></span> </small></p></div></div></li><li class="trials-list--trial card border trials-list--trial-not-joinable trials-list--trial-open-to-age-under-18 trials-list--trial-open-to-age-18-and-over trials-list--trial-open-to-sex-female trials-list--trial-open-to-sex-male trials-list--trial-institution-name-UCLA trials-list--trial-institution-name-UCSF "><div class="card-body"><h2 class="h4 card-title"> <a href="https://clinicaltrials.ucbraid.org/trial/NCT01748149" class="stretched-link">Vemurafenib in Children With Recurrent/Refractory BRAF Gene V600E (BRAFV600E)-Mutant Gliomas</a> </h2><div class="trials-list--trial-details"><p class="h6 text-danger"> <i class="fa fa-ban" aria-hidden="true"></i> <span class="sr-only">Sorry, </span> in progress, not accepting new patients </p><div class="trials-list--trial-summary"><p>This is a multicenter, safety and pharmacokinetic trial to determine the MTD and/or select a recommended phase 2 dose (RP2D) of vemurafenib in children with recurrent or refractory gliomas containing the BRAFV600E or BRAF Ins T mutation.</p></div><p class="comma-list text-right text-muted"><small> <i class="fa fa-map-marker fa-fw" aria-hidden="true"></i> at <span class="comma-list-item"> <strong>UCLA</strong></span><span class="comma-list-item"> <strong>UCSF</strong></span> </small></p></div></div></li><li class="trials-list--trial card border trials-list--trial-not-joinable trials-list--trial-open-to-age-under-18 trials-list--trial-open-to-age-18-and-over trials-list--trial-open-to-sex-female trials-list--trial-open-to-sex-male trials-list--trial-institution-name-UCSF "><div class="card-body"><h2 class="h4 card-title"> <a href="https://clinicaltrials.ucbraid.org/trial/NCT03220035" class="stretched-link">Vemurafenib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With BRAF V600 Mutations (A Pediatric MATCH Treatment Trial)</a> </h2><div class="trials-list--trial-details"><p class="h6 text-danger"> <i class="fa fa-ban" aria-hidden="true"></i> <span class="sr-only">Sorry, </span> in progress, not accepting new patients </p><div class="trials-list--trial-summary"><p>This phase II Pediatric MATCH trial studies how well vemurafenib works in treating patients with solid tumors, non-Hodgkin lymphoma, or histiocytic disorders with BRAF V600 mutations that have spread to other places in the body (advanced) and have come back (recurrent) or do not respond to treatment (refractory). Vemurafenib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.</p></div><p class="comma-list text-right text-muted"><small> <i class="fa fa-map-marker fa-fw" aria-hidden="true"></i> at <span class="comma-list-item"> <strong>UCSF</strong></span> </small></p></div></div></li><li class="trials-list--trial card border trials-list--trial-not-joinable trials-list--trial-open-to-age-under-18 trials-list--trial-open-to-age-18-and-over trials-list--trial-open-to-sex-female trials-list--trial-open-to-sex-male trials-list--trial-institution-name-UCLA trials-list--trial-institution-name-UCSF "><div class="card-body"><h2 class="h4 card-title"> <a href="https://clinicaltrials.ucbraid.org/trial/NCT06478212" class="stretched-link">Vorasidenib in Combination With Temozolomide (TMZ) in IDH-mutant Glioma</a> </h2><div class="trials-list--trial-details"><p class="h6 text-danger"> <i class="fa fa-ban" aria-hidden="true"></i> <span class="sr-only">Sorry, </span> not yet accepting patients </p><div class="trials-list--trial-summary"><p>The objective of this study is to determine the safety and tolerability of vorasidenib in combination with temozolomide (TMZ) and to establish the recommended combination dose (RCD) of vorasidenib. The study will begin as a Phase Ib study to determine the RCD and then will transition to a Phase II study to assess the clinical efficacy of vorasidenib at the RCD in combination with TMZ. During the treatment period participants will have study visits on day 1 and 22 of each cycle, with additional visits occurring during the first cycle of the Phase 1b study. Approximately 30 days after treatment has ended, a safety follow-up visit will occur and then participants will be followed for survival every 3 months. Study visits may include questionnaires, blood tests, ECG, vital signs, and a physical examination.</p></div><p class="comma-list text-right text-muted"><small> <i class="fa fa-map-marker fa-fw" aria-hidden="true"></i> at <span class="comma-list-item"> <strong>UCLA</strong></span><span class="comma-list-item"> <strong>UCSF</strong></span> </small></p></div></div></li><li class="trials-list--trial card border trials-list--trial-not-joinable trials-list--trial-open-to-age-18-and-over trials-list--trial-open-to-sex-female trials-list--trial-open-to-sex-male trials-list--trial-institution-name-UCLA trials-list--trial-institution-name-UCSF "><div class="card-body"><h2 class="h4 card-title"> <a href="https://clinicaltrials.ucbraid.org/trial/NCT00268385" class="stretched-link">Vorinostat and Temozolomide in Treating Patients With Malignant Gliomas</a> </h2><div class="trials-list--trial-details"><p class="h6 text-danger"> <i class="fa fa-ban" aria-hidden="true"></i> <span class="sr-only">Sorry, </span> in progress, not accepting new patients </p><div class="trials-list--trial-summary"><p>This phase I trial is studying the side effects and best dose of vorinostat when given together with temozolomide in treating patients with malignant gliomas. Drugs used in chemotherapy, such as vorinostat and temozolomide, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Vorinostat may also stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Vorinostat may help temozolomide work better by making tumor cells more sensitive to the drug. Giving vorinostat together with temozolomide may kill more tumor cells.</p></div><p class="comma-list text-right text-muted"><small> <i class="fa fa-map-marker fa-fw" aria-hidden="true"></i> at <span class="comma-list-item"> <strong>UCLA</strong></span><span class="comma-list-item"> <strong>UCSF</strong></span> </small></p></div></div></li><li class="trials-list--trial card border trials-list--trial-not-joinable trials-list--trial-open-to-age-18-and-over trials-list--trial-open-to-sex-female trials-list--trial-open-to-sex-male trials-list--trial-institution-name-UCLA "><div class="card-body"><h2 class="h4 card-title"> <a href="https://clinicaltrials.ucbraid.org/trial/NCT06650163" class="stretched-link">Zr-89 Crefmirlimab Berdoxam and Immuno-Positron Emission Tomography for the Imaging of Patients with Resectable Brain Tumors</a> </h2><div class="trials-list--trial-details"><p class="h6 text-danger"> <i class="fa fa-ban" aria-hidden="true"></i> <span class="sr-only">Sorry, </span> not yet accepting patients </p><div class="trials-list--trial-summary"><p>This phase I trial studies how well zirconium (Zr)-89 crefmirlimab berdoxam and immuno-positron emission tomography (PET) identifies areas of immune cell activity in patients with brain tumors that can be removed by surgery (resectable). One important predictor of the immune response is the presence and change in CD8 positive (+) tumor infiltrating lymphocytes (TIL) cells. Identifying the presence and changes in CD8+ cells can be challenging, particularly for participants with central nervous system (CNS) tumors, and usually requires invasive procedures such as repeat tissue biopsies, which may not accurately represent the immune status of the entire tumor. Zr-89 crefmirlimab berdoxam is known as a radioimmunoconjugate which consists of a radiolabeled anti-CD8+ minibody whose uptake can be imaged with PET. Upon administration, Zr 89 crefmirlimab berdoxam specifically targets and binds to the CD8+ cells. This enables PET imaging and may detect CD8+ T-cell distribution and activity and may help determine the patient's response to cancer immunotherapeutic agents more accurately. Giving Zr-89 crefmirlimab berdoxam along with undergoing immuno-PET imaging may work better at identifying immune cell activity in patients with resectable brain tumors.</p></div><p class="comma-list text-right text-muted"><small> <i class="fa fa-map-marker fa-fw" aria-hidden="true"></i> at <span class="comma-list-item"> <strong>UCLA</strong></span> </small></p></div></div></li><li class="trials-list--trial card border trials-list--trial-not-joinable trials-list--trial-open-to-age-18-and-over trials-list--trial-open-to-sex-female trials-list--trial-open-to-sex-male trials-list--trial-institution-name-UCSF "><div class="card-body"><h2 class="h4 card-title"> <a href="https://clinicaltrials.ucbraid.org/trial/NCT03561207" class="stretched-link">3D Prediction of Patient-Specific Response</a> </h2><div class="trials-list--trial-details"><p class="h6 text-danger"> <i class="fa fa-ban" aria-hidden="true"></i> <span class="sr-only">Sorry, </span> in progress, not accepting new patients </p><div class="trials-list--trial-summary"><p>This is a prospective, non-randomized, observational registry study evaluating a patient-specific ex vivo 3D (EV3D) assay for drug response using a patient's own biopsy or resected tumor tissue for assessing tissue response to therapy in patients with advanced cancers, including ovarian cancer, high-grade gliomas, and high-grade rare tumors.</p></div><p class="comma-list text-right text-muted"><small> <i class="fa fa-map-marker fa-fw" aria-hidden="true"></i> at <span class="comma-list-item"> <strong>UCSF</strong></span> </small></p></div></div></li><li class="trials-list--trial card border trials-list--trial-not-joinable trials-list--trial-open-to-age-18-and-over trials-list--trial-open-to-sex-female trials-list--trial-open-to-sex-male trials-list--trial-open-to-healthy trials-list--trial-institution-name-UCSF "><div class="card-body"><h2 class="h4 card-title"> <a href="https://clinicaltrials.ucbraid.org/trial/NCT06594315" class="stretched-link">Assessing Brain Metabolism Using MRS With Deuterated Glucose</a> </h2><div class="trials-list--trial-details"><p class="h6 text-danger"> <i class="fa fa-ban" aria-hidden="true"></i> <span class="sr-only">Sorry, </span> in progress, not accepting new patients </p><div class="trials-list--trial-summary"><p>This study will investigate the use of Hydrogen 1 (1H) magnetic resonance spectroscopy (MRS) with deuterated glucose (2H-glucose) to detect dynamic glucose uptake in the brain.</p></div><p class="comma-list text-right text-muted"><small> <i class="fa fa-map-marker fa-fw" aria-hidden="true"></i> at <span class="comma-list-item"> <strong>UCSF</strong></span> </small></p></div></div></li><li class="trials-list--trial card border trials-list--trial-not-joinable trials-list--trial-open-to-age-under-18 trials-list--trial-open-to-age-18-and-over trials-list--trial-open-to-sex-female trials-list--trial-open-to-sex-male trials-list--trial-institution-name-UCSF "><div class="card-body"><h2 class="h4 card-title"> <a href="https://clinicaltrials.ucbraid.org/trial/NCT01377532" class="stretched-link">Compassionate Use of 131I-MIBG for Patients With Malignant Pheochromocytoma</a> </h2><div class="trials-list--trial-details"><p class="h6 text-danger"> <i class="fa fa-ban" aria-hidden="true"></i> <span class="sr-only">Sorry, </span> not accepting new patients </p><div class="trials-list--trial-summary"><p>This is a compassionate use protocol to allow palliative therapy for patients with malignant pheochromocytoma and paragangliomas.</p></div><p class="comma-list text-right text-muted"><small> <i class="fa fa-map-marker fa-fw" aria-hidden="true"></i> at <span class="comma-list-item"> <strong>UCSF</strong></span> </small></p></div></div></li><li class="trials-list--trial card border trials-list--trial-not-joinable trials-list--trial-open-to-age-18-and-over trials-list--trial-open-to-sex-female trials-list--trial-open-to-sex-male trials-list--trial-institution-name-UC%20Irvine trials-list--trial-institution-name-UCLA "><div class="card-body"><h2 class="h4 card-title"> <a href="https://clinicaltrials.ucbraid.org/trial/NCT02146066" class="stretched-link">GBM Patients With Already Manufactured DCVax®-L Who Have Screen-Failed Protocol 020221</a> </h2><div class="trials-list--trial-details"><p class="h6 text-danger"> <i class="fa fa-ban" aria-hidden="true"></i> <span class="sr-only">Sorry, </span> not accepting new patients </p><div class="trials-list--trial-summary"><p>The study is an open-label expanded access study for patients for whom vaccine was manufactured during the Northwest Biotherapeutics' 020221 DCVax-L for GBM screening process, but who subsequently failed to meet specific enrollment criteria. Patients will receive therapy per investigator discretion (standard of care) as well as active vaccine per the 020221 protocol administration schedule. It is estimated that approximately 99 patients will enroll in this study.</p></div><p class="comma-list text-right text-muted"><small> <i class="fa fa-map-marker fa-fw" aria-hidden="true"></i> at <span class="comma-list-item"> <strong>UC Irvine</strong></span><span class="comma-list-item"> <strong>UCLA</strong></span> </small></p></div></div></li><li class="trials-list--trial card border trials-list--trial-not-joinable trials-list--trial-open-to-age-18-and-over trials-list--trial-open-to-sex-female trials-list--trial-open-to-sex-male trials-list--trial-institution-name-UCSF "><div class="card-body"><h2 class="h4 card-title"> <a href="https://clinicaltrials.ucbraid.org/trial/NCT04708171" class="stretched-link">PROGRAM-study: Awake Mapping Versus Asleep Mapping Versus No Mapping for Glioblastoma Resections</a> </h2><div class="trials-list--trial-details"><p class="h6 text-danger"> <i class="fa fa-ban" aria-hidden="true"></i> <span class="sr-only">Sorry, </span> not currently recruiting here </p><div class="trials-list--trial-summary"><p>The study is designed as an international, multicenter prospective cohort study. Patients with presumed glioblastoma (GBM) in- or near eloquent areas on diagnostic MRI will be selected by neurosurgeons. Patients will be treated following one of three study arms: 1) a craniotomy where the resection boundaries for motor or language functions will be identified by the "awake" mapping technique (awake craniotomy, AC); 2) a craniotomy where the resection boundaries for motor functions will be identified by "asleep" mapping techniques (MEPs, SSEPs, continuous dynamic mapping); 3) a craniotomy where the resection boundaries will not be identified by any mapping technique ("no mapping group"). All patients will receive follow-up according to standard practice.</p></div><p class="comma-list text-right text-muted"><small> <i class="fa fa-map-marker fa-fw" aria-hidden="true"></i> at <span class="comma-list-item"> <strong>UCSF</strong></span> </small></p></div></div></li></ul><div itemscope itemtype="https://schema.org/WebPage"><p class="text-muted small comma-list"> Our lead scientists for Glioma research studies include <span class="pi-name comma-list-item" itemprop="author" itemscope itemtype="https://schema.org/Person"><a href="https://profiles.ucla.edu/robert.prins" target="_blank" rel="noopener author" itemprop="url" class="condition--link-to-pi-profile"><span itemprop="name">Robert M Prins</span></a></span> <span class="pi-name comma-list-item" itemprop="author" itemscope itemtype="https://schema.org/Person"><a href="https://profiles.ucsf.edu/paul.fitzgerald" target="_blank" rel="noopener author" itemprop="url" class="condition--link-to-pi-profile"><span itemprop="name">Paul Fitzgerald, MD</span></a></span> <span class="pi-name comma-list-item" itemprop="author" itemscope itemtype="https://schema.org/Person"><a href="https://profiles.ucla.edu/johannes.czernin" target="_blank" rel="noopener author" itemprop="url" class="condition--link-to-pi-profile"><span itemprop="name">Johannes Czernin, MD</span></a></span> <span class="pi-name comma-list-item" itemprop="author" itemscope itemtype="https://schema.org/Person"><a href="https://profiles.ucsf.edu/alyssa.reddy" target="_blank" rel="noopener author" itemprop="url" class="condition--link-to-pi-profile"><span itemprop="name">Alyssa T. Reddy</span></a></span> <span class="pi-name comma-list-item" itemprop="author" itemscope itemtype="https://schema.org/Person"><a href="https://profiles.ucsf.edu/john.degroot" target="_blank" rel="noopener author" itemprop="url" class="condition--link-to-pi-profile"><span itemprop="name">John de Groot, M.D.</span></a></span> <span class="pi-name comma-list-item" itemprop="author" itemscope itemtype="https://schema.org/Person"><a href="https://profiles.ucsd.edu/jessica.schulte" target="_blank" rel="noopener author" itemprop="url" class="condition--link-to-pi-profile"><span itemprop="name">Jessica Schulte, MD</span></a></span> <span class="pi-name comma-list-item" itemprop="author" itemscope itemtype="https://schema.org/Person"><a href="https://profiles.ucsf.edu/jennifer.michlitsch" target="_blank" rel="noopener author" itemprop="url" class="condition--link-to-pi-profile"><span itemprop="name">Jennifer G. Michlitsch</span></a></span> <span class="pi-name comma-list-item" itemprop="author" itemscope itemtype="https://schema.org/Person"><a href="https://profiles.ucsf.edu/sabine.mueller" target="_blank" rel="noopener author" itemprop="url" class="condition--link-to-pi-profile"><span itemprop="name">Sabine Mueller</span></a></span> <span class="pi-name comma-list-item" itemprop="author" itemscope itemtype="https://schema.org/Person"><a href="https://profiles.icts.uci.edu/daniela.bota" target="_blank" rel="noopener author" itemprop="url" class="condition--link-to-pi-profile"><span itemprop="name">Daniela Bota, MD PHD</span></a></span> <span class="pi-name comma-list-item" itemprop="author" itemscope itemtype="https://schema.org/Person"><a href="https://profiles.icts.uci.edu/xiao-tang.kong" target="_blank" rel="noopener author" itemprop="url" class="condition--link-to-pi-profile"><span itemprop="name">Xiao-Tang Kong, MD, PhD</span></a></span> <span class="pi-name comma-list-item" itemprop="author" itemscope itemtype="https://schema.org/Person"><a href="https://profiles.ucsf.edu/yang.li" target="_blank" rel="noopener author" itemprop="url" class="condition--link-to-pi-profile"><span itemprop="name">Yan Li, PhD</span></a></span> <span class="pi-name comma-list-item" itemprop="author" itemscope itemtype="https://schema.org/Person"><a href="https://profiles.ucsf.edu/hideho.okada" target="_blank" rel="noopener author" itemprop="url" class="condition--link-to-pi-profile"><span itemprop="name">Hideho Okada, MD, PhD</span></a></span> <span class="pi-name comma-list-item" itemprop="author" itemscope itemtype="https://schema.org/Person"><a href="https://profiles.ucdavis.edu/orin.bloch" target="_blank" rel="noopener author" itemprop="url" class="condition--link-to-pi-profile"><span itemprop="name">Orin Bloch, MD</span></a></span> <span class="pi-name comma-list-item" itemprop="author" itemscope itemtype="https://schema.org/Person"><a href="https://profiles.ucla.edu/linda.liau" target="_blank" rel="noopener author" itemprop="url" class="condition--link-to-pi-profile"><span itemprop="name">Linda Liau</span></a></span> <span class="pi-name comma-list-item" itemprop="author" itemscope itemtype="https://schema.org/Person"><a href="https://profiles.ucsf.edu/rahul.aggarwal" target="_blank" rel="noopener author" itemprop="url" class="condition--link-to-pi-profile"><span itemprop="name">Rahul Aggarwal</span></a></span> <span class="pi-name comma-list-item" itemprop="author" itemscope itemtype="https://schema.org/Person"><a href="https://profiles.ucsf.edu/arun.rangaswami" target="_blank" rel="noopener author" itemprop="url" class="condition--link-to-pi-profile"><span itemprop="name">Arun A. Rangaswami</span></a></span> <span class="pi-name comma-list-item" itemprop="author" itemscope itemtype="https://schema.org/Person"><a href="https://profiles.ucla.edu/joel.hecht" target="_blank" rel="noopener author" itemprop="url" class="condition--link-to-pi-profile"><span itemprop="name">Joel Hecht</span></a></span> <span class="pi-name comma-list-item" itemprop="author" itemscope itemtype="https://schema.org/Person"><a href="https://profiles.ucsf.edu/nancyann.oberheimbush" target="_blank" rel="noopener author" itemprop="url" class="condition--link-to-pi-profile"><span itemprop="name">Nancy Ann Oberheim Bush, MD, PhD</span></a></span> <span class="pi-name comma-list-item" itemprop="author" itemscope itemtype="https://schema.org/Person"><a href="https://profiles.ucsf.edu/susan.chang" target="_blank" rel="noopener author" itemprop="url" class="condition--link-to-pi-profile"><span itemprop="name">Susan Chang, MD</span></a></span> <span class="pi-name comma-list-item" itemprop="author" itemscope itemtype="https://schema.org/Person"><a href="https://profiles.ucsf.edu/caroline.hastings" target="_blank" rel="noopener author" itemprop="url" class="condition--link-to-pi-profile"><span itemprop="name">Caroline A. Hastings</span></a></span> <span class="pi-name comma-list-item" itemprop="author" itemscope itemtype="https://schema.org/Person"><a href="https://profiles.ucdavis.edu/orwa.aboud" target="_blank" rel="noopener author" itemprop="url" class="condition--link-to-pi-profile"><span itemprop="name">Orwa Aboud</span></a></span> <span class="pi-name comma-list-item" itemprop="author" itemscope itemtype="https://schema.org/Person"><a href="https://profiles.ucla.edu/timothy.cloughesy" target="_blank" rel="noopener author" itemprop="url" class="condition--link-to-pi-profile"><span itemprop="name">Timothy Cloughesy</span></a></span> <span class="pi-name comma-list-item" itemprop="author" itemscope itemtype="https://schema.org/Person"><a href="https://profiles.ucla.edu/phioanh.nghiemphu" target="_blank" rel="noopener author" itemprop="url" class="condition--link-to-pi-profile"><span itemprop="name">PHIOANH Leia NGHIEMPHU</span></a></span> <span class="pi-name comma-list-item" itemprop="author" itemscope itemtype="https://schema.org/Person"><a href="https://profiles.ucsf.edu/nicholas.butowski" target="_blank" rel="noopener author" itemprop="url" class="condition--link-to-pi-profile"><span itemprop="name">Nicholas Butowski, MD</span></a></span> <span class="pi-name comma-list-item" itemprop="author" itemscope itemtype="https://schema.org/Person"><a href="https://profiles.ucla.edu/anthony.wang" target="_blank" rel="noopener author" itemprop="url" class="condition--link-to-pi-profile"><span itemprop="name">Anthony C Wang, MD</span></a></span> <span class="pi-name comma-list-item" itemprop="author" itemscope itemtype="https://schema.org/Person"><a href="https://profiles.ucla.edu/richard.everson" target="_blank" rel="noopener author" itemprop="url" class="condition--link-to-pi-profile"><span itemprop="name">Richard Everson, MD</span></a></span> <span class="pi-name comma-list-item" itemprop="author" itemscope itemtype="https://schema.org/Person"><a href="https://profiles.ucsf.edu/jennifer.clarke" target="_blank" rel="noopener author" itemprop="url" class="condition--link-to-pi-profile"><span itemprop="name">Jennifer Clarke, MD, MPH</span></a></span> <span class="pi-name comma-list-item" itemprop="author" itemscope itemtype="https://schema.org/Person"><a href="https://profiles.ucla.edu/lee.rosen" target="_blank" rel="noopener author" itemprop="url" class="condition--link-to-pi-profile"><span itemprop="name">Lee Rosen</span></a></span> <span class="pi-name comma-list-item" itemprop="author" itemscope itemtype="https://schema.org/Person"><a href="https://profiles.ucla.edu/benjamin.ellingson" target="_blank" rel="noopener author" itemprop="url" class="condition--link-to-pi-profile"><span itemprop="name">Benjamin Ellingson, PhD</span></a></span> <span class="pi-name comma-list-item" itemprop="author" itemscope itemtype="https://schema.org/Person"><a href="https://profiles.ucsf.edu/kieuhoa.vo" target="_blank" rel="noopener author" itemprop="url" class="condition--link-to-pi-profile"><span itemprop="name">Kieuhoa Vo</span></a></span> <span class="pi-name comma-list-item" itemprop="author" itemscope itemtype="https://schema.org/Person"><a href="https://profiles.ucsf.edu/jennie.taylor" target="_blank" rel="noopener author" itemprop="url" class="condition--link-to-pi-profile"><span itemprop="name">Jennie Taylor</span></a></span> <span class="pi-name comma-list-item" itemprop="author" itemscope itemtype="https://schema.org/Person"><a href="https://profiles.ucsd.edu/david.piccioni" target="_blank" rel="noopener author" itemprop="url" class="condition--link-to-pi-profile"><span itemprop="name">David E. Piccioni</span></a></span>. </p><p class="text-muted small">Last updated: <time itemprop="dateModified" datetime="2024-11-13">November 13, 2024</time></p></div></div> </div> </div> </main><footer class="mt-auto" role="contentinfo" data-nosnippet><div style="background: #00324e" class="container-fluid py-3"><div class="row align-items-center"><div class="col-12 col-md-8 text-white"> <a href="https://www.ucbraid.org/" class="d-block d-md-inline-block pr-md-3 "><img src="https://clinicaltrials.ucbraid.org/assets/local/uchealth/img/ucbraid-logo-white-on-transparent.png" style="height: 2em" alt="UC BRAID"></a> <a href="https://health.universityofcalifornia.edu/patient-care/cancer-consortium" class="d-block d-md-inline-block">Cancer Consortium</a> <a href="https://health.universityofcalifornia.edu/patient-care/cardiac-surgery-consortium" class="d-block d-md-inline-block">Cardiac Surgery Consortium</a> <a href="https://health.universityofcalifornia.edu/research" class="d-block d-md-inline-block">Research at University of California Health</a> </div><div class="col-12 col-md-4 text-md-right"> © The Regents of the University of California </div></div></div></footer></body></html>